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Background: Asthma control is suboptimal, resulting in quality of life (QoL) impairment and costs.
Breathing retraining exercises have evidence of effectiveness as adjuvant treatment, but are
infrequently used.
Objectives: To transfer the contents of a brief (three-session) physiotherapist-delivered breathing
retraining programme to a digital versatile disc (DVD) and booklet format; to compare the effectiveness of
the self-guided intervention with that of ‘face-to-face’ physiotherapy and usual care for QoL and other
asthma-related outcomes; to perform a health economic assessment of both interventions; and to perform
a process evaluation using quantitative and qualitative methods.
Design: Parallel-group three-arm randomised controlled trial.
Setting: General practice surgeries in the UK.
Participants: In total, 655 adults currently receiving asthma treatment with impaired asthma-related QoL
were randomly allocated to the DVD (n = 261), physiotherapist (n = 132) and control (usual care) (n = 262)
arms in a 2 : 1 : 2 ratio. It was not possible to blind participants but data collection and analysis were
performed blinded.
Interventions: Physiotherapy-based breathing retraining delivered through three ‘face-to-face’ respiratory
physiotherapist sessions or a self-guided programme (DVD plus our theory-based behaviour change booklet)
developed by the research team, with a control of usual care.
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Main outcome measures: The primary outcome measure was asthma-specific QoL, measured using the
Asthma Quality of Life Questionnaire (AQLQ). Secondary outcomes included asthma symptom control
[Asthma Control Questionnaire (ACQ)], psychological state [Hospital Anxiety and Depression Scale (HADS)],
hyperventilation symptoms (Nijmegen questionnaire), generic QoL [EuroQol-5 Dimensions (EQ-5D)],
assessments of airway physiology (spirometry) and inflammation (exhaled nitric oxide) and health resource
use and costs. Assessments were carried out at baseline and at 3, 6 and 12 months post randomisation.
Patient engagement and experience were also assessed using quantitative and qualitative methods.
Results: Primary efficacy analysis was between-group comparison of changes in AQLQ scores from baseline
to 12 months in the intention-to-treat population with adjustments for prespecified covariates. Significant
improvements occurred in the DVD group compared with the control group [adjusted mean difference
0.28, 95% confidence interval (CI) 0.11 to 0.44; p < 0.001] and in the face-to-face physiotherapy group
compared with the control group (adjusted mean difference 0.24, 95% CI 0.04 to 0.44; p < 0.05), with
equivalence between the DVD and the face-to-face physiotherapy groups (adjusted mean difference 0.04,
95% CI –0.16 to 0.24). In all sensitivity analyses, both interventions remained significantly superior to the
control and equivalence between the interventions was maintained. In other questionnaire outcome
measures and in the physiological measures assessed, there were no significant between-group differences.
Process evaluations showed that participants engaged well with both of the active interventions, but that
some participants in the DVD arm would have liked to receive tuition from a professional. Asthma health-
care costs were lower in both intervention arms than in the control group, indicating ‘dominance’ for both
of the interventions compared with the control, with lowest costs in the DVD arm. The rate of adverse
events was lower in the DVD and face-to-face physiotherapy groups than in the control group.
Conclusions: Only 10% of the potentially eligible population responded to the study invitation. However,
breathing retraining exercises improved QoL and reduced health-care costs in adults with asthma whose
condition remains uncontrolled despite standard pharmacological therapy, were engaged with well by
patients and can be delivered effectively as a self-guided intervention. The intervention should now be
transferred to an internet-based platform and implementation studies performed. Interventions for younger
patients should be developed and trialled.
Trial registration: Current Controlled Trials ISRCTN88318003.
Funding: This project was primarily funded by the NIHR Health Technology Assessment programme and
will be published in full in Health Technology Assessment; Vol. 21, No. 53. See the NIHR Journals Library
website for further project information. Additional financial support was received from Comprehensive
Local Research Networks.
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Plain English summary
Most adults with asthma have symptoms that affect their lives, despite taking appropriate medications,and many are interested in non-drug approaches. We compared breathing retraining delivered
through ‘face-to-face’ physiotherapy sessions with both a self-guided programme [digital versatile disc
(DVD) plus booklet] of breathing retraining that could be carried out at home and usual care. Adults with
incompletely controlled asthma in primary care were randomised into one of these groups. They were
assessed before starting the intervention and at 3, 6 and 12 months afterwards for asthma quality of life
(QoL) and were also assessed with other questionnaire and physiological measures; in addition, qualitative
interviews were carried out to obtain the perspectives of patients and an economic evaluation was performed.
We recruited 655 volunteers from general practice surgeries. QoL significantly improved in both active
groups compared with usual care, with equivalent improvements between active groups. Patients reported
feeling that the exercises were helpful and acceptable, although some participants who received the DVD
would have appreciated talking to a physiotherapist. Lung function and inflammation were unaffected.
There were consistent improvement trends in the active arms for symptom scores, rescue medication use,
anxiety and depression and asthma attacks, but these improvements were not statistically significant and
so could have occurred through chance. Asthma-related costs were lower in both of the active groups.
People with asthma felt and functioned better following breathing retraining delivered by either a DVD or
a physiotherapist and programme costs were exceeded by savings from better asthma control, with the
DVD being most cost-effective. Patients still had asthma but coped with it better. These simple exercises
can be carried out at home and have the potential to improve asthma control and save money.
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Scientific summary
Background
Asthma affects > 5 million people in the UK, with costs in excess of £1B annually. Although pharmacotherapy
is effective and can provide full control for some, surveys repeatedly show that outcomes remain suboptimal,
with persisting symptoms and quality of life (QoL) impairment for the majority. Symptoms attributed to
dysfunctional breathing overlap with those of asthma and have been reported to be more frequent in
people with asthma, providing a rationale for using breathing retraining to improve asthma control.
Randomised controlled trials (RCTs) have reported beneficial outcomes from breathing retraining in asthma,
particularly from physiotherapist-administered breathing exercises, which are now advocated in guidelines
as adjuvant treatment for those who remain uncontrolled on pharmacological treatment. Previous research
from members of this study group provided evidence supporting this recommendation, with two positive
RCTs supporting physiotherapist-delivered breathing retraining. However, the cost-effectiveness of this
intervention was not addressed and resource constraints mean that the majority of people with asthma
who could benefit are not able to access a suitably trained respiratory physiotherapist. Two preliminary
studies have investigated the use of breathing retraining delivered by videotape or digital versatile disc
(DVD), with some evidence of effectiveness. Such self-guided programmes have the potential to be
accessed easily, conveniently and inexpensively by large numbers of people. No studies have compared the
clinical effectiveness and cost-effectiveness of a self-guided programme with those of face-to-face
breathing retraining interventions.
We hypothesised that breathing retraining exercises taught as a self-guided programme would improve
asthma-related QoL above ‘usual care’ and would be equivalent to ‘face-to-face’ physiotherapist instruction.
Objectives
l To use an iterative patient-focused approach to transfer the contents of a three-session physiotherapist-
delivered breathing retraining programme, previously shown to improve asthma control, to a
self-guided format that is acceptable to patients.
l To perform a RCT in adults with impaired asthma control, comparing the effectiveness of breathing
retraining delivered by the self-guided programme with the effectiveness of a face-to-face breathing
retraining programme delivered by a respiratory physiotherapist and with usual care, for asthma-related
QoL and other asthma control measures.
l To perform quantitative and qualitative process evaluations.
l To perform a health economic assessment using data collected from the trial and from general practice
clinical records.
Methods
Trial design
We carried out a pragmatic, observer-blinded, three-arm, parallel-group RCT comparing a breathing
retraining programme delivered in DVD format with a breathing retraining programme delivered face-to-face
by a physiotherapist and with a control of usual care for adults with asthma and impaired health status.
Participants
In total, 655 adult patients with diagnosed and currently treated asthma were recruited from 34 primary
UK NHS general practices in the Wessex region.
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Inclusion criteria
l Full practice registration for 12 months prior to enrolment.
l Age 16–70 years.
l Physician-diagnosed asthma in medical records.
l One or more anti-asthma medication prescriptions in the previous year.
l Impaired asthma-related health status [Asthma Quality of Life Questionnaire (AQLQ) score of < 5.5].
l Able to give informed consent.
Exclusion criteria
l Asthma dangerously unstable and in need of urgent medical review at baseline.
l Concomitant chronic obstructive pulmonary disease if forced expiratory volume in 1 second (FEV1)
is < 60% predicted.
Broad entry criteria were pragmatically used (with the inclusion of smokers and not insisting on
physiological demonstration of reversible airflow obstruction) to allow the generalisability of the research
findings to mild-to-moderate UK asthma populations treated in primary care NHS practice.
Outcome measures
Primary outcome
The primary outcome was the between-group [intention-to-treat (ITT)] 12-month asthma-specific health
status (AQLQ score), adjusted for prespecified covariates.
Secondary outcomes
l Prespecified sensitivity analyses on the main outcome [unadjusted analysis of between-group ITT AQLQ
score changes, per-protocol (PP) between-group AQLQ score changes, sensitivity analysis including
patients without full AQLQ data].
l Analysis of the between-group ITT and PP changes in:
¢ Asthma Control Questionnaire (ACQ) scores
¢ lung function [FEV1, FEV1-to-forced volume vital capacity (FVC) ratio, peak expiratory flow rate (PEFR)]
¢ fraction of exhaled nitric oxide (FeNO)
¢ generic health status [EuroQol-5 Dimensions (EQ-5D)]
¢ anxiety and depression scores [Hospital Anxiety and Depression Scale (HADS)]
¢ hyperventilation (Nijmegen) questionnaire scores
¢ asthma exacerbations (oral corticosteroid courses)
¢ bronchodilator use
¢ asthma-related health resource use
¢ cost-effectiveness/utility
¢ patient-reported process evaluations (qualitative assessments and questionnaires)
¢ patient engagement in breathing retraining programmes.
Study procedures
Development phase
We transferred an existing ‘face-to-face’ programme of breathing retraining taught by physiotherapists to
patients with dysfunctional breathing to a self-guided programme format delivered through a DVD with
printed supportive materials, and undertook qualitative piloting of these materials to optimise acceptability and
effectiveness. Patient educational materials were developed by a team including physicians, physiotherapists,
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health psychologists, communications technology specialists and patient representatives. The DVD and
accompanying booklet were created iteratively with extensive patient input. The DVD content included:
l detailed explanations and illustrations of how to carry out the exercises, with footage showing a
physiotherapist teaching the exercises to patients
l motivational components explaining the rationale for the exercises and addressing common doubts
and concerns.
The materials were piloted with a panel of 29 members of the target population, purposively sampled
for diversity in terms of age, sex, education and symptom profile. In audio-recorded face-to-face and
telephone interviews we used open-ended questions to explore attitudes to the proposed treatment
method in the context of health beliefs and then used ‘think-aloud’ methods to elicit reactions to the
proposed materials, with modification of the scripts based on this feedback. Professional production of the
DVD and booklet were undertaken and the materials were reviewed by the panel, who provided final
feedback in face-to-face and telephone interviews.
Randomised controlled trial
Potentially eligible patients were identified by computer searches of general practice clinical and prescribing
records. These patients were mailed the study information and an invitation letter, and were asked to
complete the AQLQ and return it by post. Those with an AQLQ score of < 5.5 were recruited. Patients
were seen at their general practice by a research nurse for a baseline assessment, consenting and
randomisation. The baseline assessment consisted of assessment of clinical data (smoking status, asthma
history, comorbidities, medication use), questionnaire data [disease-specific health status (AQLQ), Nijmegen
hyperventilation questionnaire, ACQ, generic health status (EQ-5D), anxiety and depression (HADS)] and
physiological data [spirometry (FEV1, FEV1-to-FVC ratio, PEFR), measured with a standardised calibrated
portable spirometer; FeNO, measured with a NIOX MINO® portable monitor (Circassia Ltd, Oxford, UK)].
Randomisation was achieved by the study nurse telephoning the Southampton Clinical Trials Unit (SCTU)
telephone randomisation service. Follow-up appointments were also arranged.
All consenting participants received postal questionnaires at 3 and 6 months and a final assessment visit at
12 months post randomisation. Those randomised to usual care received no other additional attention.
Those randomised to the DVD were also provided with the booklet. Those randomised to face-to-face
physiotherapy received three sessions (30–40 minutes each) with a respiratory physiotherapist at their
general practice, at 2-weekly intervals following randomisation, and also received the instructional booklet.
The final 12-month assessment was performed by a different study nurse blinded to randomisation group.
The assessment consisted of the same clinical, questionnaire and physiological measurements performed at
baseline, plus a short questionnaire exploring participants’ perceptions and experiences of being in the trial
and adherence and collection of routine clinical data.
A group of participants in the active arms selected by purposive sampling underwent qualitative interviews
to assess their experiences of the interventions, until data saturation was achieved.
Statistical methods
The primary statistical analysis consisted of a repeated-measures mixed model using the 12-month AQLQ
score across the three arms with adjustments for prespecified covariates [baseline AQLQ score, general
practice, age, sex, smoking status, British Thoracic Society (BTS) treatment step, baseline HADS score and
baseline Nijmegen questionnaire score], with pairwise comparisons between the DVD group and the
control group, the physiotherapy group and the control group (superiority study) and the DVD group and
the physiotherapy group (equivalence study, equivalence margin 0.3).
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Results
Recruitment, retention and missing data
The recruitment target of 585 was increased to 655 by the Data Monitoring and Ethics Committee as
an early unblinded analysis suggested a slightly higher dropout rate in the DVD arm. We successfully
randomised 655 patients from 34 primary care sites. A total of 15,203 invitation letters were mailed,
with 1481 responses received (response rate 9.7%). In total, 680 (45.9%) respondents were ineligible
and 655 (81.8% of eligible respondents) were randomised, 261 (39.8%) to the DVD group, 262 (40.0%)
to the control (usual care) group and 132 (20.2%) to the physiotherapy group. All 655 randomised
participants were included in the ITT population. The PP population included 556 participants (DVD,
n = 215; physiotherapy, n = 110; control, n = 231; 84.9% of the randomised population). A very low
proportion of data were missing for all other questionnaires (< 2%). Spirometry data (FEV1, FEV1-to-FVC
ratio) were missing for 4% of participants and FeNO values were missing for 7.5% of participants; missing
data values were similar between treatment arms. Only 21 patients withdrew (3.2%), with similar rates of
withdrawal between arms. The AQLQ was returned at 12 months by 556 participants and at one or more
follow-up points by all 655 participants.
Primary outcome
In the primary efficacy analysis, the between-group comparison of 12-month AQLQ scores in the ITT
population adjusted for prespecified covariates, we observed a statistically significant improvement in mean
AQLQ score in the DVD arm compared with the control arm [adjusted mean difference 0.28, 95% confidence
interval (CI) 0.11 to 0.44] and in the physiotherapy arm compared with the control arm (adjusted mean
difference 0.24, 95% CI 0.04 to 0.44), confirming the superiority of both active arms over usual care.
The adjusted mean difference between the DVD arm and the physiotherapy arm was 0.04 (95% CI –0.16
to 0.24), confirming equivalence of the active arms. In subdomain analysis, the largest improvements in
the active arms compared with usual care were in the emotions domain (DVD vs. control: adjusted mean
difference 0.38, 95% CI 0.16 to 0.60; physiotherapy vs. control: adjusted mean difference 0.43, 95% CI
0.16 to 0.71); significant improvements were also seen for symptoms, activities and environment in the
DVD arm compared with usual care and for symptoms for the physiotherapy arm compared with usual
care, with no significant differences between the active arms. The statistically significant differences were
largely unchanged in the sensitivity analyses, with minor changes in magnitude. Analysis of the 3-month
and 6-month AQLQ changes showed improvements in both active arms compared with the control arm
by the first assessment, which were maintained or increased over 12 months. In the DVD arm, the
improvements in mean total AQLQ score from baseline in the ITT population were 0.9 at 3 months, 1.0 at
6 months and 1.1 at 12 months; in the physiotherapy arm the equivalent figures were 1.0, 1.1 and 1.1
respectively. In the control arm, improvements in mean total AQLQ score from baseline were 0.6, 0.6 and
0.8 respectively.
An analysis in the ITT population of individual patient data using a cut-off point of 0.5 to define a clinically
important change showed that 62% of participants in the DVD group improved over 12 months, compared
with 64% in the physiotherapy group and 56% in the control group. The figures for deterioration were
5%, 4% and 8% respectively. The proportions improving in the PP population were slightly higher. A
number needed to treat (NNT) analysis showed a NNT of eight for the DVD group compared with usual
care, seven for the physiotherapy arm compared with usual care and 41 for the physiotherapy arm compared
with the DVD arm.
Secondary outcomes
Physiology
There were no significant changes in lung function within or between treatment arms. Median (interquartile
range) FeNO changes between baseline and 12 months were minor [DVD: from 21 parts per billion (p.p.b.)
(14–35 p.p.b.) to 20 p.p.b. (13–33 p.p.b.); physiotherapy: from 23 p.p.b. (15–33 p.p.b.) to 21 p.p.b.
(13–32 p.p.b.); control: from 23 p.p.b. (14–34 p.p.b.) to 20 p.p.b. (13–34 p.p.b.)], with no statistically
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significant between-group differences when adjusted for covariates. These data indicate that breathing
retraining by either modality did not significantly affect airway physiology or inflammation and so did not
affect the pathophysiology of asthma.
Questionnaires
We found no significant between-group changes in asthma symptom control (ACQ), anxiety scores or
hyperventilation symptom scores in either the ITT population or the PP population, although there
were modest within-group changes from baseline in all within-group analyses and consistent trends
favouring the intervention groups above the control group. There was a small but statistically significant
improvement in depression scores in the DVD group compared with the control group.
Asthma attacks
Only 12% of the ITT population had one or more asthma attack over the 12-month period. The proportion
of patients in the three randomisation groups (DVD, physiotherapy, control) having one or more asthma
attack was 9%, 11% and 15% respectively. There was no statistically significant difference in exacerbation
rate between the DVD group and the physiotherapy group (p = 0.6) or between the physiotherapy group
and the control group (p = 0.4). The DVD group showed a marginal statistically significant reduction in
exacerbations compared with the control group (p = 0.06). In a negative binomial regression model, the
adjusted risk ratio for DVD compared with the control was 0.68 (95% CI 0.39 to 1.20) and for physiotherapy
compared with the control was 0.85 (95% CI 0.43 to 1.67).
Short-acting bronchodilator use
A between-group analysis of rescue medication use in the 12 months post randomisation showed trends
for lower bronchodilator use in the DVD group compared with the control group [incidence rate ratio (IRR)
0.83, 95% CI 0.68 to 1.03] and in the physiotherapy group compared with the control group (IRR 0.81,
95% CI 0.63 to 1.04).
Patient engagement and experience
In total, 95% of participants attended at least one of the three face-to-face physiotherapy sessions and
93% attended all three. Patient experience of the different intervention components was favourable,
with most devoting time to practising techniques, the main hindrance being finding time to practise.
Engagement was also good in the DVD group, although with lower engagement scores and practice
times than in the physiotherapy group. Qualitative analysis revealed that both interventions were valued,
although some in the DVD arm would have liked to be able to receive instruction from a practitioner.
Adverse events
The adverse event profile was as expected in the recruited population, with fewer events in the active arms
than in the control group. There was no indication of treatment-related adverse effects from either the
DVD programme or the physiotherapy programme, with both appearing to be well tolerated.
Economic evaluation
Costs were lower in both active treatment arms than in the control group, with the increased intervention
costs offset by reductions in total costs, indicating a dominant health economic strategy favouring the
DVD intervention. The quality-adjusted life-year changes were in the same direction as the primary
outcome but were smaller. The DVD programme dominated the physiotherapy programme, having
equivalent outcomes at a lower cost.
Conclusions
Using a rigorous patient-focused iterative development process, we produced a self-guided version of a
face-to-face physiotherapy-based breathing retraining programme to improve QoL in people with asthma
and performed a pragmatic RCT in primary care asthma patients to test the clinical effectiveness and
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cost-effectiveness and patient acceptability of the programme. We showed that the self-guided intervention
is superior to usual care and equivalent to face-to-face physiotherapy in improving asthma-related QoL in
this patient group, and constitutes a dominant economic strategy. However, lung function and airway
inflammation were not significantly affected, with the intervention helping people to cope better and suffer
less despite not modifying the underlying pathophysiology of asthma. The exacerbation risk was one-third
lower in the DVD group than in the usual-care group, but the study was underpowered to provide statistical
significance for this outcome.
In conclusion, this intervention is potentially of benefit to large numbers of asthma patients and may save
the NHS money.
Recommendations for future research
Larger studies to investigate a possible effect of the intervention on exacerbations, implementation studies
and extensions to paediatric populations are needed.
Trial registration
This trial is registered as ISRCTN88318003.
Funding
Funding for this study was primarily provided by the Health Technology Assessment programme of the
National Institute for Health Research, with additional financial support received from Comprehensive Local
Research Networks.
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Chapter 1 Introduction
Asthma affects > 5 million people in the UK and costs the NHS in excess of £1B. Althoughpharmacotherapy is effective and can provide full control for some patients,1 surveys repeatedly show
that outcomes remain suboptimal. A recent European survey showed that fewer than half of adults with
asthma achieved good symptom control2 and that quality of life (QoL) is affected for most, with consequent
costs to the community both directly from health service use and indirectly from lost productivity. Many
patients have concerns about taking regular medication, particularly inhaled corticosteroids. Surveys of
complementary and alternative medicines in asthma show high levels of use, with up to 79% of adults and
78% of children reporting trying different treatments, include breathing modification.3 Breathing techniques
are among the most commonly used complementary techniques, with up to 30% reporting having used
them to control their symptoms.4 The James Lind Alliance and the patient organisation Asthma UK have
both identified breathing exercises for asthma as a priority area for research.5 Asthma encompasses a variety
of phenotypes and different therapeutic approaches may be effective in different patients.6 Symptoms
attributed to dysfunctional breathing have been reported to be more frequent in people with asthma than
in the general population.7,8 A number of controlled studies have investigated breathing modification
techniques and have reported beneficial outcomes. Breathing control techniques investigated have included
the Butekyo breathing method9–13 and yogic breathing.14–16 Recent studies have shown clinically important
effectiveness of physiotherapist-administered breathing exercises for people with asthma in the UK.17–19 The
evidence base for the effectiveness of breathing therapies for treating asthma has been assessed in several
reviews. A recent systematic review of the effectiveness of physiotherapist-taught breathing retraining was
carried out as part of a review of physiotherapy interventions in the treatment of respiratory diseases in
adults.20 This was a collaborative multidisciplinary review undertaken by the British Thoracic Society (BTS)
and the Association of Chartered Physiotherapists in Respiratory Care (ACPRC), the respiratory clinical
interest group of the Chartered Society of Physiotherapy (CSP). Its purpose was to critically appraise the
evidence for respiratory physiotherapy techniques in respiratory diseases and it used an explicit evidence-
based methodology. This consisted of an initial literature search, conducted by the Centre for Research and
Dissemination (CRD), York, UK. Papers and abstracts identified were appraised and graded by two trained
assessors using Scottish Intercollegiate Guidelines Network (SIGN) methodology, with recourse to a third
assessor in the event of disagreements. The review found that ‘Breathing exercises, incorporating reducing
respiratory rate and/or tidal volume and relaxation training, should be offered to patients to help control the
symptoms of asthma and improve QoL (Grade A)’. In the latest iterations of both the BTS/SIGN UK national
asthma guideline21 and the World Health Organization (WHO)-endorsed Global Initiative for Asthma (GINA)
guideline,22 breathing exercises are endorsed as adjuvant treatment for people with inadequately controlled
asthma despite standard pharmacological treatment. Previous research from members of this study group
has provided evidence supporting this recommendation. A prior Cochrane review of breathing exercises for
asthma was performed in 2004,23 before several large studies informing the BTS review had reported. This
review stated that, because of the diversity of breathing exercises and outcomes used, it was impossible at
that time to draw conclusions from the available evidence. The review stated that trends for improvements
were noted in a number of outcomes and that large-scale studies were warranted to clarify the effectiveness
of breathing exercises in the management of asthma. Subsequently, Slader et al.3 reported a double-blind
randomised controlled trial (RCT) of breathing techniques in asthma and concluded that breathing
techniques may be useful in patients with mild asthma who use a reliever inhaler frequently. This Australian
study investigated the effects of two different breathing retraining programmes taught by physiotherapists
and delivered as videotaped instruction programmes that the participants completed at home, without
face-to-face supervision. Both programmes were associated with improved health status and major
reductions in bronchodilator use compared with baseline values.
These instructional interventions have subsequently been made available as internet downloads and
have been used in Australia to improve asthma control in routine clinical practice. This study provided
provisional evidence that breathing retraining programmes delivered in a self-guided audio-visual format
are feasible and may potentially produce beneficial outcomes in asthma. A 2007 UK primary care-based
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1
RCT18 demonstrated that breathing retraining taught by a physiotherapist in face-to-face sessions
significantly reduced respiratory symptoms and improved health-related QoL compared with usual care.
The population studied consisted of community-treated asthmatics with mild and moderate disease.
The contents of the breathing retraining programme in this study were very similar to those in our study,
but only face-to-face instruction was investigated and no economic analysis was carried out. A Canadian
RCT published in 200813 added further support for breathing retraining in asthma, also finding significant
reductions in asthma symptoms. In this study, a breathing retraining intervention delivered by physiotherapists
in a face-to-face setting was compared with the Butekyo breathing method (also taught in face-to-face
sessions by a therapist). Large magnitude but similar improvements in health status and symptoms from
baseline levels were seen in both treatment arms.
A further RCT published in 2009 investigated the effects of a physiotherapist-delivered breathing retraining
intervention, with similar content to that included in the face-to-face arm of our trial.17 This study controlled
for the non-specific ‘placebo-like’ effect of professional contact and sympathetic attention by giving
the control group the same amount of professional contact time (with an experienced respiratory nurse
providing asthma education). Significant improvements from baseline were seen in patient-reported asthma
outcomes for both treatment arms after 1 month, with trends favouring the breathing retraining group;
at 6 months a large and significant difference between treatment arms was found in favour of breathing
retraining. Significant improvements were seen between treatment arms in asthma-related QoL, anxiety and
depression and Nijmegen questionnaire scores (measuring hyperventilation-related symptoms) and a trend
was seen for an improvement in symptomatic asthma control. No effect on airway inflammation or
physiology was found. No economic evaluation was carried out.
The addition of these subsequent trials to those in the Cochrane review23 as part of the BTS review20 led the
authors to conclude that the evidence supporting breathing retraining for people with asthma was of 1++
strength. However, no recommendation on the most clinically effective or cost-effective way of providing
breathing retraining was made. Most of the studies contributing to the evidence base involved face-to-face
interventions and it is here that the evidence is strongest. Only two preliminary studies have investigated the
use of instructional interventions delivered by videotape or DVD,9,14 with some evidence that this modality
may also be effective. To our knowledge, no previous studies have compared a DVD breathing retraining
intervention with a face-to-face breathing retraining intervention. In our study we aimed to assess the
effectiveness of the intervention not only in comparison with usual care or a placebo but also in comparison
with an intervention of known benefit. The logistic and economic implications of making this intervention
available to all who could potentially benefit in the UK through a face-to-face physiotherapy programme are
considerable. We felt that if comparable effectiveness could be shown for a self-guided breathing retraining
programme, this is likely to provide a more efficient, convenient and cost-effective service to patients. The
available evidence prior to this study suggested that a programme of breathing retraining consisting of three
or more face-to-face sessions delivered by a specialist respiratory physiotherapist was effective in improving
patient-reported end points, particularly health status (the outcome measure that most accurately captures
patient experiences and QoL impairment) and psychological well-being, for people with asthma, and may be
effective in reducing rescue bronchodilator medication usage. There were suggestions that similar beneficial
effects may be achieved through the use of self-guided interventions instead of face-to-face instruction.
However, the relative clinical effectiveness and cost-effectiveness of different approaches to breathing
retraining have not been adequately assessed. If similar benefits could be demonstrated without face-to-face
contact with a health-care professional, the health resource implications of providing breathing retraining
would be improved and this intervention could realistically be made available to the many people with
asthma who could potentially benefit from it. Therefore, we proposed to transfer the key components of the
physiotherapist-delivered programme that we (and others) have shown to be effective into a self-guided
format (delivered in this study through a DVD, but able to be delivered through internet-based technologies)
and to compare the effects of this intervention with those of face-to-face sessions with a physiotherapist and
with usual care. Our study included a full health economic evaluation, as previous research has focused on
the clinical effectiveness, rather than the cost-effectiveness, of breathing retraining. We also included
qualitative research to capture patient perspectives on the interventions and a full process evaluation.
INTRODUCTION
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Chapter 2 Methods
Trial design
The BREATHE (Breathing REtraining for Asthma – Trial of Home Exercises) trial was a pragmatic,
observer-blinded, three-arm, parallel-group RCT comparing breathing retraining delivered using a DVD with
face-to-face physiotherapy and with usual care (control) for adults with asthma and impaired health status.
Participants
We recruited 655 adult patients with a diagnosis of asthma and impaired asthma-related health status from
34 primary care sites (UK NHS general practices) in the Wessex region. Patients were recruited between
November 2012 and January 2015, with follow-up ending in February 2016. Practices were recruited and
supported by the UK Clinical Research Network (CRN), who also supported patient recruitment and follow-up.
Inclusion criteria
Inclusion criteria
l Full practice registration for 12 months prior to enrolment.
l Age 16–70 years.
l Physician-diagnosed asthma in medical records.
l One or more anti-asthma medication prescriptions in the previous year (determined from physician
prescribing records).
l Impaired asthma-related health status [Asthma Quality of Life Questionnaire (AQLQ)24 score of < 5.5].
l Able to give informed consent.
Exclusion criteria
Exclusion criteria
l Asthma judged at the baseline assessment to be dangerously unstable and in need of urgent medical
review (if these participants were referred back to their usual primary care clinician for review).
l Patients with an additional documented diagnosis of chronic obstructive pulmonary disease (COPD)
with a forced expiratory volume in 1 second (FEV1) of < 60% predicted.
We aimed to allow broad entry criteria (with the inclusion of smokers and not insisting on physiological
demonstration of reversible airflow obstruction) to allow the generalisability of the research findings to
mild-to-moderate UK asthma populations treated in primary care NHS practice.
Interventions
Development of the self-guided intervention
The development process for the self-guided intervention is described in detail in Chapter 5.
Briefly, in phase 1 of the study, the development phase, we transferred an existing face-to-face programme
of breathing retraining taught by physiotherapists to patients with dysfunctional breathing, and previously
shown to be effective for people with poorly controlled asthma, to audio-visual media (trialled in DVD
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format in this study), and developed printed supportive materials and undertook qualitative piloting of these
materials to optimise their acceptability and effectiveness.
Patient educational materials were developed by members of the team including physicians, physiotherapists,
health psychologists, communications technology specialists and patient representatives. The DVD and
accompanying booklet were created iteratively, with extensive qualitative patient input. The DVD content
consisted of:
l a detailed explanation and illustration of how to carry out the exercises
l motivational components explaining the rationale for the exercises and addressing common doubts
and concerns.
The materials were piloted with a panel of 29 members of the target population, purposively sampled
for diversity in terms of age, sex, education and symptom profile. In audio-recorded face-to-face and
telephone interviews we used open-ended questions to explore attitudes to the proposed treatment
method in the context of health beliefs and then used ‘think-aloud’ methods12 to elicit spontaneous
reactions to all of the proposed materials. We modified the scripts based on this feedback. Professional
production of the DVD and booklet were undertaken and the materials were reviewed by members of our
panel, who provided final feedback in face-to-face and telephone interviews.
Face-to-face physiotherapy
Participants randomised to the face-to-face physiotherapy arm were treated by a single, very experienced
respiratory physiotherapist over three sessions, based on the face-to-face breathing retraining interventions
studied in previous research and on the standard Papworth breathing retraining programme widely taught
by physiotherapists in the UK and globally.17–19 The content of the programme was very similar to that in
the DVD arm of the study. The patient support booklet produced in the development phase to support the
DVD-based breathing retraining, as described in the previous section, was also provided to patients in this
arm of the study. The details and fidelity assessment of the physiotherapy intervention are described in
more detail in Chapter 5.
Control group
Patients randomly assigned to the control arm (usual care) received no additional treatment or care.
They underwent the same baseline and 12-month assessments and completed the 3- and 6-month postal
questionnaires. Control participants were informed that they would subsequently be offered the DVD
intervention if it was shown to be effective in the study, to encourage participation and retention.
Randomised controlled trial processes
We performed a parallel-group, three-arm RCT over a 12-month period to assess the effect of the DVD
programme compared with usual care and face-to-face physiotherapist-led training with a similar content
on the following parameters: asthma-related health status, parameters of symptomatic and physiological
asthma control and asthma-related health resource use. Consenting participants were randomly assigned
to (1) receipt of the DVD intervention plus supporting written material, (2) three sessions of face-to-face
physiotherapy breathing instruction, consisting of an initial ‘small-group’ (up to five patients) session of
approximately 45 minutes and two subsequent individual sessions of up to 45 minutes or (3) usual care,
which included recruitment and follow-up assessments but no additional intervention or care.
Identification, recruitment and randomisation of participants
Potentially eligible patients in the participating practices were identified by searches of the practice
computerised clinical record and prescribing systems. The searches were facilitated by the CRN, based on
the inclusion criteria described earlier. Potentially eligible participants were sent information about the
study, an AQLQ questionnaire to complete and return if interested in participating and a stamped return
envelope. Contact telephone numbers were provided for patients who wished to discuss the study.
METHODS
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Those returning information and interested in participating in the study and who met the inclusion criteria
were seen by one of the study research nurses [from the CRN Primary Care Research Network (PCRN)
team] at their own general practice during a prearranged appointment. Patients who met the inclusion
criteria at the research nurse review and who still wanted to participate provided written informed
consent, had baseline measurements taken and were randomly allocated to one of the three study arms
following a telephone call to the randomisation service of the Southampton Clinical Trials Unit (SCTU).
Follow-up and intervention arrangements were made according to participant convenience and availability.
All participants were informed that they would receive postal questionnaires to complete and return at 3
and 6 months, and would be invited for a further research nurse appointment at 12 months. Usual care
for their asthma was otherwise allowed to continue.
DVD arm
Participants allocated to the DVD arm received a copy of the self-guided programme in DVD format and
the printed support booklet. To cover the possibility of lack of access to a DVD player we were able to
provide an inexpensive DVD player for participant use; however, none of the participants allocated to the
DVD arm required this.
Physiotherapy arm
Those allocated to the face-to-face physiotherapy arm consented to be contacted by the physiotherapist
delivering the intervention by telephone within the following week to arrange the first session. This took
place at their general practice at a mutually convenient time. Subsequent sessions were arranged during
the first session.
Usual-care arm
Participants in the control arm received no additional information or care during the study beyond their
usual care.
Postal questionnaire
The AQLQ questionnaires were posted to all participants at 3 and 6 months after baseline along with a
prepaid return envelope. A single reminder telephone call was made after 4 weeks.
Final visit
All participants were invited to a final study visit with a blinded research nurse (a different research nurse
from the research nurse who carried out the baseline assessments) at their usual general practice 12 months
after baseline. All baseline physiological and questionnaire measurements were repeated. Process evaluation
questionnaires were completed and information on personal costs was collected. Participants who did not
attend were sent a reminder and, if they were unwilling or unable to attend for a face-to-face visit but were
willing to answer questions over the telephone, the AQLQ was completed to allow maximum collection of
the primary efficacy outcome.
Health resource use
Health resource use information was extracted from medical records for all participants following the
12-month assessment. This included all respiratory-related medical encounters (primary and secondary care),
investigations relating to asthma and respiratory-related prescribing.
Outcomes
Prespecified outcome measures were between-group and within-group changes from baseline to the end
of the study (12 months). The statistical analysis plan (SAP) is provided below (see Statistical analysis plan).
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The primary outcome was the between-group [intention-to-treat (ITT) population] change in asthma-specific
health status [AQLQ (short version)] score, adjusted for potential confounders.
Secondary outcome measures were between-group (ITT population) change in Asthma Control Questionnaire
(ACQ)25 score, lung function [FEV1, forced volume vital capacity (FVC), FEV1-to-FVC ratio, peak expiratory
flow rate (PEFR)], fraction of exhaled nitric oxide (FeNO), health status [EuroQol-5 Dimensions (EQ-5D)26],
anxiety and depression [Hospital Anxiety and Depression Scale (HADS)27], hyperventilation (Nijmegen)
questionnaire28 score, oral corticosteroid courses for asthma exacerbations and bronchodilator use.
Sensitivity analyses included analyses of the primary and secondary outcomes in both the ITT and
per-protocol (PP) populations. We also performed a prespecified sensitivity analysis including participants
with missing baseline or outcome data for the primary efficacy parameter, the AQLQ, as described below
and in the SAP. In addition, health economic and process evaluation analyses were carried out and are
presented in Chapters 4 and 6 respectively.
Sample size
For equivalence of the DVD-delivered and face-to-face programmes
In a previous Health Technology Assessment (HTA) study,29 treatments were deemed to be equivalent if
the 95% confidence interval (CI) for the mean difference in AQLQ score between treatment arms was
wholly included between –0.3 and +0.3. The BREATHE sample size calculation for equivalence used the
same equivalence boundary (i.e. between –0.3 and +0.3). However, we assumed that the standard
deviation (SD) of the between-group difference in AQLQ score would be a conservative 25% smaller
(i.e. SD 0.77) than that reported in a previous study (SD 1.03).18 The justification for this was that the
proposed equivalence analysis compared two breathing retraining interventions as opposed to a breathing
intervention compared with usual care, as in the GLAD study. As this was an equivalence study, as
opposed to a non-inferiority study, a two-tailed 5% significance level was used in the calculations.
Sample sizes of 210 in the DVD breathing retraining group and 105 in the face-to-face physiotherapy
group were required to assess treatment equivalence with 90% power using an equivalence boundary for
AQLQ score of 0.3. This assumed that the expected between-group difference in mean AQLQ score was
zero; a two-tailed 5% significance level; a common SD for the AQLQ score of 0.77; and a lower/upper
limit of –0.3/+0.3 for the 95% CI of the between-group difference in AQLQ score.
In the unlikely event that the between-group AQLQ score SD was higher than our estimated 0.77,
assuming that all other parameters stayed the same, we would still have 80% power to declare
equivalence between the DVD breathing retraining group and the face-to-face physiotherapy group as
long as the between-group SD was no higher than 0.89.
For superiority of both the DVD-delivered and the face-to-face programme over
usual care
For the superiority sample size calculations, there was no widely acceptable minimal clinically important
difference (MCID) for between-group change in AQLQ score, although the MCID for within-person change
in AQLQ score was reported to be 0.5 (SD 0.41).24 Therefore, two approaches were used for the superiority
sample size calculation: (1) using the published within-person MCID of 0.5 and (2) using the estimate from
the previous study18 – a between-group mean (SD) difference in AQLQ score at 6 months of 0.38 (1.03).
Although the original sample size calculations for the superiority study were carried out using a one-sided
5% significance level, subsequent open discussions between the trial team and the Data Monitoring and
Ethics Committee (DMEC) and the Trial Management Group (TMG) resulted in a protocol change and the
METHODS
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decision to use a two-sided 5% significance level. The following superiority study sample size calculations
have been updated to reflect this change:
1. Using a MID of 0.5. A two-group t-test with a two-sided 5% significance level will have 90% power to
detect a difference in mean AQLQ score of ≥ 0.5, assuming that the common SD is 0.41, when the
sample sizes are 12 in the face-to-face breathing retraining group and 24 in the usual-care group.
Similarly, a two-group t-test with a two-sided 5% significance level will have 90% power to detect a
difference in mean AQLQ score of ≥ 0.5, assuming that the common SD is 0.41, when the sample size
is 16 in both the DVD-delivered breathing retraining group and the usual-care group.
2. Using a MID of 0.38. A two-group t-test with a two-sided 5% significance level will have 90% power
to detect a difference in mean AQLQ score of ≥ 0.38, assuming that the common SD is 1.03, when the
sample sizes are 117 in the face-to-face breathing retraining group and 234 in the usual-care group.
Similarly, a two group t-test with a two-sided 5% significance level will have 90% power to detect a
difference in mean AQLQ score of ≥ 0.38, assuming that the common SD is 1.03, when the sample size
is 156 in both the DVD-delivered breathing retraining group and the usual-care group.
Final sample size
Assuming a 10% dropout rate and a two-sided 5% significance level for each of the equivalence and
superiority studies, we therefore aimed to recruit a total sample size of 650 patients (260 each in the DVD
and usual-care arms and 130 in the face-to-face physiotherapy arm).
Changes to the original protocol
There were two significant amendments to the original protocol developed in 2012. There was concern
from the DMEC that the attrition rate may be higher than the 10% initially anticipated. The protocol was
subsequently amended to allow recruitment to be extended to ensure that the original target of 525
complete data sets was reached.
The second noteworthy amendment was to the hypothesis tests of the statistical analysis. The decision was
made to change the trial’s superiority sample size calculations from a one-sided 5% analysis to a two-sided
5% analysis. The trial was adequately powered for either option but, after extensive discussions with
the funder, sponsor, Trial Steering Committee (TSC), TMG and DMEC, it was agreed that the use of a
two-sided sample size calculation would be optimum.
Statistical analysis plan
Statistical analysis plan objective
The objective of this SAP is to describe the quantitative statistical analyses to be carried out for the equivalence
and superiority studies within BREATHE. This SAP is based on protocol version 7 (25 November 2015).
General principles
Categorical variables will be described with number and percentage in each category. Continuous variables
will be described with mean and SD or median and interquartile range (IQR) depending on their distribution.
The number of missing data will be provided for each variable.
Software
All analyses will be carried out using Stata® version 14 (StataCorp LP, College Station, TX, USA) or SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA). Data will be stored on a secure drive, with limited access to
those who need it.
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Study populations
All primary efficacy analyses are carried out on the ITT population. Safety analyses are carried out on the
safety population.
Intention-to-treat population
All participants who were randomised and for whom at least one follow-up observation of the primary
outcome (AQLQ score) is available. Participants will be analysed in the treatment arm to which they
were randomised.
Per-protocol population
All participants of the ITT population excluding participants who were not compliant with their randomised
study arm. Non-compliance is defined as those not having any primary outcome data and/or those not
attending at least two physiotherapy appointments in the physiotherapy arm.
Effectiveness outcomes
Primary outcome
The primary outcome measure will be the 12-month post-intervention AQLQ score.
Secondary outcomes
Clinical
l ACQ score.
l Lung function (FEV1, FEV1-to-FVC ratio, PEFR).
l FeNO.
l Health status (EQ-5D).
l Anxiety and depression scores (HADS questionnaire).
l Hyperventilation (Nijmegen) questionnaire.
l Oral corticosteroid courses.
l Bronchodilator use.
l Smoking status.
l Process evaluations.
l Patient-reported process evaluations (qualitative).
Engagement
l Estimates of engagement with use of physiotherapy exercises in the physiotherapy arm.
l Estimates of engagement with the breathing retraining.
Economic
l Quality-adjusted life-years (QALYs).
l Asthma-related health resource use.
l Cost-effectiveness/utility.
Safety outcomes
l Serious adverse events.
l Non-serious adverse events.
l Suspected unexpected serious adverse reactions.
METHODS
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Analysis
General principles
For the equivalence study, the adjusted repeated-measures mixed-model ITT analysis will be deemed the
primary analysis with an adjusted repeated-measures mixed-model per-protocol analysis as a sensitivity
analysis. For the superiority study, in accordance with Consolidated Standards of Reporting Trials (CONSORT)
guidelines, all comparative analysis will be conducted on an ITT repeated-measures mixed-model basis with
a per-protocol repeated-measures mixed-model analysis performed as a sensitivity analysis. All analyses will
be governed by this comprehensive SAP which will be agreed by the TSC and approved by the independent
DMEC prior to any analyses being undertaken. There will be no formal interim analyses undertaken. Unless
prespecified, a 5% two-sided significance level will be used to denote statistical significance throughout. As
we specify a clear sequence of tests with a priori effect sizes to inform treatment selection, no adjustments
will be made for multiple testing.
Data description
All variables will be described for each treatment group separately and for all participants together. This
will be the number and percentage within each category for binary and categorical variables. Continuous
variables will be described using the mean and SD (if normally distributed) or median (IQR) if skewed.
Missing data
A CONSORT flow diagram will provide the detail of the flow of trial participants, withdrawals and
post-randomisation exclusions.
Missing baseline data
As this is collected at clinic by the research nurse it is anticipated that missing baseline data will be minimal
(< 10%). Missing baseline data will be reported in the form of the number and percentage [n (%)] by variable
and by randomised group. If a baseline variable has more than 10% missing data, we will use the missing
indicator method recommended by White and Thompson.30 This method is deemed a good approach
irrespective of whether any missing baseline data does or does not predict the outcome. For missing baseline
AQLQ scores, the method specified in Juniper et al.24 was adopted. Values for each domain were calculated
provided at least two-thirds of the items were scored; otherwise the domain value was set to missing. If any
domain score was missing the overall AQLQ score was set to missing.
(a) Missing primary outcome data. The repeated-measures mixed-model approach will account for missing
data as long as at least one assessment of outcome is available. Compared to analysis of covariance
(ANCOVA), a mixed-model approach is thought to give a more precise estimate of treatment effect at
the final time point. Participants who do not provide any primary outcome follow-up data will therefore
be excluded from the analysis. However, a prespecified sensitivity analysis will be carried out to include
all randomised participants using the strategy reported by White et al.31 This involves substituting the
missing baseline AQLQ score by the specific trial arm mean and for missing 12-month AQLQ scores
the method of last observation carried forward (LOCF) will be applied. If 12-month value is missing, the
6-month AQLQ score will be used to replace. If both 12-month and 6 month are missing, the 3-month
AQLQ score will be used to replace the 12-month score. If all 3-month, 6-month and 12-month are
missing, i.e. no follow-up information is available, then it will be assumed that the patient returned to
their baseline AQLQ value.
(b) Missing secondary outcome data. The number of baseline missing data per secondary outcome will be
reported per randomised group and overall. Secondary outcomes analysed by repeated-measures
mixed-effects models will assume missing at random. If this assumption is thought to be violated,
we will consider alternative modelling strategies such as pattern mixture models.
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Analysis of the primary outcome
Equivalence study
A 95% CI will be constructed for the mean difference in 12-month total AQLQ score between the DVD arm
and the ‘face-to-face’ breathing retraining arm. Since the equivalence boundary is set at 0.3, equivalence
will be declared if the 95% Cl is wholly included between –0.3 and +0.3. If equality is not evident, then a
repeated-measures mixed-model will be used to examine whether the ‘face-to-face’ breathing retraining
arm is superior to the DVD arm via examination of the difference (and 95% CI) of 12-month total AQLQ
score (and each of the four domain scores) before and after adjustment for baseline AQLQ score and a set
of prespecified variables. The prespecified variables are AQLQ score at baseline and the fixed effects of
treatment arm, time, arm by time interaction plus the random effects of general practice and the patient-
level covariates of age, sex, smoking status, BTS treatment step, baseline HADS score and baseline Nijmegen
score. Correlations between baseline variables will be explored for the overall population on unblinded data
and, if collinearity is evident, the most appropriate variables will be included in the final model. Models with
different covariance assumptions were compared by using the Akaike information criterion (AIC); changes
at 12 months between physiotherapy vs. usual care; DVD vs. usual care; DVD vs. physiotherapy were
estimated from these models. Results from the adjusted ITT repeated-measures mixed model are deemed
the primary analyses.
For participants that are lost to follow-up at some time during the 12-month follow-up their information
will be included in the statistical analysis up to the point that they are lost to follow-up. The mixed-effects
model assumes that data are missing at random and allows for unbalance or missing observations within
subject.
Superiority study
Baseline comparability between the three arms of the trial will be evaluated by examination of summary
statistics (the mean and SD or median and IQR for continuous variables, dependent on their distribution,
and the number and percentage for categorical variables). In accordance with CONSORT guidelines,
all comparative analysis will be conducted on an ITT basis with a per-protocol analysis performed as a
sensitivity analysis.
For the primary outcome, a repeated-measures mixed model will be used to examine the 12-month total
AQLQ score (and each of the four domain scores) across the three arms with adjustment for baseline
AQLQ score and a set of prespecified variables. The same model procedure used in the equivalence study
will be adapted here. Pairwise comparisons of AQLQ differences will be examined between the ‘usual-care’
arm and each of the DVD and ‘face-to-face’ breathing retraining arms via calculation of two sided 95% CIs.
If the CI includes +0.3 then superiority of either the DVD or ‘face-to-face’ breathing retraining arms over
usual care will be rejected.
Analysis of secondary outcomes
Equivalence study
A repeated-measures mixed model will be used to analyse the difference (and 95% CI) for the secondary
outcome measures (ACQ, EQ-5D, HADS score) at 12 months before and after adjustment for baseline
values and a set of prespecified variables. The list of prespecified variables is general practice (as a random
effect), age, sex, smoking status, BTS treatment step, baseline HADS score and baseline Nijmegen score.
For those secondary outcomes collected only at baseline and 12 months’ follow-up such as lung function,
FeNO, Nijmegen score, ANCOVA will be used to analyse 12-month group differences before and after
adjustment for baseline values and a set of aforementioned prespecified variables.
METHODS
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For those secondary outcomes that involve count data (i.e. oral corticosteroid courses, bronchodilator use,
asthma-related health-care resource use), Poisson regression analysis (or negative binomial regression on
failure of the assumptions of Poisson regression) with a log link function will be performed to give rate
ratios (and their 95% CIs) in the DVD and ‘face-to-face’ breathing retraining arm both before and after
adjustment for prespecified variables of general practice, age, sex, smoking status, BTS treatment step,
baseline HADS score and baseline Nijmegen score. The exact number of covariates that will be included in
the adjusted model will be dependent on the distribution of the secondary outcome and avoidance of loss
of power.
Superiority study
A repeated-measures mixed model will be used to analyse the continuous secondary outcome measures
[ACQ, EQ-5D and HADS score (both anxiety and depression scores)]. The ‘usual-care’ arm will be
compared with each of the DVD and ‘face-to-face’ breathing retraining arms in turn.
For those secondary outcomes collected only at baseline and 12 months’ follow-up, such as lung function,
FeNO and Nijmegen score, ANCOVA will be used to analyse 12-month group differences before and after
adjustment for baseline values and a set of aforementioned prespecified variables.
For those secondary outcomes that involve count data (i.e. oral corticosteroid courses, bronchodilator use,
asthma-related health-care resource use), Poisson regression (or negative binomial regression on failure of
the assumption of Poisson regression) with a log link function will be performed to give rate ratios (and
their 95% CIs) in the DVD and ‘face-to-face’ breathing retraining arm compared with ‘usual care’ both
before and after adjustment for list of prespecified variables such as general practice, age, sex, smoking
status, BTS treatment step, baseline HADS score and baseline Nijmegen score. The exact number of
covariates that will be included in the adjusted model will be dependent on the distribution of the
secondary outcome and avoidance of loss of power.
Engagement
The proportion (n) of participants who attended none, one, two and all three physiotherapy sessions in the
physiotherapy arm will be tabulated.
Primary and secondary efficacy (equivalence study) analyses relating to the AQLQ (and each of the four
domain scores) at 3 and 12 months will be repeated as a sensitivity analyses in two ways:
1. Engagement. Participants who did not engage with the breathing retraining at 3 months will be
excluded. Engagement will be included as a binary variable defined by any response above ‘never
started’ to any of the first three questions (number of weeks, days per week and times per day) in the
‘carrying out the breathing retraining’ block of treatment engagement questions at 3 months.
2. Amount of practice. Participants who did not engage with the breathing retraining at 3 months will be
excluded and a new covariate – the amount of practice undertaken – will be added to the models.
Amount of practice is a continuous variable which will be calculated by multiplying weights from each
of the three questions shown in Table 1.
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TABLE 1 Questionnaire used to quantify amount of practice
Question Response Score Example
Q1. For how many weeks did you carry
out the breathing retraining?
Never started 0 If a participant carried out breathing retraining
for 3–5 weeks, for 3–4 days at least twice a day,
this would be a score of 32 (4 × 4 × 2) for the
number of practice sessions completed
1 week 1
1–2 weeks 2
3–5 weeks 4
6–8 weeks 7
≥ 9 weeks 10
Q2. How many times a week, on average,
did you carry out the breathing retraining?
Never started 0
1–2 days 2
3–4 days 4
5–6 days 6
Most days 7
Q3. How many times a day, on average,
did you carry out the breathing retraining?
Never started 0
Once a day 1
At least twice
a day
2
Note
Incongruent responses across the three questions (e.g. if a participant gives a response of 1 week for Q1 and a response of
never started for Q2 and Q3) will be reviewed individually for coding. However, it is anticipated that responses will be
rounded up to the next lowest response (e.g. a response of 1 week for Q1 and a response of never started for Q2 and Q3
will be rounded up from 1 × 0 × 0 to be given a score of 1 × 2 × 1 = 2).
METHODS
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Chapter 3 Results
Recruitment
We recruited patients from 34 primary care sites in Wessex through the PCRN (subsumed during the study
into the CRN). We identified potential recruits to the study by searching general practice electronic medical
records for patients with a coded diagnosis for asthma, undergoing current treatment and meeting inclusion
criteria. Potential recruits were sent information about the study, the AQLQ (as impaired disease-specific
health status was an inclusion criteria to enable an improvement to be demonstrated) and a prepaid
return envelope.
A total of 15,203 invitation letters were mailed to potential participants and 1481 responses were
received (a response rate of 9.7%). In total, 680 (45.9%) respondents were deemed ineligible, with lack
of impairment according to AQLQ score being the most common reason for ineligibility; 655 participants
(81.8% of the eligible respondents) were randomised, 261 (39.8% of randomised participants) to the
DVD-delivered breathing retraining group, 262 (40.0%) to the usual-care group and 132 (20.2%) to
the physiotherapist breathing retraining group (Table 2). The numbers of patients randomised from the
different practices are shown in Appendix 1. The CONSORT diagram showing the flow of participants
through the trial is provided in Figure 1.
Because of errors in completion of the primary outcome (AQLQ) at baseline for 45 out of 655 participants
(7%), it was not possible to assign an AQLQ score to these patients. However, one or more AQLQ returns
was achieved for all randomised participants.
Baseline characteristics and demographics
Baseline demographic and clinical features of the participants in the study are shown in Table 3.
The demographic and clinical profiles of the recruited population were typical of adult patients with
mild-to-moderate asthma in the community and were similar between treatment arms. More women than
men consented to participate in the trial and the median age of participants was 57 years, with approximately
one-third of participants aged < 50 years. The median (IQR) age at diagnosis of asthma was 29 (11–45) years.
In total, 8% of participants were current smokers and 33% were ex-smokers. Approximately one-third of
participants had a family history of asthma. The most common self-reported asthma triggers were dust (77%),
pollen (64%), smoke (64%), exercise (63%), stress (46%), cats (41%), dogs (24%) and food (19%).
Participants had mildly impaired lung function, with a mean FEV1% predicted of 91% and a mean
FEV1-to-FVC ratio of 0.8. The median (IQR) FeNO, a measure of eosinophilic airway inflammation, was 22
(14–34) parts per billion, which is at the top end of the normal range; over one-quarter of participants had
a raised reading, indicative of persisting active inflammation despite inhaled steroid treatment. In terms of
the BTS treatment step, our patient sample was typical of adult asthma patients treated in the community,
TABLE 2 Numbers of patients randomised and in the ITT and PP populations, overall and by treatment arm
Population
Treatment arm, n
Overall, nDVD Physiotherapy Usual care
ITT 261 132 262 655
PP 215 110 231 556
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with 7% at step 1 (needing short-acting beta-agonists only), 27% at step 2, 42% at step 3 and 12% at
step 4 or 5. Self-reported atopic comorbidity was common (Table 4), with approximately two-thirds of
participants reporting allergic problems including allergic rhinitis (69%) and eczema (31%), with most
requiring pharmacological treatment. Over one-third of participants reported psychological problems
(anxiety and depression), again with most requiring medication. Diagnosed COPD was present in only 2%
of participants and had to be mild to meet entry criteria.
BREATHE CONSORT diagram
Total number of letters sent
(n = 15,203)
Total responses received and
screened
[n = 1481 (9.7%)]
11 April 2016
Not randomised
[n = 146 (18.2%)]
Group 1
DVD, n = 261 (39.8%)
Breathing retraining
Questionnaires sent, n = 651
Questionnaires expected back, n = 651
Questionnaires received, n = 495 (76.0%)
Questionnaires sent, n = 638
Questionnaires expected back, n = 638
Questionnaires received, n = 475 (74.5%)
Completed, n = 598
Visit, n = 444
Telephone/post, n = 154
Reasons for non-completion
•  Withdrawn, n = 14
•  Lost to follow-up, n = 36
•  Death, n = 3
•  Other, n = 4
Ineligible
•  Not meeting inclusion criteria, n = 577
•  Pre-randomisation withdrawal, n = 48
•  Unknown responses, n = 23
•  Pending responses, n = 27
•  Declined responses, n = 5
•  Total number ineligible, n = 680 (45.9%)
Analysed, n = 655
Excluded from analysis, n = 0
Group 2 
Standard care, n = 262 (40%)
Group 3
 Physiotherapy, n = 132 (20.2%)
Breathing retraining
•  Number of patients
    eligible, n = 801 (54.1%)
Randomised
[n = 655 (81.8%)]
Is the patient eligible?
Has the patient been
randomised?
Allocation
3-month postal follow-up
Final analysis
12-month assessment visit
6-month postal follow-up
YES NO
NO
YES
Eligible
FIGURE 1 Consolidated Standards of Reporting Trials diagram.
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TABLE 3 Baseline characteristics of participants by treatment arm
Characteristic
Treatment arm
Overall (N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
Sex, n (%)
Male 97 (37.2) 41 (31.1) 98 (37.4) 236 (36.0)
Female 164 (62.8) 91 (68.9) 164 (62.6) 419 (63.9)
Age (years), median (IQR) 56 (45–65) 55 (47–63) 57 (47–65) 57 (46–64)
Age group (years), n (%)
≤ 40 47 (18.0) 21 (15.9) 43 (16.4) 111 (16.9)
41–50 54 (20.7) 28 (21.2) 45 (17.2) 127 (19.4)
51–60 59 (22.6) 35 (26.5) 73 (27.9) 167 (25.5)
> 60 101 (38.7) 48 (36.4) 101 (38.5) 250 (38.2)
Weight (kg)
Number included 258 132 261 651
Mean (SD) 79.9 (17.6) 80.6 (20.2) 83.1 (18.1) 81.3 (18.4)
Height (cm)
Number included 258 132 261 651
Mean (SD) 167.1 (9.0) 165.7 (8.8) 166.1 (9.1) 166.4 (9.0)
Smoking status, n (%)
Current smoker 16 (6.1) 13 (9.8) 21 (8.0) 50 (7.6)
Ex-smoker 74 (28.4) 43 (32.6) 102 (38.9) 219 (33.4)
Never 169 (64.8) 76 (57.6) 139 (53.1) 384 (58.6)
What they currently smoke, n (%)
Cigarettes 10 (3.8) 8 (6.1) 15 (5.7) 33 (5.0)
Tobacco 6 (2.3) 5 (3.8) 7 (2.7) 18 (2.7)
Cigars 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.2)
Cigarettes/tobacco 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.2)
Tobacco/cigars 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.2)
What they used to smoke, n (%)
Cigarettes 69 (26.4) 40 (30.3) 96 (36.6) 205 (31.3)
Tobacco 6 (2.3) 4 (3.0) 8 (3.1) 18 (2.7)
Cigars 3 (1.1) 3 (2.3) 1 (0.4) 7 (1.1)
Cigarettes/tobacco 2 (0.8) 1 (0.8) 2 (0.8) 5 (0.8)
Tobacco/cigars 1 (0.4) 1 (0.8) 0 (0.0) 2 (0.3)
Cigarettes/cigars 2 (0.8) 2 (1.5) 1 (0.4) 5 (0.8)
Cigarettes/tobacco/cigars 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.2)
continued
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TABLE 3 Baseline characteristics of participants by treatment arm (continued )
Characteristic
Treatment arm
Overall (N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
Average number of cigarettes per day for ever smokers
Number included 78 47 111 236
Median (IQR) 20 (10–21) 15 (10–20) 15 (6–20) 15 (8–20)
Minimum, maximum 1, 80 3, 60 1, 100 1, 100
Pack-years of smoking among ever smokers
Number included 82 49 113 244
Median (IQR) 15 (5–30) 13 (3–27) 10 (3–23) 12 (3–25)
Minimum, maximum 0.05, 112.5 0.25, 159 0.05, 300 0.05, 300
Age diagnosed with asthma (years)
Number included 259 132 259 650
Median (IQR) 27 (12–45) 32 (14–45) 28 (8–46) 29 (11–45)
Family history of asthma, n (%)
Mother
Yes 35 (13.4) 28 (21.2) 43 (16.4) 106 (16.2)
No 220 (84.3) 99 (75.0) 212 (80.9) 531 (81.1)
Unknown 2 (0.8) 4 (3.0) 7 (2.7) 13 (2.0)
Father
Yes 31 (11.9) 17 (12.9) 26 (9.9) 74 (11.3)
No 218 (83.5) 108 (81.8) 219 (83.6) 545 (83.2)
Unknown 8 (3.1) 6 (4.6) 17 (6.5) 31 (4.7)
Siblings
Yes 67 (25.7) 35 (26.5) 61 (23.3) 163 (24.9)
No 180 (69.0) 84 (63.6) 176 (67.2) 440 (67.2)
n/a 7 (2.7) 13 (9.9) 23 (8.8) 43 (6.6)
Children
Yes 85 (32.6) 38 (28.8) 83 (31.7) 206 (31.5)
No 125 (47.9) 66 (50.0) 129 (49.2) 320 (48.9)
n/a 48 (18.4) 27 (20.5) 50 (19.1) 125 (19.1)
Other family members
Yes 87 (33.3) 50 (37.9) 94 (35.9) 231 (35.2)
No 159 (60.9) 76 (57.6) 159 (60.7) 394 (60.2)
Unknown 5 (1.9) 3 (2.3) 4 (1.5) 12 (1.8)
Asthma triggers, n (%)
Cats 119 (45.6) 60 (45.5) 109 (41.6) 288 (43.9)
Dogs 68 (26.1) 37 (28.0) 73 (27.9) 178 (27.2)
Dust 214 (81.9) 108 (81.8) 215 (82.1) 537 (81.9)
Exercise 185 (70.9) 100 (75.8) 191 (72.9) 476 (72.7)
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TABLE 3 Baseline characteristics of participants by treatment arm (continued )
Characteristic
Treatment arm
Overall (N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
Pollen 164 (62.8) 89 (67.4) 177 (67.6) 430 (65.7)
Smoke 186 (71.3) 97 (73.5) 174 (66.4) 457 (69.8)
Stress 133 (50.9) 67 (50.8) 133 (50.8) 333 (50.8)
Food 42 (16.1) 33 (25.0) 58 (22.1) 133 (20.3)
Other 211 (80.8) 92 (69.7) 198 (75.6) 501 (76.5)
FeNO (p.p.b.)
Number included 238 126 242 606
Median (IQR) 21 (14–35) 23 (15–23) 23 (14–34) 22 (14–34)
FEV1 (l)
Number included 246 130 253 629
Mean (SD) 2.6 (0.8) 2.5 (0.7) 2.6 (0.8) 2.6 (0.8)
FVC (l)
Number included 246 130 253 629
Mean (SD) 3.5 (0.9) 3.3 (0.9) 3.4 (0.9) 3.4 (0.9)
FEV1-to-FVC ratio
Number included 246 130 253 629
Mean (SD) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
FEV1% predicted
Number included 246 130 253 629
Mean (SD) 90.5 (18.8) 88.8 (18.1) 91.9 (21.6) 90.7 (19.8)
PEFR (l/second)
Number included 244 129 249 622
Mean (SD) 425.5 (115.8) 414.9 (110.0) 423.4 (120.7) 422.5 (116.5)
BTS treatment step,a n (%)
1 19 (7.3) 8 (6.1) 20 (7.6) 47 (7.2)
2 65 (24.9) 41 (31.1) 69 (26.3) 175 (26.7)
3 107 (41.0) 52 (39.4) 117 (44.7) 276 (42.1)
4 26 (10.0) 16 (12.1) 33 (12.6) 75 (11.5)
5 0 (0.0) 0 (0.0) 1 (0.4) 1 (0.2)
Unknown/unspecified 44 (16.9) 15 (11.4) 22 (8.4) 81 (12.4)
n/a, not applicable; p.p.b., parts per billion.
a The variable BTS treatment step is derived from a medical notes review at 12 months, not at baseline. To be able to
include BTS treatment step as a covariate in the adjusted analyses, a category of ‘unknown/unspecified’ was created to
account for all patients.
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Baseline questionnaire data (Table 5) showed moderate impairment in asthma-specific QoL, with a mean
(SD) AQLQ score of 4.3 (0.9), and also impaired symptomatic asthma control, with a mean (SD) ACQ score
of 1.5 (0.9). The baseline psychological assessment with the HADS questionnaire showed a median (IQR)
anxiety score of 6 (4–9) and depression score of 3 (1–5). A score of ≤ 7 on this tool is considered ‘normal’
and so > 255 patients had scores suggestive of significant anxiety, in keeping with population-based
survey data. Across the five domains of the EQ-5D generic QoL questionnaire, 42% of participants
reported problems with pain or discomfort, 31% with activities, 27% with anxiety or depression, 23%
with mobility and 5% with self-care.
In summary, we successfully recruited a population of primary care asthma patients with mild-to-moderate
asthma and with evidence of incomplete asthma control and QoL impairment, our target group. Their
demographic profile was similar between randomisation arms and appears to be typical of the demographic
and disease control profile of UK primary care adult asthma populations reported in recent surveys of
asthma control.
TABLE 4 Self-reported comorbidities and other regular medication use at baseline by treatment arm
Comorbidity
Treatment arm
Overall
(N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
Allergies
Yes, n (%) 179 (68.6) 81 (61.4) 177 (67.6) 437 (66.7)
If yes, on current medication, n 179 81 175 435
Unknown, n 4 2 3 9
Hay fever/rhinitis
Yes, n (%) 183 (70.1) 94 (71.2) 174 (66.4) 451 (68.9)
If yes, on current medication, n 183 94 173 450
Unknown, n 3 0 8 12
Eczema
Yes, n (%) 75 (28.7) 46 (34.8) 80 (30.5) 201 (30.7)
If yes, on current medication, n 75 46 78 199
Unknown, n 2 4 3 9
Heart disease
Yes, n (%) 19 (7.3) 13 (9.8) 22 (8.4) 54 (8.2)
If yes, on current medication, n 19 13 22 54
Unknown, n 2 1 3 6
Depression/anxiety
Yes, n (%) 92 (35.2) 50 (37.9) 91 (34.7) 233 (35.6)
If yes, on current medication, n 92 50 90 232
Unknown, n 1 0 1 2
Documented diagnosis of COPD
Yes, n (%) 2 (0.8) 2 (1.5) 11 (4.2) 15 (2.3)
No, n (%) 259 (99.2) 130 (98.5) 251 (95.8) 640 (97.7)
RESULTS
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TABLE 5 Baseline questionnaire assessments by treatment arm
Questionnaire
Treatment arm
Overall
(N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
Mini AQLQ
n 244 120 246 610
Mean (SD) score 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 4.3 (0.9)
Nijmegen questionnaire
n 259 132 262 653
Mean (SD) score 19.0 (8.8) 19.0 (10.5) 19.4 (9.4) 19.2 (9.4)
HADS
n 257 131 261 649
Anxiety, median (IQR) score 7.0 (4–8) 6.0 (4–9) 6.0 (4–9) 6.0 (4–9)
Depression, median (IQR) score 3.0 (1–5) 2.0 (1–5) 3.0 (1–5) 3.0 (1–5)
EQ-5D
Mobility
n 259 132 262 653
No problems, n (%) 202 (78.0) 97 (73.5) 203 (77.5) 502 (76.9)
Some problems, n (%) 57 (22.0) 35 (26.5) 59 (22.5) 151 (23.1)
Self-care
n 258 131 262 651
No problems, n (%) 251 (96.3) 120 (91.6) 246 (93.9) 617 (94.8)
Some problems, n (%) 7 (2.7) 11 (8.4) 16 (6.1) 34 (5.2)
Usual activities
n 259 132 262 653
No problems, n (%) 186 (71.8) 82 (62.1) 183 (69.8) 451 (69.1)
Some problems, n (%) 73 (28.2) 50 (37.9) 79 (30.2) 202 (30.9)
Pain/discomfort
n 259 131 261 651
No problems, n (%) 161 (62.2) 79 (60.3) 137 (52.5) 377 (57.9)
Some problems, n (%) 98 (37.8) 52 (39.7) 124 (47.5) 274 (42.1)
Anxiety/depression
n 259 132 262 653
No problems, n (%) 187 (72.2) 99 (75.0) 192 (73.3) 478 (73.0)
Some problems, n (%) 72 (27.8) 33 (25.0) 70 (26.7) 175 (27.0)
EQ-5D VAS
n 256 131 258 645
Median (IQR) 80 (69.3–88.8) 75 (60–85) 80 (68–89) 80 (67.5–88)
Mean (SD) 74.9 (16.8) 71.7 (19.5) 74.4 (16.9) 74.1 (17.4)
continued
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Missing data, withdrawals and study retention
Missing baseline data (see Appendix 2)
Because of errors in completion of the primary outcome questionnaire (AQLQ) at baseline for 45 out of
655 participants (7%), it was not possible to assign an AQLQ score to these patients. There was a very low
level of missing baseline data for the other questionnaires (< 2%).
Spirometry values (FEV1, FVC and FEV1-to-FVC ratio) were missing for 4% of participants, PEFR values for
5% and FeNO values for 7.5%, with similar proportions of missing data between randomisation arms.
Withdrawals
Only 21 of the 655 randomised patients withdrew from the study (3.2%), with similar withdrawal rates
between the DVD (5.4%), physiotherapy (2.3%) and control (2.3%) arms. The reasons for withdrawals are
provided in Appendix 3. The baseline characteristics of those who withdrew were similar to the baseline
characteristics of the randomised population (see Appendix 4).
Primary outcome measure: disease-specific health status measured using
the Asthma Quality of Life Questionnaire
The primary efficacy analysis was a comparison of between-group changes in AQLQ scores in the ITT
population, with adjustments for prespecified covariates. Secondary analyses included an unadjusted
comparison of between-group changes in AQLQ scores in the ITT population, adjusted and unadjusted
comparisons of between-group changes in AQLQ scores in the PP population and analyses of the subdomains
measured by the AQLQ instrument. Prespecified sensitivity analyses are also reported. We also assessed the
time course of changes in AQLQ score from 3-month and 6-month AQLQ postal questionnaire data.
Table 6 presents the baseline and 12-month mean (SD) AQLQ scores and the unadjusted mean changes in
AQLQ scores (with 95% CIs) in the DVD, physiotherapy and usual-care arms in the ITT and PP populations.
Table 7 presents the primary efficacy analysis, the adjusted mean difference in 12-month AQLQ scores in
the DVD, physiotherapy and usual-care treatment arms in the ITT and PP populations, with comparisons
between the DVD arm and the control arm and between the physiotherapy arm and the control arm
(superiority analysis) and between the DVD arm and the physiotherapy arm (equivalence analysis). The total
AQLQ score (the primary efficacy measure) and the scores on the four subdomains of the AQLQ (which
may be analysed and compared individually, measuring symptoms, activity, emotions and environment)
are presented. The time course of AQLQ score changes in the ITT and PP populations is shown in Table 8.
Within-group Asthma Quality of Life Questionnaire score changes
There was a large within-group change in mean AQLQ score of 1.1 from baseline to the 12-month
assessment in both breathing retraining arms. There was also a smaller improvement of 0.8 in the control
arm. The MCID in AQLQ score for an individual patient is 0.5 and a change of 1.0 equates to a large difference.
TABLE 5 Baseline questionnaire assessments by treatment arm (continued )
Questionnaire
Treatment arm
Overall
(N= 655)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
ACQ
n 258 132 262 652
Mean (SD) 1.5 (0.9) 1.6 (0.8) 1.5 (0.9) 1.5 (0.9)
RESULTS
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TABLE 6 Baseline to 12-month unadjusted changes in AQLQ scores in the DVD, physiotherapy and usual-care arms in the ITT and PP populations
AQLQ domain
Time point, mean (SD) score
Unadjusted mean difference (95% CI)Baseline 12 months
DVD Physiotherapy Usual care DVD Physiotherapy Usual care
Physiotherapy vs.
usual care DVD vs. usual care DVD vs. physiotherapy
ITT population
n 244 120 246 231 121 246
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.4 (1.1) 5.3 (1.1) 5.1 (1.2) 0.32 (0.08 to 0.56)** 0.27 (0.08 to 0.47)** –0.04 (–0.28 to 0.20)
Symptoms 4.2 (1.0) 4.0 (1.1) 4.2 (1.1) 5.2 (1.3) 5.2 (1.1) 4.9 (1.2) 0.41 (0.13 to 0.70)** 0.24 (0.01 to 0.47)* –0.17 (–0.45 to 0.11)
Activities 5.0 (1.4) 4.8 (1.5) 5.0 (1.3) 5.9 (1.3) 5.7 (1.4) 5.7 (1.3) 0.23 (–0.04 to 0.51) 0.23 (0.002 to 0.44)* –0.01 (–0.29 to 0.28)
Emotion 4.0 (1.3) 4.0 (1.4) 3.9 (1.4) 5.4 (1.5) 5.5 (1.3) 5.0 (1.6) 0.42 (0.08 to 0.75)* 0.36 (0.08 to 0.63)** –0.06 (–0.39 to 0.28)
Environment 4.0 (1.1) 3.8 (1.2) 3.9 (1.2) 5.1 (1.5) 5.0 (1.3) 4.8 (1.5) 0.28 (–0.02 to 0.57) 0.31 (0.05 to 0.56)* 0.03 (–0.27 to 0.33)
PP population
n 215 110 231 215 110 231
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.4 (1.2) 5.3 (1.1) 5.1 (1.2) 0.32 (0.08 to 0.55)** 0.28 (0.08 to 0.47)* –0.04 (–0.28 to 0.20)
Symptoms 4.2 (0.9) 4.0 (1.1) 4.2 (1.0) 5.2 (1.3) 5.1 (1.1) 4.9 (1.2) 0.39 (0.10 to 0.68)** 0.24 (0.01 to 0.47)* –0.16 (–0.44 to 0.13)
Activities 5.0 (1.4) 4.8 (1.4) 5.0 (1.3) 5.9 (1.3) 5.6 (1.4) 5.7 (1.3) 0.22 (–0.06 to 0.50) 0.22 (0.01 to 0.44) 0.01 (–0.28 to 0.28)
Emotion 4.0 (1.2) 4.0 (1.4) 4.0 (1.3) 5.4 (1.5) 5.5 (1.3) 5.0 (1.5) 0.43 (0.09 to 0.77)* 0.37 (0.09 to 0.65)** –0.06 (–0.40 to 0.28)
Environment 3.9 (1.1) 3.8 (1.2) 3.9 (1.2) 5.1 (1.5) 4.9 (1.4) 4.8 (1.5) 0.26 (–0.04 to 0.56) 0.31 (0.06 to 0.57)* 0.05 (–0.24 to 0.35)
*p < 0.05, **p< 0.001.
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Between-group Asthma Quality of Life Questionnaire score changes
In the primary efficacy analysis, the between-group comparison of AQLQ scores in the ITT population
adjusted for the prespecified covariates, we observed a statistically significant improvement in mean AQLQ
score of 0.28 (95% CI 0.11 to 0.44; p < 0.001) in the DVD arm compared with the control arm and of
0.24 (95% CI 0.04 to 0.44; p < 0.05) in the physiotherapy arm compared with the control arm, confirming
the superiority of the two active interventions over usual care. The adjusted mean difference between the
DVD arm and the physiotherapy arm was 0.04 (95% CI –0.16 to 0.24), which was not significantly
different; the 95% CI was within the prespecified equivalence margin, confirming the equivalence of the
two active interventions. Across the AQLQ subdomains, the largest improvements in AQLQ scores for the
active treatments compared with usual care were in the emotions subdomain (DVD vs. control: adjusted
mean difference 0.38, 95% CI 0.16 to 0.60; p < 0.001; physiotherapy vs. control: adjusted mean
difference 0.43, 95% CI 0.16 to 0.71; p < 0.001); significant improvements were also seen in the
symptoms, activities and environment domains in the DVD arm compared with the usual-care arm and in
the symptoms domain in the physiotherapy arm compared with the usual-care arm (with non-significant
numerical improvements in the physiotherapy arm compared with the usual-care arm for activities and
environment). There were no significant differences in subdomain scores between the DVD arm and the
physiotherapy arm.
The overall messages were unchanged in the PP population analyses, with superiority of both active
treatment arms over usual care and equivalence between the active arms, with the magnitude of the
improvements very similar to the magnitude of the improvements in the ITT population. Similarly, in the
unadjusted analyses in both the ITT and the PP populations, the overall messages were identical, with
superiority of both interventions over usual care and equivalence of the active interventions and only minor
differences in the magnitude of the differences between treatment arms.
Time course of Asthma Quality of Life Questionnaire score improvements
The improvements in AQLQ scores in both active arms compared with the control arm were observed at
the first post-intervention assessment at 3 months and were maintained or increased over the 12-month
study period. In the DVD arm, the improvement in mean total AQLQ score compared with baseline in the
ITT population was 0.9 at 3 months, 1.0 at 6 months and 1.1 at 12 months; the equivalent values in the
TABLE 7 Adjusted mean difference in 12-month AQLQ scores in the DVD, physiotherapy and usual-care treatment
arms in the ITT and PP populations
AQLQ
domain
ITT population PP population
Adjusted mean differencea (95% CI) Adjusted mean differencea (95% CI)
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Total 0.24
(0.04 to 0.44)*
0.28
(0.11 to 0.44)**
0.04
(–0.16 to 0.24)
0.22
(0.02 to 0.43)*
0.26
(0.10 to 0.43)**
0.04
(–0.17 to 0.25)
Symptoms 0.27
(0.04 to 0.49)*
0.24
(0.05 to 0.42)*
–0.03
(–0.26 to 0.20)
0.25
(0.02 to 0.49)*
0.21
(0.02 to 0.40)*
–0.04
(–0.27 to 0.19)
Activities 0.08
(–0.14 to 0.31)
0.21
(0.04 to 0.41)*
0.13
(–0.10 to 0.36)
0.08
(–0.15 to 0.30)
0.21
(0.02 to 0.39)*
0.13
(–0.10 to 0.36)
Emotion 0.43
(0.16 to 0.71)**
0.38
(0.16 to 0.60)**
–0.06
(–0.33 to 0.22)
0.41
(0.14 to 0.68)**
0.35
(0.13 to 0.58)**
–0.05
(–0.33 to 0.22)
Environment 0.19
(–0.06 to 0.44)
0.32
(0.11 to 0.53)**
0.13
(–0.12 to 0.39)
0.18
(–0.07 to 0.44)
0.32
(0.11 to 0.54)**
0.14
(–0.12 to 0.40)
*p< 0.05, **p< 0.001.
a Adjusted for prespecified list of covariates.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
22
TABLE 8 Mean AQLQ scores across all time points in the DVD, physiotherapy and usual-care arms in the ITT and PP populations
AQLQ domain
Time point, mean (SD) score
Baseline 3 months 6 months 12 months
DVD Physiotherapy
Usual
care DVD Physiotherapy
Usual
care DVD Physiotherapy
Usual
care DVD Physiotherapy
Usual
care
ITT population
n 244 120 246 171 105 226 163 101 217 231 121 241
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.1 (1.2) 5.2 (1.0) 4.9 (1.1) 5.3 (1.3) 5.3 (1.0) 4.9 (1.2) 5.4 (1.1) 5.3 (1.1) 5.1 (1.2)
Symptoms 4.2 (1.0) 4.0 (1.1) 4.2 (1.1) 5.1 (1.2) 5.1 (1.1) 4.7 (1.2) 5.2 (1.2) 5.3 (1.1) 4.7 (1.3) 5.2 (1.3) 5.2 (1.1) 4.9 (1.2)
Activities 5.0 (1.4) 4.8 (1.5) 5.0 (1.3) 5.7 (1.4) 5.6 (1.3) 5.5 (1.4) 5.7 (1.4) 5.7 (1.2) 5.4 (1.4) 5.9 (1.3) 5.7 (1.4) 5.7 (1.3)
Emotion 4.0 (1.3) 4.0 (1.4) 3.9 (1.4) 5.0 (1.4) 5.1 (1.4) 4.8 (1.6) 5.2 (1.4) 5.3 (1.4) 4.8 (1.5) 5.4 (1.5) 5.5 (1.3) 5.0 (1.6)
Environment 4.0 (1.1) 3.8 (1.2) 3.9 (1.2) 4.8 (1.4) 4.8 (1.4) 4.5 (1.3) 4.9 (1.4) 5.0 (1.2) 4.5 (1.4) 5.1 (1.5) 5.0 (1.3) 4.8 (1.5)
PP population
n 215 110 231 154 94 204 148 92 197 215 110 231
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.2 (1.1) 5.2 (1.0) 4.9 (1.1) 5.3 (1.2) 5.3 (1.0) 4.9 (1.2) 5.4 (1.2) 5.3 (1.0) 5.1 (1.2)
Symptoms 4.2 (0.9) 4.0 (1.1) 4.2 (1.0) 5.1 (1.2) 5.1 (1.1) 4.7 (1.2) 5.1 (1.2) 5.3 (1.1) 4.7 (1.3) 5.2 (1.3) 5.1 (1.1) 4.9 (1.2)
Activities 5.0 (1.4) 4.8 (1.4) 5.0 (1.3) 5.7 (1.3) 5.6 (1.2) 5.4 (1.3) 5.7 (1.4) 5.7 (1.2) 5.4 (1.4) 5.9 (1.3) 5.6 (1.4) 5.7 (1.3)
Emotion 4.0 (1.2) 4.0 (1.4) 3.9 (1.3) 5.0 (1.4) 5.2 (1.4) 4.7 (1.5) 5.2 (1.4) 5.4 (1.3) 4.8 (1.5) 5.4 (1.5) 5.5 (1.3) 5.0 (1.5)
Environment 3.9 (1.1) 3.8 (1.2) 3.9 (1.1) 4.8 (1.4) 4.8 (1.4) 4.5 (1.3) 4.9 (1.4) 5.0 (1.2) 4.5 (1.4) 5.1 (1.5) 4.9 (1.4) 4.8 (1.5)
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physiotherapy arm were 1.0, 1.1 and 1.1, respectively, and in the control arm were 0.6, 0.6 and 0.8
respectively. Similar patterns of change were seen in the PP population and for the subdomain scores in
both the ITT and the PP populations.
Number needed to treat to achieve a clinically important improvement in
the primary outcome measure, Asthma Quality of Life Questionnaire score
The number needed to treat (NNT) was calculated using the formula recommended by Guyatt et al.32
(Juniper and Guyatt produced the AQLQ24 and ACQ25 tools). This analysis is based on an individual patient
assessment of the proportions in each treatment arm showing a clinically significant improvement (≥ 0.5),
the proportions showing unchanged scores (–0.49 to 0.49) and the proportions with a clinically significant
deterioration (≤ –0.5) (see Appendix 5).
We found that, in the ITT population, 62% of participants in the DVD group reported a clinically significant
improvement compared with 64% in the physiotherapy group and 56% in the control group (Table 9).
The corresponding figures for deterioration were 5% in the DVD group, 4% in the physiotherapy group
and 9% in the control group. The proportions in the PP population were slightly higher (see Table 9), with
74% of the DVD group, 76% of the physiotherapy group and 62% of the control group showing an
improvement in QoL and 6% of the DVD group, 5% of the physiotherapy group and 10% of the control
group showing a deterioration in QoL.
In between-group comparisons, these figures equated to a NNT for one patient to have a clinically relevant
improvement in QoL in the ITT population of eight for the DVD arm compared with the usual-care arm
(Table 10), seven for the physiotherapy arm compared with the usual-care arm (Table 11) and 41 for the
physiotherapy arm compared with the DVD arm (Table 12). In the PP population the corresponding NNTs
were eight, seven and 56 (Tables 13–15).
TABLE 9 Proportions of participants by margin of change in AQLQ score from baseline to 12 months in the DVD,
physiotherapy and usual-care arms in the ITT and PP populations
Change in AQLQ score
Treatment arm, n (%)
Total, n (%)DVD Physiotherapy Usual care
ITT population
n 261 132 262 655
Improved 161 (61.7) 85 (64.4) 146 (55.7) 392 (59.8)
Stayed the same 47 (18.0) 24 (18.2) 71 (27.1) 142 (21.7)
Deteriorated 14 (5.4) 5 (3.8) 24 (9.2) 43 (6.6)
Could not be calculated 39 (14.9) 18 (13.6) 21 (8.0) 78 (11.9)
Total 261 (100.0) 132 (100.0) 262 (100.0) 655 (100.0)
PP population
n 215 110 231 556
Improved 159 (74.0) 83 (75.5) 142 (61.5) 384 (69.1)
Stayed the same 43 (20.0) 22 (20.0) 67 (29.0) 132 (23.7)
Deteriorated 13 (6.0) 5 (4.5) 22 (9.5) 40 (7.2)
Total 215 (100.0) 110 (100.0) 231 (100.0) 556 (100.0)
RESULTS
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TABLE 12 Between-group comparisons in the ITT population: physiotherapy vs. DVD
Physiotherapy
DVD
Improved (0.725) Stayed the same (0.212) Deteriorated (0.063)
Improved (0.746) 0.54 0.16 0.05
Stayed the same (0.211) 0.15 0.04 0.01
Deteriorated (0.044) 0.03 0.01 0.00
NNT for physiotherapy vs. DVDa 41.0
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
TABLE 10 Between-group comparisons in the ITT population: DVD vs. usual care
Usual care
DVD
Improved (0.725) Stayed the same (0.212) Deteriorated (0.063)
Improved (0.606) 0.44 0.13 0.04
Stayed the same (0.295) 0.21 0.06 0.02
Deteriorated (0.010) 0.07 0.02 0.01
NNT for DVD vs. usual carea 8.2
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
TABLE 11 Between-group comparisons in the ITT population: physiotherapy vs. usual care
Usual care
Physiotherapy
Improved (0.746) Stayed the same (0.211) Deteriorated (0.044)
Improved (0.606) 0.45 0.13 0.03
Stayed the same (0.295) 0.22 0.06 0.01
Deteriorated (0.010) 0.07 0.02 0.00
NNT for physiotherapy vs. usual carea 6.8
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
TABLE 13 Between-group comparisons in the PP population: DVD vs. usual care
Usual care
DVD
Improved (0.725) Stayed the same (0.212) Deteriorated (0.063)
Improved (0.614) 0.45 0.12 0.04
Stayed the same (0.290) 0.21 0.06 0.02
Deteriorated (0.010) 0.07 0.02 0.01
NNT for DVD vs. usual carea 7.92
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
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Prespecified sensitivity analysis on the primary outcome
As per the prespecified SAP, we carried out a sensitivity analysis on the primary outcome data, the change
in AQLQ scores between baseline and 12 months adjusted for the prespecified covariates. In this analysis
we included all randomised patients regardless of whether baseline or follow-up AQLQ data were present
and we used the following rules (based on recommendations from Juniper) to assign values to missing data:
1. For missing baseline AQLQ scores, the following rules were adopted. Values for each AQLQ subdomain
(symptoms, emotions, activities, environment) were calculated provided at least two-thirds of the items
were scored, otherwise the domain value was set to missing. If any domain score was missing, the
overall AQLQ score was set to missing and step 2 was followed.
2. Following step 1, any remaining missing baseline AQLQ scores were replaced by their cohort mean
(as specified in the SAP).
3. For missing 12-month AQLQ scores, the method of LOCF was applied. If the 12-month score was
missing, the 6-month score was used. If both the 12-month and 6-month scores were missing, the
3-month score was used to replace the 12-month score. If the 3-month, 6-month and 12-month scores
were missing, that is, no follow-up information was available, then it was assumed that the patient
returned to his or her baseline AQLQ score. Hence, the baseline and 12-month scores were the same.
Table 16 shows the baseline and 12-month unadjusted scores and the unadjusted mean differences in the
three treatment arms in the ITT and PP populations, and Table 17 shows the adjusted mean difference in
12-month AQLQ scores in the three treatment arms in the ITT and PP populations. This sensitivity analysis
provides a similar message to the primary analyses: we see that there are significant improvements in both
of the active arms (DVD and physiotherapy) above usual care in both the ITT and PP populations, although
predictably of slightly lower magnitude (as we assume ‘no change’ in cases with missing data) than in the
main analysis. We continue to show equivalence between the two active arms.
TABLE 15 Between-group comparisons in the PP population: physiotherapy vs. DVDa
Physiotherapy
DVD
Improved (0.725) Stayed the same (0.212) Deteriorated (0.063)
Improved (0.755) 0.56 0.15 0.05
Stayed the same (0.2) 0.15 0.04 0.01
Deteriorated (0.045) 0.03 0.01 0.00
NNT for physiotherapy vs. DVDa 55.52
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
TABLE 14 Between-group comparisons in the PP population: physiotherapy vs. usual carea
Usual care
Physiotherapy
Improved (0.755) Stayed the same (0.2) Deteriorated (0.045)
Improved (0.614) 0.46 0.12 0.03
Stayed the same (0.290) 0.22 0.06 0.01
Deteriorated (0.010) 0.07 0.02 0.00
NNT for physiotherapy vs. usual carea 6.86
a The NNT for one participant to benefit from breathing retraining is calculated by adding up the values for those who
improved, subtracting the values for those who deteriorated and dividing 1 by the result.
RESULTS
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TABLE 16 Baseline to 12 month unadjusted change in AQLQ scores in the DVD, physiotherapy and usual-care arms in the ITT populationa
AQLQ domain
Time point, mean (SD) score
Unadjusted mean difference (95% CI)Baseline 12 months
DVD Physiotherapy Usual care DVD Physiotherapy Usual care
Physiotherapy vs.
usual care DVD vs. usual care DVD vs. physiotherapy
ITT population
n 261 132 262 261 132 262
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.3 (1.1) 5.3 (1.1) 5.1 (1.2) 0.26 (0.05 to 0.48)* 0.17 (–0.01 to 0.35) –0.09 (–0.31 to 0.12)
Symptoms 4.2 (1.0) 4.1 (1.1) 4.2 (1.0) 5.1 (1.3) 5.1 (1.2) 4.9 (1.2) 0.37 (0.10 to 0.63)** 0.17 (–0.04 to 0.38) –0.19 (–0.45 to 0.06)
Activities 5.0 (1.3) 4.8 (1.4) 5.0 (1.3) 5.8 (1.4) 5.6 (1.4) 5.6 (1.4) 0.16 (–0.09 to 0.42) 0.11 (–0.09 to 0.32)* –0.05 (–0.30 to 0.20)
Emotion 4.0 (1.3) 4.1 (1.3) 4.0 (1.3) 5.2 (1.6) 5.4 (1.4) 5.0 (1.6) 0.31 (0.001 to 0.62)* 0.25 (–0.01 to 0.50) –0.06 (–0.37 to 0.24)
Environment 4.0 (1.1) 3.8 (1.2) 3.9 (1.1) 5.0 (1.5) 5.0 (1.4) 4.8 (1.5) 0.21 (–0.05 to 0.48) 0.13 (–0.10 to 0.37) –0.08 (–0.36 to 0.20)
PP population
n 261 123 262 261 123 262
Total 4.3 (0.9) 4.2 (0.9) 4.3 (0.9) 5.3 (1.2) 5.3 (1.1) 5.1 (1.2) 0.30 (0.08 to 0.52)* 0.17 (–0.01 to 0.35) –0.13 (–0.35 to 0.09)
Symptoms 4.2 (1.0) 4.0 (1.1) 4.2 (1.0) 5.1 (1.3) 5.1 (1.2) 4.9 (1.2) 0.40 (0.12 to 0.67)* 0.17 (–0.04 to 0.38) –0.22 (–0.49 to 0.04)
Activities 5.0 (1.3) 4.8 (1.4) 5.0 (1.3) 5.8 (1.4) 5.6 (1.4) 5.6 (1.4) 0.19 (–0.08 to 0.45) 0.11 (–0.09 to 0.32) –0.08 (–0.33 to 0.18)
Emotion 4.0 (1.3) 4.0 (1.3) 4.0 (1.3) 5.2 (1.6) 5.4 (1.4) 5.0 (1.6) 0.36 (0.04 to 0.68)* 0.25 (–0.01 to 0.50) –0.11 (–0.43 to 0.20)
Environment 4.0 (1.1) 3.8 (1.2) 3.9 (1.1) 5.0 (1.5) 5.0 (1.4) 4.8 (1.5) 0.27 (–0.005 to 0.53) 0.13 (–0.10 to 0.37) –0.13 (–0.42 to 0.15)
*p < 0.05, **p< 0.001.
a Using prespecified sensitivity analysis, as described in accompanying text.
D
O
I:10.3310/hta21530
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2017
VO
L.21
N
O
.53
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2017.
This
w
ork
w
as
produced
by
Thom
as
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professionaljournals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
27
Secondary outcome measures
Physiological measures
Physiological outcome measures studied related-to-lung function (FEV1, FEV1% predicted, FVC, FEV1/FVC
ratio, PEFR) and airway inflammation (FeNO). Measures were taken at baseline and 12 months. The primary
analysis (Table 18) assessed change in physiological parameters between baseline and 12 months in the ITT
population, adjusted for the prespecified covariates; secondary analyses assessed these parameters in the
unadjusted ITT population (Table 19) and the adjusted and unadjusted PP populations (see Tables 14 and 15).
TABLE 17 Adjusted mean difference in 12-month AQLQ scores in the DVD, physiotherapy and usual-care treatment
arms in the ITT and PP populationsa
AQLQ
domain
ITT population PP population
Adjusted mean differenceb (95% CI) Adjusted mean differenceb (95% CI)
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Total 0.21
(0.02 to 0.40)*
0.17
(0.02 to 0.33)*
–0.04
(–0.23 to 0.15)
0.25
(0.06 to 0.44)*
0.17
(0.01 to 0.33)*
–0.08
(–0.27 to 0.12)
Symptoms 0.26
(0.04 to 0.47)*
0.16
(–0.02 to 0.34)
–0.09
(–0.31 to 0.12)
0.29
(0.07 to 0.51)*
0.16
(–0.02 to 0.34)
–0.13
(–0.35 to 0.09)
Activities 0.06
(–0.14 to 0.27)
0.13
(–0.05 to 0.30)
0.06
(–0.15 to 0.27)
0.10
(–0.11 to 0.31)
0.12
(–0.05 to 0.30)
0.02
(–0.19 to 0.24)
Emotion 0.32
(0.06 to 0.58)*
0.23
(0.02 to 0.45)*
–0.09
(–0.34 to 0.17)
0.36
(0.10 to 0.62)*
0.23
(0.02 to 0.44)*
–0.13
(–0.39 to 0.14)
Environment 0.16
(–0.07 to 0.40)
0.18
(–0.02 to 0.38)
0.01
(–0.23 to 0.25)
–0.18
(–0.46 to 0.9)
0.22
(–0.03 to 0.46)
–0.04
(–0.29 to 0.21)
*p< 0.05.
a Using prespecified sensitivity analysis, as described in accompanying text.
b Adjusted for prespecified list of covariates.
TABLE 18 Adjusted change in physiological parameters at 12 months in the DVD, physiotherapy and usual-care
treatment arms in the ITT and PP populations
Parameters
ITT population PP population
Adjusted mean differencea (95% CI) Adjusted mean differencea (95% CI)
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
FEV1 (l) –0.04
(–0.11 to 0.04)
–0.001
(–0.07 to 0.07)
0.03
(–0.05 to 0.12)
0.02
(–0.06 to 0.11)
–0.01
(–0.08 to 0.07)
–0.03
(–0.12 to 0.06)
FVC (l) –0.04
(–0.16 to 0.08)
–0.03
(–0.14 to 0.07)
0.01
(–0.12 to 0.13)
0.03
(–0.09 to 0.16)
0.02
(–0.09 to 0.13)
–0.01
(–0.14 to 0.12)
FEV1-to-FVC
ratio
–0.01
(–0.02 to 0.01)
0.004
(–0.01 to 0.02)
0.01
(–0.01 to 0.03)
0.01
(–0.02 to 0.02)
–0.003
(–0.02 to 0.01)
–0.004
(–0.03 to 0.02)
FEV1%
predicted
0.44
(–3.23 to 4.12)
0.53
(–2.75 to 3.81)
0.09
(–3.81 to 3.99)
–1.49
(–5.33 to 2.36)
–0.98
(–4.35 to 2.39)
0.51
(–3.55 to 4.57)
PEFR
(l/second)
–4.79
(–22.35 to 12.77)
–1.99
(–17.83 to 13.85)
2.80
(–15.94 to 21.54)
3.19
(–15.41 to 21.80)
2.91
(–13.66 to 19.48)
–0.29
(–20.10 to 19.53)
FeNOb
(p.p.b.)
1.05
(0.95 to 1.23)
1.13
(0.98 to 1.29)
1.07
(0.91 to 1.25)
1.05
(0.89 to 1.23)
1.14
(0.98 to 1.31)
1.08
(0.92 to 1.28)
p.p.b., parts per billion.
a Adjusted for prespecified list of covariates.
b Geometric mean difference.
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TABLE 19 Unadjusted change in physiological parameters from baseline to 12 months in the DVD, physiotherapy and usual-care treatment arms in the ITT and PP populations
Parameters
Time point
Unadjusted mean difference (95% CI)Baseline 12 months
DVD Physiotherapy Usual care DVD Physiotherapy Usual care
Physiotherapy vs.
usual care DVD vs. usual care
DVD vs.
physiotherapy
ITT population
n 261 132 262 143 92 189
FEV1 (l), mean (SD) 2.6 (0.8) 2.5 (0.7) 2.6 (0.8) 2.6 (0.8) 2.4 (0.7) 2.5 (0.7) 0.01 (–0.06 to 0.09) –0.02 (–0.08 to 0.04) –0.03 (–0.09 to 0.02)
FVC (l), mean (SD) 3.5 (0.9) 3.3 (0.9) 3.4 (0.9) 3.6 (1.0) 3.2 (0.8) 3.4 (0.9) 0.01 (–0.11 to 0.13) –0.01 (–0.09 to 0.09) –0.01 (–0.10 to 0.09)
FEV1/FVC ratio, mean
(SD)
0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.7 (0.1) 0.8 (0.1) 0.003 (–0.02 to 0.02) –0.02 (–0.02 to 0.02) –0.005 (–0.02 to 0.01)
FEV1% predicted, mean
(SD)
90.5 (18.8) 88.8 (18.1) 91.9 (21.6) 90.5 (19.2) 89.5 (19.5) 91.9 (17.4) –2.05 (–5.78 to 1.68) –2.02 (–4.9 to 0.89) 0.03 (–2.89 to 2.96)
PEFR (l/second), mean
(SD)
425.5 (115.7) 414.9 (110.0) 423.4 (120.7) 422.7 (122.3) 400.1 (114.7) 415.1 (117.2) 4.49 (–11.15 to 20.13) 2.32 (–11.36 to 15.99) –2.17 (–15.54 to 11.19)
FeNO (p.p.b.), median
(IQR)
21 (14–35) 23 (15–33) 23 (14–34) 20 (13–33) 21 (13–32) 20 (13–31) Unadjusted median difference, p-value:
Z= –1.09, r= –0.07;a
p= 0.28
Z= –2.412, r= –0.14;a
p= 0.02
Z= –0.941, r= –0.06;a
p= 0.35
PP population
n 215 110 231 134 83 180
FEV1 (l), mean (SD) 2.6 (0.8) 2.4 (0.7) 2.6 (0.8) 2.6 (0.8) 2.4 (0.7) 2.5 (0.7) –0.003 (–0.08 to 0.08) –0.03 (–0.001 to 0.07) –0.02 (–0.08 to 0.03)
FVC (l), mean (SD) 3.5 (0.9) 3.2 (0.8) 3.4 (0.9) 3.5 (1.0) 3.3 (0.8) 3.4 (0.9) –0.004 (–0.13 to 0.13) –0.02 (–0.13 to 0.09) –0.01 (–0.1 to 0.09)
FEV1/FVC ratio, mean
(SD)
0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.7 (0.1) 0.8 (0.1) –0.0004 (–0.02 to 0.02) –0.001 (–0.02 to 0.02) –0.001 (–0.02 to 0.02)
FEV1% predicted, mean
(SD)
90.3 (19.3) 87.6 (17.9) 92.2 (21.8) 90.5 (16.6) 89.8 (18.9) 91.6 (17.3) –3.29 (–7.16 to 0.57) –2.39 (–5.45 to 0.66) 0.90 (–1.99 to 3.79)
PEFR (l/second), mean
(SD)
422.5 (118.8) 410.5 (108.1) 421.9 (120.4) 419.6 (121.4) 401.3 (110.2) 413.3 (118.0) 3.0 (–13.56 to 19.57) 3.3 (–11.05 to 17.71) 0.33 (–13.67 to 14.33)
FeNO (p.p.b.), median
(IQR)
21 (15–35) 22 (15–34) 22.5
(14–34.5)
19 (13–33) 21 (13–32) 20 (13–31) Unadjusted median difference, p-value:
Z= –0.85, r= –0.05;a
p= 0.40
Z= –2.12, r= –0.13;a
p= 0.03
Z= –0.91, r= –0.06;a
p= 0.36
p.p.b., parts per billion.
a Cohen’s effect size.
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In the primary analysis we observed no significant between-group changes in our measures of airway
physiology or inflammation, indicating that the interventions did not change obstruction or inflammation
in the airways and so were not disease modifying. The within-group changes from baseline to 12 months
were small and non-significant.
We observed no significant changes in the within-group mean scores (geometric mean for FeNO readings)
between baseline and 12 months for any of these parameters. In the unadjusted analyses there was a small
but statistically significant difference in the change in median FeNO score from baseline to 12 months in
the ITT population in the DVD group (from 21 to 20) compared with the control group (from 23 to 20;
p = 0.03), but this difference was not seen in the primary (i.e. adjusted for covariates) analysis. None of the
lung function parameters changed significantly from baseline in any of the treatment arms in the ITT and
PP populations.
These findings suggest that the improvements in QoL seen in our primary outcome measure (AQLQ score)
were not mediated by changes in the pathophysiology of asthma; this will be considered in Chapter 7.
Patient-reported outcome measures (questionnaires)
We included a number of validated questionnaires as secondary outcome measures: the ACQ (measuring
asthma symptoms), the Nijmegen questionnaire (measuring symptoms related to hyperventilation and
dysfunctional breathing) and the HADS, with separate domains measuring anxiety and depression. Our
main analysis was a comparison of the mean score changes between baseline and 12 months in the ITT
population between the study arms, with adjustments for prespecified covariates (Table 20). In secondary
analyses we compared mean score changes between baseline and 12 months in the PP population
between study arms, with adjustments for prespecified covariates (see Table 16) and unadjusted changes
in questionnaire scores in the ITT population and the PP population (Table 21).
We found no significant changes in asthma symptom control, anxiety scores or Nijmegen questionnaire
scores in the active intervention groups compared with the control group in either the ITT or the PP
population. We did observe a small magnitude but statistically significant improvement in depression
scores in the DVD treatment arm compared with the control arm, with a similar magnitude but statistically
non-significant difference in the physiotherapy arm compared with the control arm. However, the baseline
TABLE 20 Adjusted questionnaire scores at 12 months in the DVD, physiotherapy and usual-care treatment arms in
the ITT and PP populations
Questionnaire
ITT population PP population
Adjusted mean differencea (95% CI) Adjusted mean differencea (95% CI)
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
Physiotherapy
vs. usual care
DVD vs. usual
care
DVD vs.
physiotherapy
ACQ –0.06
(–0.23 to 0.13)
–0.09
(–0.25 to 0.06)
–0.04
(–0.23 to 0.15)
–0.04
(–0.22 to 0.15)
–0.05
(–0.21 to 0.11)
–0.01
(–0.20 to 0.19)
HADS
Anxiety –0.04
(–0.73 to 0.64)
–0.22
(–0.81 to 0.38)
–0.18
(–0.89 to 0.54)
0.03
(–0.71 to 0.75)
–0.16
(–0.79 to 0.47)
–0.17
(–0.94 to 0.58)
Depression –0.55
(–1.14 to 0.04)
–0.56
(–1.07 to –0.05)*
–0.01
(–0.63 to 0.60)
–0.58
(–1.19 to 0.04)
–0.56
(–1.10 to –0.03)*
0.02
(–0.62 to 0.66)
Nijmegen
questionnaire
1.28
(–0.55 to 3.12)
0.90
(–0.71 to 2.51)
–0.38
(–2.30 to 1.55)
1.41
(–0.50 to 3.32)
0.99
(–0.67 to 2.65)
–0.42
(–2.42 to 1.58)
*p< 0.05.
a Adjusted for prespecified list of covariates.
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TABLE 21 Unadjusted change in questionnaire scores from baseline to 12 months in the DVD, physiotherapy and usual-care treatment arms in the ITT and PP populations
Questionnaire
Time point
Unadjusted mean difference (95% CI)Baseline 12 months
DVD Physiotherapy
Usual
care DVD Physiotherapy
Usual
care
Physiotherapy vs.
usual care DVD vs. usual care
DVD vs.
physiotherapy
ITT population
n 260 132 262 159 96 194
ACQ, mean (SD) 1.5 (0.9) 1.6 (0.8) 1.5 (0.9) 1.2 (0.9) 1.3 (0.8) 1.2 (0.8) –0.15 (–0.3 to 0.04) –0.09 (–0.27 to 0.08) 0.06 (–0.13 to 0.26)
Nijmegen questionnaire,
mean (SD)
19.0 (8.8) 18.9 (10.5) 19.4 (9.4) 16.9 (9.4) 17.1 (9.8) 18.3 (9.3) 0.87 (–0.7 to 2.5) 0.8 (–0.5 to 2.2) –0.03 (–1.6 to 1.5)
HADS
Anxiety
Median (IQR) 7 (4–8) 6 (4–9) 6 (4–9) 5 (3–8) 6 (3–8) 6 (3–9) Unadjusted median difference, p-value:
Minimum, maximum 0, 19 0, 20 0, 20 0, 16 0, 18 0, 18.7 Z = –0.04, r = –0.0021;
p = 0.96
Z = –0.66, r = –0.041;
p = 0.5
Z = –0.50, r = –0.031;
p = 0.62
Depression
Median (IQR) 3 (1–5) 2 (1–5) 3 (1–5) 2 (1–5) 3 (1–4) 3 (1–5) Unadjusted median difference, p-value:
Minimum, maximum 0, 17 0, 17 0, 14 0, 13 0, 17 0, 16 Z = –1.92, r = –0.11;a
p = 0.6
Z= –2.94,* r= –0.161;a
p= 0.03
Z= –0.65, r= –0.041;a
p= 0.52
PP population
n 215 110 231 147 91 193
ACQ, mean (SD) 1.5 (0.8) 1.6 (0.8) 1.5 (0.9) 1.2 (0.9) 1.3 (0.8) 1.3 (0.8) 0.13 (–0.07 to 0.34) 0.05 (–0.13 to 0.24) –0.08 (–0.28 to 0.12)
Nijmegen questionnaire,
mean (SD)
18.6 (8.7) 18.7 (10.5) 19.6 (9.2) 16.8 (9.5) 17.1 (9.5) 18.7 (9.2) 0.96 (–0.74 to 2.66) 0.81 (–0.61 to 2.22) –0.15 (–1.77 to 1.47)
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TABLE 21 Unadjusted change in questionnaire scores from baseline to 12 months in the DVD, physiotherapy and usual-care treatment arms in the ITT and PP populations
(continued )
Questionnaire
Time point
Unadjusted mean difference (95% CI)Baseline 12 months
DVD Physiotherapy
Usual
care DVD Physiotherapy
Usual
care
Physiotherapy vs.
usual care DVD vs. usual care
DVD vs.
physiotherapy
HADS
Anxiety
Median (IQR) 6 (4–8) 6 (4–9) 6 (4–9) 5 (3–9) 6 (3–8) 6 (4–9) Unadjusted median difference, p-value:
Minimum, maximum 0, 19 0, 18 0, 18 0, 16 0, 18 0, 19 Z = –0.12, r = –0.01;a
p = 0.91
Z = –0.37, r = –0.02;a
p = 0.7
Z = –0.28, r = –0.02;a
p = 0.78
Depression
Median (IQR) 3 (1–5) 2 (1–5) 3 (1–4) 2 (1–5) 3 (1–5) 3 (1–6) Unadjusted median difference, p-value:
Minimum, maximum 0, 17 0, 17 0, 14 0, 13 0, 17 0, 16 Z = –2.07, r = –0.001;a
p = 0.04
Z = –2.7, r = –0.15;a
p = 0.01
Z = –0.23, r = –0.02;a
p = 0.82
*p< 0.05.
a Cohen’s effect size.
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depression scores were low and few participants met ‘caseness’ criteria for depression, with depression
scores being lower than anxiety scores in the study population. This suggests that depression was not a
significant factor in these patients and that the low magnitude changes in depression scores are unlikely to
explain the improvements in QoL observed in the active treatment arms. We did observe within-group
changes from baseline of 0.2–0.3 units in the mean ACQ score (with a change of 0.5 signifying a clinically
important change for an individual patient), indicating that there were modest improvements in the
asthma symptoms experienced in all treatment arms. Similarly, although there were improvements in
anxiety and Nijmegen questionnaire scores between baseline and 12 months in each group, there was no
significant between-group difference in these parameters, indicating that the active interventions did not
significantly improve anxiety or hyperventilation-related symptoms and that the mechanism responsible for
the improved disease-specific QoL scores in the active treatment groups was not related to improvements
in these factors.
Asthma exacerbations
Asthma exacerbations (attacks) were assessed [using the European Respiratory Society (ERS)/American
Thoracic Society (ATS) Task Force on asthma outcomes recommendations for defining an exacerbation33]
according to prescribed short courses of oral corticosteroids for worsening of asthma by the usual
physician, with data obtained from the manual and electronic reviews of the patient medical record at
12 months. In keeping with the mild asthma population recruited, only 12% of the ITT population (13% of
the PP population) had one or more asthma attack over the 12-month period (Table 22). The percentage of
patients in the ITT population randomisation treatment arms (DVD, physiotherapy, control) having one or
more asthma attack was 9%, 11% and 15%, respectively, and in the PP population was 10%, 12% and
16% respectively (Table 23). There was no statistically significant difference in the crude exacerbation rate
between the DVD arm and the physiotherapy arm (p = 0.6 in the ITT population, p = 0.8 in the PP population;
Table 24) or between the physiotherapy arm and the control arm (p = 0.4 for both populations; Table 25).
The DVD group narrowly failed to reach a statistically significant reduction in exacerbations compared with
the control group, with a p-value of 0.06 in the ITT population and 0.12 in the PP population) (Table 26).
A negative binomial regression model was constructed to assess the between-group differences in asthma
exacerbation frequency in the ITT (Tables 27–29 and Figure 2) and PP (Figure 3 and see Appendix 6)
populations, adjusting for differences in exacerbation frequency at baseline and for covariates (age, sex, BTS
treatment step and smoking status). In the adjusted analysis for the ITT population, the risk of exacerbations
TABLE 22 Oral corticosteroid courses at 12 months in the DVD, physiotherapy and usual-care treatment arms in the
ITT and PP populations
Oral
corticosteroid
courses
ITT population, n (%) PP population, n (%)
DVD
(N= 261)
Physiotherapy
(N= 132)
Usual
care
(N= 262)
Total
(N= 655)
DVD
(N= 215)
Physiotherapy
(N= 110)
Usual
care
(N= 231)
Total
(N= 556)
None 237
(90.8)
117
(88.6)
223
(85.1)
577
(88.1)
193
(89.8)
97
(88.2)
195
(84.4)
485
(87.2)
1 17
(6.5)
10
(7.6)
26
(9.9)
53
(8.1)
16
(7.4)
9
(8.2)
26
(11.3)
51
(9.2)
2 2
(0.8)
4
(3.0)
10
(3.8)
16
(2.4)
2
(0.9)
3
(2.7)
8
(3.5)
13
(2.3)
3 2
(0.8)
0
(0.0)
1
(0.4)
3
(0.5)
2
(0.9)
0
(0.0)
1
(0.4)
3
(0.5)
≥ 4 3
(1.1)
1
(0.8)
2
(0.8)
6
(0.9)
2
(0.9)
1
(0.9)
1
(0.4)
4
(0.7)
Total 261
(100.0)
132
(100.0)
262
(100.0)
655
(100.0)
215
(100.0)
110
(100.0)
231
(100.0)
556
(100.0)
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TABLE 23 Oral corticosteroid courses at 12 months in the DVD, physiotherapy and usual-care treatment arms in the
ITT and PP populations: one or more courses
Oral
corticosteroid
courses
ITT population, n (%) PP population, n (%)
DVD
(N= 261)
Physiotherapy
(N= 132)
Usual
care
(N= 262)
Total
(N= 655)
DVD
(N= 215)
Physiotherapy
(N= 110)
Usual
care
(N= 231)
Total
(N= 556)
None 237
(90.8)
117
(88.6)
223
(85.1)
577
(88.1)
193
(89.8)
97
(88.2)
195
(84.4)
485
(87.2)
≥ 1 24
(9.2)
15
(11.4)
39
(14.9)
78
(11.9)
22
(10.2)
13
(11.8)
36
(15.6)
71
(12.8)
Total 261
(100.0)
132
(100.0)
262
(100.0)
655
(100.0)
215
(100.0)
110
(100.0)
231
(100.0)
556
(100.0)
TABLE 24 Comparison of oral corticosteroid courses at 12 months in the ITT and PP populations: DVD vs. physiotherapy
treatment arms
Oral corticosteroid courses
ITT population, n PP population, n
DVD
(N= 261)
Physiotherapy
(N= 132) p-value
DVD
(N= 215)
Physiotherapy
(N= 110) p-value
None 237 117 0.62 193 97 0.81
≥ 1 24 15 22 13
Total 261 132 215 110
TABLE 25 Comparison of oral corticosteroid courses at 12 months in the ITT and PP populations: physiotherapy vs.
usual care
Oral corticosteroid courses
ITT population, n PP population, n
Physiotherapy
(N= 132)
Usual care
(N= 262) p-value
Physiotherapy
(N= 110)
Usual care
(N= 231) p-value
None 117 223 0.42 97 195 0.45
≥ 1 15 39 13 36
Total 132 262 110 231
TABLE 26 Comparison of oral corticosteroid courses at 12 months in the ITT and PP populations: DVD vs. usual care
Oral corticosteroid courses
ITT population, n PP population, n
DVD (N= 261)
Usual care
(N= 262) p-value DVD (N= 215)
Usual care
(N= 231) p-value
None 237 223 0.06 193 195 0.12
≥ 1 24 39 22 36
Total 261 132 215 231
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was lower in the DVD arm than in the usual-care arm [incidence rate ratio (IRR) 0.68), but the 95% CI
crossed the line of unity (95% CI 0.34 to 1.38) and so this finding was not statistically significant and could
have occurred through chance. The analysis of the physiotherapy arm compared with the usual-care arm
produced a similar result, with a (lower magnitude) non-significant reduction in the risk of an asthma attack
in the physiotherapy arm (IRR 0.85, 95% CI 0.36 to 1.98). There was also no significant difference in the
risk of an exacerbation in the DVD group compared with the physiotherapy group, but the DVD group was
favoured (IRR 0.81, 95% CI 0.33 to 1.99). The unadjusted negative binomial regression model produced
very similar results, as did the adjusted and unadjusted models in the PP population. Our study was not
powered to show an effect on exacerbations and, as the annual exacerbation rate is modest in patients
with mild and moderate asthma treated in the community, a larger sample would be needed to show a
statistically significant reduction in exacerbations. This will be considered further in Chapter 7.
TABLE 27 Group differences in asthma exacerbations in the 12 months post randomisation in the ITT population
Oral corticosteroid courses
Treatment arm, n
Total, nDVD Physiotherapy Usual care
0 237 117 223 577
1 17 10 26 53
2 2 4 10 16
3 2 0 1 3
4 2 1 1 4
6 1 0 0 1
10 0 0 1 1
Total 261 132 262 655
TABLE 28 Unadjusted analysis of the negative binomial regression for asthma exacerbations in the 12 months post
randomisation in the ITT population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 0.69 0.34 to 1.41 0.31
DVD vs. usual care 0.65 0.37 to 1.16 0.15
DVD vs. physiotherapy 0.94 0.45 to 1.96 0.87
TABLE 29 Adjusted analysis of the negative binomial regression for asthma exacerbations in the 12 months post
randomisation in the ITT population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 0.85 0.36 to 1.98 0.89
DVD vs. usual care 0.68 0.34 to 1.38 0.42
DVD vs. physiotherapy 0.81 0.33 to 1.99 0.84
a As there were only 78 cases with one or more oral corticosteroid courses, only the covariates age, sex, BTS treatment
step and smoking status were included in the model.
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FIGURE 2 Frequency of one or more exacerbations in the 12 months post randomisation by treatment arm in the
ITT population. OC, oral corticosteroid.
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FIGURE 3 Frequency of one or more exacerbations in the 12 months post randomisation by treatment arm in the
PP population. OC, oral corticosteroid.
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Bronchodilator use
In the 12 months following the baseline assessment, 177 of 261 (67.8%) participants randomised to the
DVD arm required one or more prescriptions for rescue bronchodilators compared with 104 of 132
(78.8%) in the physiotherapy arm and 206 of 262 (78.6%) in the control arm. The number of inhalers
prescribed over the 12 months post randomisation by treatment arm in the ITT population is shown in
Table 30 and the proportions of participants having each number of inhalers are shown graphically in
Figure 4. A negative binomial regression model was constructed for the ITT population to estimate the
difference in rescue bronchodilator use between arms. In the unadjusted analysis (Table 31) there was a
non-significant trend for lower bronchodilator use in the DVD arm compared with the usual-care arm
(IRR 0.83, 95% CI 0.68 to 1.03; p = 0.09) and for the DVD arm compared with the physiotherapy arm
(IRR 0.81, 95% CI 0.63 to 1.04; p = 0.10), with little difference between physiotherapy arm and the usual-care
arm (IRR 1.03, 95% CI 0.81 to 1.33; p = 0.80). In the regression model adjusted for covariates (age, sex, BTS
treatment step, baseline smoking status, baseline HADS scores and baseline Nijmegen questionnaire score;
TABLE 30 Distribution of rescue inhaler use in the 12 months post randomisation in the ITT population
Number of rescue inhalers
Treatment arm, n
Total, nDVD Physiotherapy Usual care
0 84 28 56 168
1 36 26 61 123
2 39 16 32 87
3 20 18 26 64
4 23 14 24 61
5 17 4 12 33
6 12 6 11 29
7 6 4 5 15
8 6 3 11 20
9 5 2 3 10
10 5 2 6 13
11 2 1 2 5
12 1 3 5 9
13 1 2 0 3
14 2 2 0 4
16 1 0 1 2
17 0 0 1 1
18 0 0 3 3
22 0 0 2 2
26 0 0 1 1
28 1 0 0 1
40 0 1 0 1
Total 261 132 262 655
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Table 32), a similar pattern was seen, with the adjusted IRR being 0.91 (95% CI 0.72 to 1.15; p= 0.61) for the
DVD arm compared with the control arm, 0.88 (95% CI 0.66 to 1.15; p= 0.50) for the DVD arm compared
with the physiotherapy arm and 1.03 (95% CI 0.79 to 1.37; p= 0.93) for the physiotherapy arm compared
with the usual-care arm. The same analyses were performed on the PP population, which also found no
significant differences in rescue bronchodilator use between randomisation treatment arms in the adjusted or
the unadjusted analysis (Figure 5 and see Appendix 5).
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FIGURE 4 Distribution of rescue bronchodilator prescriptions in the 12 months post randomisation by treatment
arm in the ITT population.
TABLE 31 Unadjusted analysis of the negative binomial regression for rescue inhaler use in the 12 months after
baseline in the ITT population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 1.03 0.81 to 1.33 0.80
DVD vs. usual care 0.83 0.68 to 1.03 0.09
DVD vs. physiotherapy 0.81 0.63 to 1.04 0.10
TABLE 32 Adjusted analysis of the negative binomial regression for rescue inhaler use in the 12 months after
baseline in the ITT population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 1.03 0.79 to 1.37 0.93
DVD vs. usual care 0.91 0.72 to 1.15 0.61
DVD vs. physiotherapy 0.88 0.66 to 1.15 0.50
a Adjusted for age, sex, BTS treatment step, baseline smoking status, baseline HADS scores and baseline Nijmegen
questionnaire score.
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Respiratory-related general practitioner consultations
In the 12 months following randomisation, the number of times that each patient saw a general
practitioner (GP) for a respiratory-related reason varied between none and 21 (Table 33). In total, 71.2%
of the DVD group, 75.1% of the physiotherapy group and 76.7% of the control group had one or more
GP consultation. Unadjusted and adjusted negative binomial regression models were constructed to
estimate the difference between treatment arms in GP consultation rates. In both adjusted and unadjusted
analyses of the ITT population (Tables 34 and 35), there were non-significant trends for lower consultation
rates in the active arms than in the control arm, with minimal differences between the active arms (DS vs.
control: unadjusted IRR 0.87, 95% CI 0.72 to 1.05; adjusted IRR 0.93, 95% CI 0.74 to 1.15; physiotherapy
vs. control: unadjusted IRR 0.90, 95% CI 0.72 to 1.12; adjusted IRR 0.94, 95% CI 0.72 to 1.24; DVD vs.
physiotherapy: unadjusted IRR 0.97, 95% CI 0.77 to 1.22; adjusted IRR 0.98, 95% CI 0.75 to 1.29).
Similar results were found for the PP population (Tables 36 and 37 and see Appendix 7).
It is not possible to determine whether the interventions reduced the need for GP consultations, as the
study was underpowered to test this hypothesis, but there is a suggestion that there may have been some
reduction in consultation rates (by approximately one-tenth in this sample).
Overall health resource use
The analysis of health resource use is considered in detail in Chapter 4.
Overall health resource use was assessed through direct medical costs. The mean NHS cost per patient by
arm was aggregated from costs of prescriptions, consultations and hospital admissions. Although there
were few hospital admissions (usual-care arm, n = 8; physiotherapy arm, n = 0; DVD arm, n = 4), they were
by far the most costly item. The main cost items for each group were asthma-related medications and GP
consultations. The mean cost per patient was highest in the control group (£356), with a similar cost in the
physiotherapy group (£355) and the lowest cost in the DVD group (£296).
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FIGURE 5 Distribution of rescue bronchodilator prescriptions in the 12 months post randomisation by treatment
arm in the PP population.
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TABLE 33 Numbers of participants in the ITT population having respiratory-related GP consultations in the
12 months post randomisation by treatment group
Number of GP consultations
Treatment arm, n (%)
Total, n (%)DVD Physiotherapy Usual care
0 75 (44.4) 33 (19.5) 61 (36.1) 169 (100.0)
1 103 (39.6) 55 (21.2) 102 (39.2) 260 (100.0)
2 42 (39.6) 24 (22.6) 40 (37.7) 106 (100.0)
3 19 (38.8) 8 (16.3) 22 (44.9) 49 (100.0)
4 8 (32.0) 3 (12.0) 14 (56.0) 25 (100.0)
5 4 (17.4) 6 (26.1) 13 (56.5) 23 (100.0)
6 4 (40.0) 1 (10.0) 5 (50.0) 10 (100.0)
7 2 (50.0) 0 (0.0) 2 (50.0) 4 (100.0)
8 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
9 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
11 1 (33.3) 1 (33.3) 1 (33.3) 3 (100.0)
12 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
15 0 (0.0) 0 (0.0) 1 (100.0) 1 (100.0)
16 0 (0.0) 1 (100.0) 0 (0.0) 1 (100.0)
21 1 (100.0) 0 (0.0) 0 (0.0) 1 (100.0)
Total 261 (39.8) 132 (20.2) 262 (40.0) 655 (100.0)
TABLE 35 Adjusted analysis of the negative binomial regression for respiratory-related GP appointments in the
12 months after baseline in the ITT population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 0.94 0.72 to 1.24 0.87
DVD vs. usual care 0.93 0.74 to 1.15 0.69
DVD vs. physiotherapy 0.98 0.75 to 1.29 0.95
a Adjusted for age, sex, BTS treatment step, baseline smoking status, baseline HADS scores and baseline Nijmegen
questionnaire score.
TABLE 34 Unadjusted analysis of the negative binomial regression for respiratory-related GP appointments in the
12 months after baseline in the ITT population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 0.90 0.72 to 1.12 0.35
DVD vs. usual care 0.87 0.72 to 1.05 0.14
DVD vs. physiotherapy 0.97 0.77 to 1.22 0.78
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Patient engagement with the intervention in the active treatment arms
Patient engagement was assessed as part of our prespecified analysis plan; the data are presented in
Tables 38 and 39. Engagement was good in the physiotherapy arm, with 95% of participants attending at
least one of the three scheduled sessions and 93% attending all three. Patient experience of the different
components of the intervention was generally favourable and the majority of patients spent a considerable
amount of time practising the various techniques taught, with over half spending half a day or more
practising each technique. The main factor hindering the practising of techniques was practical problems,
for example finding time.
Similarly, engagement was good in the DVD arm, although the overall engagement scores for the different
components of the intervention were generally slightly lower than those in the physiotherapy arm and the
time spent practising the various techniques was lower. Practical problems were again the main hindering
factor, although some participants reported uncertainty or doubts over the instructions provided.
These findings are discussed further in Chapter 6.
As a prespecified analysis, we compared changes in the primary outcome (AQLQ) between the physiotherapy
arm and the DVD arm, including the ‘amount of practice’ as a covariate and excluding participants who did
not engage with the breathing retraining at 3 months in the physiotherapy arm, with data presented for the
3-month evaluation and the 12-month evaluation (see Appendix 8). This was carried out to assess whether
engagement with the exercises was different between the active arms and whether this could be reflected in
differences in primary outcome scores, as the physiotherapists suspected that some patients failed to engage
and so had poor outcomes from the face-to-face training programmes, whereas those who did engage
generally did well.
Compared with the primary efficacy analysis, this analysis including engagement and time spent practising
increased the magnitude of the AQLQ changes in the physiotherapy arm at 3 months, but did not result in
significant differences between the DVD arm and the physiotherapy arm, which continued to reach the
equivalence margin at the 12-month evaluation, and did not change the message emerging from the
study. These findings are discussed further in Chapter 6.
TABLE 36 Unadjusted analysis of the negative binomial regression for respiratory-related GP appointments in the
12 months after baseline in the PP population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 0.90 0.71 to 1.14 0.37
DVD vs. usual care 0.85 0.71 to 1.04 0.11
DVD vs. physiotherapy 0.95 0.75 to 1.21 0.68
TABLE 37 Adjusted analysis of the negative binomial regression for respiratory-related GP appointments in the
12 months after baseline in the PP population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 0.93 0.71 to 1.22 0.84
DVD vs. usual care 0.88 0.69 to 1.10 0.35
DVD vs. physiotherapy 0.96 0.72 to 1.24 0.84
a Adjusted for age, sex, BTS treatment step, baseline smoking status, baseline HADS scores and baseline Nijmegen
questionnaire score.
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TABLE 38 Measures of treatment engagement: physiotherapy arm
Measure
Physiotherapy arm
(N= 132)
Number of sessions attended, n (%)
n 132
None 6 (4.5)
At least one 126 (95.5)
At least two 123 (93.2)
At least three 123 (93.2)
Treatment experience scorea
n 104
Stomach breathing, median (IQR); minimum, maximum 8 (6–9); 3, 10
Nose breathing, median (IQR); minimum, maximum 8 (6–9); 3, 10
Slow breathing, median (IQR); minimum, maximum 7 (5–8); 1, 10
Controlled breath holding, median (IQR); minimum, maximum 5 (4–7); 1, 10
Relaxation training, median (IQR); minimum, maximum 8 (6–9); 1, 10
Total time spent on each breathing technique,b n (%)c
Stomach breathing
Weeks – did not use 1 (1.0)
1–5 weeks 20 (19.0)
≥ 6 weeks 79 (75.2)
Hours – did not use 1 (1.0)
Up to 1 hour 44 (41.9)
Up to half a day or more 54 (51.4)
Nose breathing
Weeks – did not use 1 (1.0)
1–5 weeks 20 (19.0)
≥ 6 weeks 80 (76.2)
Hours – did not use 3 (2.9)
Up to 1 hour 33 (31.4)
Up to half a day or more 65 (61.9)
Slow breathing
Weeks – did not use 2 (1.9)
1–5 weeks 32 (30.5)
≥ 6 weeks 67 (63.8)
Minutes – did not use 3 (2.9)
Up to 10 minutes 54 (51.4)
> 10 minutes 44 (41.9)
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Adverse events
Adverse events were collected for all randomised patients by patients and study centre principal investigators
(PIs) on adverse event report forms and by manual and electronic review of medical records at 12 months.
Adverse events were categorised by PIs according to the classification scheme provided in Appendix 9.
Serious adverse events
The serious adverse event rate was low, with no study-related serious adverse events and an overall rate of
5%. The highest serious adverse event rate was in the control group (7.6%), with lower rates in the DVD
group (4.2%) and the physiotherapy group (3%) (Table 40). A full list of all serious adverse events reported
is provided in Appendix 10.
Other adverse events
In total, 744 adverse events were reported from 272 patients (41.5% of the randomised population), with
quantification by category and randomisation group provided in Table 41. Of the adverse events, 47%
occurred in the control arm, 36% occurred in the DVD arm and 17% occurred in the physiotherapy arm
(note that there was a 2 : 1 : 2 randomisation schedule between the DVD, physiotherapy and control
arms and so the adverse event rate was very similar between the DVD arm and the physiotherapy arm).
TABLE 38 Measures of treatment engagement: physiotherapy arm (continued )
Measure
Physiotherapy arm
(N= 132)
Controlled breath holding
Weeks – did not use 10 (9.5)
1–5 weeks 38 (36.2)
≥ 6 weeks 53 (50.5)
Minutes – did not use 12 (11.4)
Up to 5 minutes 64 (61.0)
> 5 minutes 25 (23.8)
Relaxation training
Weeks – did not use 13 (12.4)
1–5 weeks 38 (36.2)
≥ 6 weeks 50 (47.6)
Minutes – did not use 15 (14.3)
Up to 10 minutes 69 (65.7)
> 10 minutes 17 (16.2)
Treatment engagement score
n 104
Problems due to symptoms, median (IQR); minimum, maximum 0 (0–0); 0, 12
Problems due to uncertainty about the therapy, median (IQR); minimum, maximum 0 (0–0); 0, 12
Problems due to doubts about the therapy, median (IQR); minimum, maximum 0 (0–0); 0, 12
Practical problems, median (IQR); minimum, maximum 4.5 (1–9); 0, 20
Problems due to lack of support, median (IQR); minimum, maximum 0 (0–0); 0, 12
a Based on different types of breathing retraining.
b Weeks, hours and minutes per day.
c Denominator is those with treatment adherence questionnaire available at 3 months (n = 105).
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TABLE 39 Measures of treatment engagement: DVD arm
Measure DVD arm (N= 244)
Treatment experience scorea
n 160
Stomach breathing, median (IQR); minimum, maximum 6 (5–8); 1, 10
Nose breathing, median (IQR); minimum, maximum 6 (5–8); 1, 10
Slow breathing, median (IQR); minimum, maximum 6 (5–8); 1, 10
Controlled breath holding, median (IQR); minimum, maximum 5 (4–7); 1, 10
Relaxation training, median (IQR); minimum, maximum 7 (6–8); 1, 10
Total time spent on each breathing technique,b n (%)c
Stomach breathing
Weeks – did not use 10 (4.1)
1–5 weeks 59 (24.2)
≥ 6 weeks 90 (36.9)
Hours – did not use 12 (4.9)
Up to 1 hour 104 (42.6)
Up to half a day or more 41 (16.8)
Nose breathing
Weeks – did not use 12 (4.9)
1–5 weeks 53 (21.7)
≥ 6 weeks 94 (38.5)
Hours – did not use 13 (5.3)
Up to 1 hour 75 (30.7)
Up to half a day or more 69 (28.3)
Slow breathing
Weeks – did not use 11 (4.5)
1–5 weeks 64 (26.2)
≥ 6 weeks 85 (34.8)
Minutes – did not use 11 (4.5)
Up to 10 minutes 100 (41.0)
> 10 minutes 48 (19.7)
Controlled breath holding
Weeks – did not use 19 (7.8)
1–5 weeks 74 (30.3)
≥ 6 weeks 67 (27.5)
Minutes – did not use 20 (8.2)
Up to 5 minutes 103 (42.2)
> 5 minutes 36 (14.8)
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A summary of the adverse events reported is provided in Table 42. A full list of each event reported as well
as severity gradings is provided in Appendix 11.
Overall, the adverse event profile was as expected in the recruited population, with fewer adverse events
in the active arms than in the control arm. There was no indication that any of the adverse events were
related to either the DVD programme or the physiotherapy programme, which appeared to be well tolerated.
TABLE 39 Measures of treatment engagement: DVD arm (continued )
Measure DVD arm (N= 244)
Relaxation training
Weeks – did not use 25 (10.2)
1–5 weeks 59 (24.2)
≥ 6 weeks 76 (31.1)
Minutes – did not use 24 (9.8)
Up to 10 minutes 91 (37.3)
> 10 minutes 45 (18.4)
Treatment engagement score
n 158
Problems due to symptoms 0 (0–2); 0, 12
Problems due to uncertainty about the therapy 0.5 (0–3); 0, 12
Problems due to doubts about the therapy 1.0 (0–4); 0, 10
Practical problems 6.5 (3–11); 0, 20
Problems due to lack of support 0 (0–3); 0, 12
a Based on different types of breathing retraining.
b Weeks, hours and minutes per day.
c Denominator is those with treatment adherence questionnaire available at 3 months (n = 244).
TABLE 40 Summary of serious adverse events/reactions
Event
Treatment arm, n (%)
Total (N= 655),
n (%)DVD (N= 261)
Physiotherapy
(N= 132)
Usual care
(N= 262)
SUSARs None
Expected serious adverse reactions None
Other serious adverse events 11 (4.2) 4 (3.0) 20 (7.6) 35 (5.3)
SUSAR, suspected unexpected serious adverse reaction.
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TABLE 41 Summary of the categories of main symptom(s) reported on the adverse event forms (as categorised
by PIs)
Categorya
Treatment arm, n (%)
Total (N= 655),
n (%)DVD (N= 261)
Physiotherapy
(N= 132)
Usual care
(N= 262)
Abdominal/GIT 19 (35.2) 5 (9.3) 30 (55.6) 54 (100.0)
Acute exacerbation of asthma 32 (45.1) 13 (18.3) 26 (36.6) 71 (100.0)
Chest pain 24 (41.4) 7 (12.1) 27 (46.6) 58 (100.0)
Increased asthma symptoms 29 (29.9) 28 (28.9) 40 (41.2) 97 (100.0)
Malignancy 3 (75.0) 1 (25.0) 0 (0.0) 4 (100.0)
Musculoskeletal 22 (35.5) 15 (24.2) 25 (40.3) 62 (100.0)
Neurological 8 (33.3) 3 (12.5) 13 (54.2) 24 (100.0)
Psychological/psychiatric 12 (28.6) 2 (4.8) 28 (66.7) 42 (100.0)
Respiratory tract infection/cough 79 (35.1) 31 (13.8) 115 (51.1) 225 (100.0)
Rhinitis/rhinosinusitis 20 (43.5) 6 (13.0) 20 (43.5) 46 (100.0)
Miscellaneous 23 (37.7) 12 (19.7) 26 (42.6) 61 (100.0)
Total 271 (36.4) 123 (16.5) 350 (47.0) 744 (100.0)
GIT, gastrointestinal.
a See Appendix 11 for details of each category.
TABLE 42 Summary of the adverse events reported
Characteristic
Treatment arm
Total (N= 655)DVD (N= 261)
Physiotherapy
(N= 132)
Usual care
(N= 262)
Patients experiencing at least one AE,a n (%) 101 (38.7) 55 (41.7) 132 (50.4) 288 (44.0)
PI assessment
Number of AEs 271 123 350 744
Number pending 0 0 0 0
Total number 271 123 350 744
Severity of AE, n (%)b
1 – mild 129 (47.6) 66 (53.7) 155 (44.3) 350 (47.0)
2 – moderate 112 (41.3) 44 (35.8) 141 (40.3) 297 (39.9)
3 – severe 25 (9.2) 13 (10.6) 50 (14.3) 88 (11.8)
4 – life threatening 4 (1.5) 0 (0.0) 2 (0.6) 6 (0.8)
5 – death related to AE 1 (0.4) 0 (0.0) 2 (0.6) 3 (0.4)
Pending 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Total 271 (100.0) 123 (100.0) 350 (100.0) 744 (100.0)
AE, adverse event.
a Denominator is the total number of patients in each arm.
b Denominator is the number of AEs.
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Chapter 4 Economic evaluation
Introduction
The health economic analysis evaluated the superiority of each intervention compared with usual care
and made a non-inferiority comparison between the DVD arm and the face-to face physiotherapy arm.
The ITT population was employed, with imputation of missing values. The time frame was that of the trial.
Adjustment was made for baseline values and for repeated measurement. The perspective was that of the
NHS, but with exploration of non-NHS costs.
Data collected
Resource use data were collected using three forms. The medication review form was used to record data on
all asthma-related NHS consultations and prescriptions over the period of the trial, collected from patient
records held by each general practice. It was also used to record outpatient visits, accident and emergency
(A&E) visits, out-of-hours consultations and hospital admissions related to asthma. A concomitant medications
form was used to record data on six conditions that might be linked to differences in outcomes. A third form
was used to record data from patients relating to over-the-counter medications, non-NHS consultations and
any other privately accessed items related to asthma or its palliation.
The results presented here relate only to the medication review data. The data on concomitant medications
proved unusable for several reasons, principally because of lack of detail provided on relevant medications
and dates. The data on patient-reported costs also proved of little use as very few items were recorded.
This we interpret as indicating that few such costs were incurred; hence, this justified taking a NHS
perspective as opposed to a societal perspective.
Intervention costs
Intervention costs (shown in Appendix 12) were £83.45 per patient in the face-to-face physiotherapy
breathing retraining group and £2.85 in the DVD breathing retraining group. The physiotherapy group
cost was based on the duration of the planned three consultations with the practice nurse, adjusted for
attendance. The cost of the DVD intervention was that of printing the discs and documentation. The
development cost of these materials was treated as a research cost and was not included here.
Resource use and costs
The unit costs for each of the resource groups (GP consultations, outpatient visits, A&E attendances,
out-of-hours consultations, inpatient admissions) and sources are shown in Appendix 12.
EuroQol-5 Dimensions and Asthma Quality of Life Questionnaire
Asthma Quality of Life Questionnaire data collection was discussed earlier (see Chapter 3). EQ-5D data
were collected at the initial visit at baseline and at 3 and 6 months (both by post) and 12 months
(assessment visit).
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Analyses
Cost–utility analyses were based on all patients randomised. Utility scores were derived based on the UK
tariff.34 QALYs were calculated based on the area under the curve approach. The time frame of the
analysis was that of the trial (12 months).
Bootstraps based on 1000 samples with replacements were used to estimate the cost per AQLQ score
improvement and cost per QALY gained, with CIs presented to illustrate the uncertainty. Scatterplots are
presented to illustrate the uncertainty in the cost–utility estimates.
Results
The medical review form was used to extract patient resource use data in the 12 months following
randomisation. Three patients died and two patients left their practice. We assumed that no additional
costs were incurred for these patients after the date of their last visit.
The mean NHS cost per patient by treatment arm was aggregated from the costs of asthma-related
prescriptions, consultations and hospital admissions. The unadjusted mean cost was highest in the usual-care
arm (£356; Table 43), with a similar cost in the physiotherapy arm (£335) and the lowest cost in the DVD
arm (£296). The main cost items for each group were asthma-related medications and GP consultations,
with lower costs reflecting low levels of use of other services; although there were few hospital admissions
(usual-care arm, n = 8; physiotherapy arm, n = 0; DVD arm, n = 4), they were by far the most costly item.
The numbers of patients using each service are also shown in Table 43.
The mean costs in each arm changed only slightly when bootstrap methods were used: £377 in the
usual-care arm, £333 in the physiotherapy arm and £293 in the DVD arm (Table 44). The differences were
not statistically significant at the 5% level.
Given that the intervention costs were higher in the physiotherapy arm (£83.5) and the DVD arm (£2.85)
than in the usual-care arm, the inclusion of NHS costs offset these higher costs, leading to lower overall
mean costs in both intervention arms than in the usual-care arm.
EuroQol-5 Dimensions data were collected at baseline (n = 653/655), 3 months (n = 519/655), 6 months
(n = 472/655) and 12 months (n = 437/655) (see Table 45). For the whole sample, completion fell from an
estimated 99% at baseline to 67% at 12 months. Some participants missed some but not all time points,
but data for at least two time point were available for 87% of participants. Linear interpolation was used
for those with two or three time points, with imputation for those with fewer time points.
The mean EQ-5D QoL scores varied between 0.751 and 0.826, with small differences at baseline and over time.
The mean EQ-5D QoL scores based on complete cases are shown in Table 46.
Cost-effectiveness analysis
The primary analysis of AQLQ score differences was based on the population with baseline measurement
of AQLQ scores (n = 244, 120 and 246 in the DVD, physiotherapy and usual-care arms respectively;
see Chapter 3). The cost-effectiveness analyses were based on the same population (n = 610 in total).
Bootstrapped mean costs per person in this population were £380 (95% CI £310 to £459), £296 (95% CI
£228 to £374) and £334 (95% CI £299 to £269) for the DVD, physiotherapy and usual-care arms respectively.
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TABLE 43 Mean NHS resource use in each treatment arm (2014/15 prices)
Resource use Category Mean (SD) for those using service Mean (SD) for all
Usual care (N = 262)
Costs (£)a Total costs 379 (672) (n= 246) 356 (657)
Medication 183 (217) (n= 242) 169 (214)
GP consultation 100 (84) (n= 201) 77 (85)
Outpatient attendance 347 (321) (n= 21) 28 (130)
Hospital admission 2581 (0) (n= 8) 79 (445)
Number of cases Medication usage 9.71 (10.14) (n= 242) 8.97 (10.08)
GP consultation 2.22 (1.87) (n= 201) 1.71 (1.89)
Outpatient attendance 2.57 (2.38) (n= 21) 0.21 (0.96)
Hospital admission 1 (0) (n= 8) 0.03 (0.17)
Physiotherapy (N = 132)
Costs (£)a Total costs 335 (254) (n= 132) 335 (254)
Medication 173 (199) (n= 120) 157 (196)
GP consultation 92 (93) (n = 99) 69 (90)
Outpatient attendance 203 (88) (n= 14) 21 (68)
Hospital admission 0 (0) (n= 0) 0 (0)
Intervention 83 (0) (n= 132) 83 (0)
Number of cases Medication usage 9.27 (7.49) (n= 120) 8.42 (7.63)
GP consultation 2.04 (2.07) (n= 99) 1.53 (2)
Outpatient attendance 1.5 (0.65) (n = 14) 0.16 (0.51)
Hospital admission 0 (0) (n= 0) 0 (0)
Intervention 1 (0) (n= 132) 1 (0)
DVD (N = 261)
Costs (£)a Total costs 296 (715) (n= 261) 296 (715)
Medication 167 (177) (n= 222) 142 (174)
GP consultation 94 (99) (n = 186) 67 (94)
Outpatient attendance 221 (122) (n= 25) 21 (75)
Hospital admission 3872 (2581) (n = 4) 59 (551)
Intervention 3 (0) (n= 261) 3 (0)
Number of cases Medication usage 9.04 (8.03) (n= 222) 7.69 (8.08)
GP consultation 2.08 (2.2) (n = 186) 1.48 (2.08)
Outpatient attendance 1.64 (0.91) (n= 25) 0.16 (0.56)
Hospital admission 1.5 (1) (n = 4) 0.02 (0.21)
Intervention 1 (0) (n= 261) 1 (0)
Note
a All costs consist of the total costs incurred. The main components of all costs were the services shown, that is, GP
consultations, medications, hospital admissions and the intervention.
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This gave a difference in costs of –£83 (95% CI –£187 to £12) for the DVD arm and –£45 (95% CI –£134 to
£33) for the physiotherapy arm compared with the usual-care arm (Table 47).
The estimated differences in AQLQ scores, based on bootstrap methods with adjustments for prespecified
covariates, were similar to those in the primary analyses, with differences of 0.23 (95% CI 0.06 to 0.40)
for the physiotherapy arm compared with the usual-care arm and 0.26 (95% CI 0.11 to 0.41) for the DVD
arm compared with the usual-care arm (see Table 47).
TABLE 46 Mean EQ-5D scores based on complete cases
Treatment arm EQ-5D score, mean (95% CI)
Number of patients with
complete data at all points
Percentage used in
the calculation
Usual care (n= 262) 0.801 (0.765 to 0.836) 154 58.8
Physiotherapy (n= 132) 0.764 (0.696 to 0.831) 70 53.0
DVD (n= 261) 0.817 (0.776 to 0.858) 113 43.3
TABLE 44 Total costs per person using bootstrap methods
Treatment arm Cost (£), mean (95% CI) Incremental cost (£), mean (95% CI)
Usual care 377 (310 to 459) –
Physiotherapy 333 (299 to 369) –41 (–134 to 33)
DVD 293 (228 to 374) –83 (–187 to 12)
TABLE 45 Mean EQ-5D scores over 12 months in each treatment arm based on complete cases
Time EQ-5D score, mean (SD) Number completing % completion
Usual care (n = 262)
Baseline 0.805 (0.236) 261 100
3 months 0.773 (0.269) 222 85
6 months 0.751 (0.301) 212 81
12 months 0.797 (0.246) 191 73
Physiotherapy (n = 132)
Baseline 0.794 (0.269) 130 98
3 months 0.789 (0.275) 105 80
6 months 0.774 (0.272) 98 74
12 months 0.747 (0.318) 93 70
DVD (n = 261)
Baseline 0.82 (0.235) 258 99
3 months 0.775 (0.275) 167 64
6 months 0.794 (0.269) 162 62
12 months 0.826 (0.221) 153 59
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The incremental cost per AQLQ score improvement was –£400 (95% CI –£1545 to £106) for the
physiotherapy arm compared with the usual-care arm and –£340 (95% CI –£986 to £52) for the DVD
arm compared with the usual-care arm (see Table 47). Both interventions dominated usual care. Given the
non-inferiority of the DVD intervention compared with the physiotherapy intervention, cost-minimisation
analysis favoured the DVD intervention over the physiotherapy intervention. This was the base case for the
cost-effectiveness analysis.
Cost–utility analysis
Incremental differences between the arms in terms of costs and QALYs and the incremental cost-effectiveness
ratios (ICERs) are shown in Table 48. There were small baseline adjusted QALY differences between the
arms, with the face-to-face physiotherapy arm having 0.007 more QALYs than the usual-care arm and the
DVD arm having 0.02 more QALYs than the usual-care arm. The DVD arm showed a gain of 0.014 QALYs
compared with the face-to-face physiotherapy arm. The gains were not statistically significant.
In the adjusted analysis (bottom part of Table 48), the ICERs had negative values for both the physiotherapy
arm and the DVD arm compared with the usual-care arm. The physiotherapy arm cost £877 less per QALY
than the usual-care arm and the DVD arm cost £3057 less per QALY than the usual-care arm. Both
interventions dominated usual care. The CIs for these ICERs were wide and not statistically significant.
Similar results were found in the unadjusted analysis.
The probability of dominance was investigated for each of the comparisons. This can be interpreted as the
proportion of the simulated results (points on a scatterplot) that fall into the lower right-hand (south-east)
quadrant. Scatterplots are shown of the joint distribution of the incremental mean cost and mean QALYs
for the DVD arm compared with the usual-care arm (Figure 6) and for the physiotherapy arm compared
with the usual-care arm (Figure 7).
The probability of usual care being dominated by the DVD intervention (lower costs and higher QALYs)
was 82%. The probability of usual care being dominated compared with the face-to-face physiotherapy
intervention (lower costs and higher QALYs) was 51%.
Discussion and conclusions
This well-conducted randomised trial provides evidence of the likely cost-effectiveness of both face-to-face
physiotherapy and breathing retraining delivered using a DVD and booklet. Limitations include the time
frame used, the reliance of the cost-effectiveness estimates on a single trial and the restriction of the
TABLE 47 Incremental cost per AQLQ score improvement (ICER) based on imputed data
Treatment arm
Cost (£), mean
(95% CI)
Difference in
costs (£), mean
(95% CI)
Difference in
AQLQ score,
mean (95% CI)
Incremental cost (£)
per AQLQ score
improvement
(95% CI)
Usual care (n = 246) 380 (310 to 459)
DVD (n= 244) 296 (228 to 374)
Physiotherapy (n= 120) 334 (299 to 269)
Physiotherapy vs. usual care –45 (–134 to 33) 0.23 (0.06 to 0.40) –400 (–1545 to 106)
DVD vs. usual care –83 (–187 to 12) 0.26 (0.11 to 0.41) –340 (–986 to 52)
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TABLE 48 Costs, QALYs and incremental cost per QALY (ICERs) using bootstrap methods based on imputed data
Treatment arm Cost (£), mean (95% CI)
Incremental cost
(£), mean (95% CI) QALYs, mean (95% CI)
Incremental QALYs,
mean (95% CI) ICER (£/QALY) (95% CI)
Usual care 377 (310 to 459) 0.767 (0.738 to 0.79)
Physiotherapy 333 (299 to 369) –41 (–134 to 33) 0.771 (0.735 to 0.807) 0.005 (–0.039 to 0.05) –671 (–14,269 to 13,814)
DVD 293 (228 to 374) –83 (–187 to 12) 0.788 (0.764 to 0.811) 0.022 (–0.013 to 0.058) –2754 (–17,739 to 12,017)
DVD vs. physiotherapy 40 (–43 to 116) 0.017 (–0.025 to 0.06) –941 (–12,260 to 11,620)
Treatment arm Cost (£), mean (95% CI)
Incremental cost (£)
(95% CI)
QALYs adjusted for
baseline QoL, mean
(95% CI)
Incremental adjusted
QALYs (95% CI)
ICER (£/adjusted QALY)
(95% CI)
Usual care 377 (310 to 459) 0.767 (0.741 to 0.788)
Physiotherapy 333 (299 to 369) –41 (–134 to 33) 0.773 (0.74 to 0.805) 0.007 (–0.033 to 0.047) –877 (–15,555 to 18,573)
DVD 293 (228 to 374) –83 (–187 to 12) 0.787 (0.765 to 0.807) 0.02 (–0.011 to 0.053) –3057 (–18,877 to 10,864)
DVD vs. physiotherapy 40 (–43 to 116) 0.014 (–0.023 to 0.052) –1145 (–14,982 to 9843)
Note
The mean incremental costs and QALYs and ICERs between two treatment arms are not directly derived from the mean cost and mean QALYs in each group because of the bootstrap
methods used.
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costing perspective to the NHS. Although longer-term follow-up would be desirable, it seems likely that
patients who have been able to improve their QoL using breathing retraining would continue to apply the
techniques that they have learned. If so, the benefits recorded here may have been understated. Although
cost-effectiveness should ideally be based on the totality of evidence, such as a meta-analytical estimate of
effect size, we note similar results for the one similar trial of breathing exercises in asthma.17 Our adoption
of a NHS, as opposed to a societal, perspective was based on the returns from a questionnaire, which
indicated that few costs fell outside the NHS.
The cost/AQLQ analysis favoured both the DVD intervention and the face-to-face physiotherapy intervention
compared with usual care, with the DVD intervention achieving equivalent outcomes to the face-to-face
physiotherapy intervention at a lower cost. The cost/QALY analysis showed similar results for the DVD and
face-to-face physiotherapy comparisons with usual care, albeit based on small non-significant differences in
outcomes. Both interventions dominated usual care. The DVD intervention had similar outcomes to the
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FIGURE 6 Scatterplot of the joint distribution of the incremental mean cost from a NHS perspective and mean
QALYs adjusted for baseline QoL over 12 months based on the imputed data: 95% CI ellipse DVD arm compared
with the usual-care arm.
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FIGURE 7 Scatterplot of the joint distribution of incremental mean cost from NHS perspective and mean QALYs
adjusted baseline QoL over 12 months based on the imputed data: 95% CI ellipse physiotherapy arm compared
with the usual-care arm.
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face-to-face physiotherapy intervention but at lower costs. The probabilities of the interventions being
dominant were 85% for the DVD intervention compared with usual care and 51% for the face-to-face
physiotherapy intervention compared with usual care. Thus, both the cost-effectiveness analysis and the
cost–utility analysis provided congruent results. Both interventions achieved outcome gains at lower total
costs than usual care. The lower cost in the DVD group meant that the DVD intervention was preferable to
face-to-face physiotherapy. The low cost of the DVD (£2.85) meant that, if effective, it was highly likely to
be cost-effective. Further, if made available on the internet, its cost would fall to close to zero.
In conclusion:
l the QALY differences between the treatment arms were in the same direction as the differences in the
primary outcome, but were smaller
l the increased cost of each intervention was offset by reductions in total costs so that both interventions
dominated usual care
l the DVD/booklet training was preferable to face-to-face physiotherapy, as the outcomes were within
the equivalence margin and the DVD intervention had a lower cost.
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Chapter 5 Intervention development
The BREATHE trial was a three-armed trial, with two active arms and one control arm. The active armsconsisted of physiotherapy breathing retraining delivered face-to-face and physiotherapy breathing
retraining delivered using a DVD, with an accompanying booklet (Breathe Freely) provided to both active
arms. This chapter describes the process of developing these three intervention components prior to
carrying out the pilot RCT.
Face-to-face physiotherapy
Although breathing retraining for asthma is provided by some physiotherapists within the NHS and privately,
in clinical practice there may be considerable variation in the content and frequency of face-to-face sessions.
For this research we needed to standardise the intervention as much as possible to ensure that each
participant received similar treatment and potentially to allow for comparability across different therapists.
Our initial plan was to recruit two to three part-time physiotherapists to provide the face-to-face intervention
during the life of the BREATHE trial.
The first step was to decide on the frequency of sessions. In clinical practice, physiotherapists have the
option to tailor their treatments to the needs of individual patients, which results in large variations in
treatment session numbers from patient to patient. However, previous related research trials by the chief
investigator17,19 had demonstrated that three face-to-face sessions were sufficient to have a positive effect
on the primary outcome, and discussions with local physiotherapists also suggested that three was the
average number of sessions provided within the NHS. It was therefore decided that all participants should
be offered three sessions with the physiotherapist, with intervention adherence being predefined as
attending any two out of these three sessions.
The content for each session was derived from discussions with physiotherapists, from AB’s own experience
and from discussion with other members of the research team. From these discussions, AB produced
two documents: a complete description of the protocol for face-to-face physiotherapy [Face-To-Face
Physiotherapy Protocol (Anne Burton, University of Southampton, 2012)] and a reduced version of the
protocol to be given to intervention physiotherapists during training workshops [Training Manual for
Physiotherapists (Anne Burton, University of Southampton, 2012)].
Training workshops were held by AB at various locations, at which the physiotherapists received information
about the trial and the training manual. Details of the training provided at these workshops can be found in
the manual. Although five physiotherapists attended these workshops, ultimately, only one physiotherapist
(Ruth DeVos) provided all of the intervention sessions throughout the life of the trial. Fidelity of intervention
delivery was determined in two ways: first, by the physiotherapist completing specifically designed checklists
(see the Face-To-Face Physiotherapy Protocol for details) and, second, through the use of direct observation,
whereby AB went out to the general practices during both the pilot trial and the main trial to observe the
physiotherapist delivering a session of the intervention for approximately 5% of the participants (6 out of the
132 recruited to this arm). There was 100% adherence to the intervention protocol by the physiotherapist
(physiotherapist adherence to the protocol had been predefined as conforming to 90% of the checklist).
Booklet development (Breathing Freely)
Previous experience from within the research team had indicated that accompanying materials (such as a
written booklet) containing behavioural content to motivate and reassure patients were very useful to support
user self-management.35 Our booklet, Breathing Freely: Your Guide to Breathing Retraining for Asthma,
was developed by a team of health psychologists, physiotherapists, physicians and patient representatives
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(Emily Arden-Close, Sarah Kirby, Emma Teasdale, Anne Bruton, Mike Thomas, Mark Stafford-Watson,
Denise Gibson, Lucy Yardley, University of Southampton, 2013).
A draft booklet was first created by three of the authors (EAC, LY), based on advice from physiotherapists
(AB, DG) and a GP with expertise in asthma (MT) and a similar booklet that LY had created that had
successfully supported the exercise-based self-management of symptoms in patients with dizziness.35 The first
part of the booklet (pages 1–8) was designed to build motivation (in terms of social cognitive theory and
positive outcome expectancies) and confidence (self-efficacy) to undertake breathing retraining. To convince
users that breathing retraining would be effective, the cognitive–behavioural rationale for breathing retraining
was first explained in terms of the vicious cycle of breathing problems, anxiety and hyperventilation and how
this could be reversed by breathing retraining. Positive expectancies for treatment benefit were promoted by
explaining how breathing retraining can improve not only breathing but also psychological well-being, and
can allow users to do more without becoming breathless. The second part of the booklet (pages 10–15)
contained detailed instructions (with illustrations) on how to progressively master breathing retraining, with
reassurance and advice addressing common difficulties and barriers. The final part of the booklet (pages 16–21)
encouraged users to use their new breathing skills to engage in more daily activities that they might have
previously found difficult because of asthma (e.g. exercise, stressful situations). Implementation of breathing
retraining was encouraged by providing success stories from other patients and charts to plan when to carry
out the breathing exercises and physical activity and log progress.
Using our ‘person-based approach’ to developing accessible, persuasive and helpful intervention materials,36
feedback on the draft version was sought through the use of semistructured think-aloud interviews lasting
approximately 1 hour with 29 people with asthma. The interviews included two components: open-ended
questions exploring attitudes to breathing retraining exercises in the context of health beliefs and lifestyle
and think-aloud methods to elicit spontaneous reactions to the booklet. Interview questions covered
participants’ experiences of managing their asthma. This included questions about breathing difficulties,
previous experience of breathing techniques for asthma management and the perceived relevance of
breathing training exercises to asthma control. Participants then read the draft booklet and provided
feedback about each page. Further open-ended questions explored impressions of the booklet, attitudes to
breathing exercises, perceived attitudes of relevant others (family, health-care professionals), barriers to
carrying out breathing exercises at home and possible ways of overcoming these barriers.
After each interview the feedback on each page was tabulated into recommended changes and positive
aspects of the booklet. After the first few interviews had been conducted, the recommended changes were
collated and a MoSCoW (must, should, could, would) analysis was conducted (breaking changes down into
things we must, could, should and were not going to do), based on the nature of the comments and how
many people mentioned each comment. The booklet was then revised before further interviews were
conducted. This cycle continued until no further major changes were suggested. Further details of this
process and the changes made in response to feedback can be found in two publications.36,37
DVD development
Our aim was to produce an intervention that replicated the experience of face-to-face physiotherapy
breathing retraining in an accessible self-guided format. We acquired the media in a high-quality video file
format to ‘future-proof’ our content as much as possible and facilitate distribution using different technologies.
The available technologies for distribution at the time of the original funding application were videotape, DVD
and the internet. Although we knew that distributing video via the internet was possible, we chose the DVD
as the distribution format for this project because, at the time, DVD players were becoming more popular
and fewer people in the UK had access to the internet. In 2009 (when the funding application was written)
the broadband network and hardware required to view internet-distributed video was not established or as
widespread as it is now. Since then, distributing video via the internet has become ubiquitous. Reformatting
our original video files for distribution via the internet will be relatively straightforward.
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To enable people to identify with the patients seen on screen on the DVD, it was decided to involve
genuine individuals with asthma (rather than actors) to take on the roles of patients. A local specialist
respiratory physiotherapist (Denise Gibson) was asked to play the role of the breathing retraining
physiotherapist. Dr Mark Porter (who has considerable experience of fronting medical programmes on
both radio and television) kindly agreed to be the ‘presenter’ for the DVD.
The DVD production team consisted of AB, MT and DG, the psychology team developing the booklet,
patient representatives, a commercial company (Zemedia) and staff at Solent University Studios, Southampton.
AB produced a draft script for the DVD, based on a combination of the written Face-To-Face Protocol, the
developing Breathing Freely booklet and discussions with physiotherapists. This was then shared with our
psychology team members, patient representatives and others in the research team. Input from TMG patient
representatives was of great importance in these revisions, and these representatives were involved in and
commented on all revision steps, providing verbal and written comment on patient perspectives of the
intervention. In addition, the iterative person-based think-aloud process for the development of digital
behavioural interventions that was used in the development process for this intervention (described in detail in
Chapter 6) used a representative sample of 29 adults with asthma purposively sampled for diversity of age,
sex, education and symptom profile. These patients looked at draft versions of the intervention and provided
feedback and comment using a formal qualitative methodology, and this was used to modify the intervention
based on their reactions and comments. Several revisions to the script were subsequently made in response
to comments and feedback from within the team. A professional media production team (Zemedia) had
been identified by AB in 2009 during the initial funding application process and its main representative
(Tim O’Riordan) had been regularly attending project meetings from 2011. Zemedia were employed to
translate our script into a filmable story, to film the scenes and to create and produce the final DVD. Script
refinement and preparation for filming continued over the first year of the research programme, during which
period there were several team meetings to agree on patient roles and locations and to design ‘story boards’
for individual scenes. Filming took place over 3 days in May and June 2012, in Solent University Studios and
on location in patients’ homes, with Steve Bowles of Zemedia and AB directing. Clips from the filming were
shared within the research team for comment in terms of what to include/exclude, what voiceovers were
appropriate and general formatting of the DVD. It was not felt appropriate to seek patient feedback on the
developing DVD itself at that stage as it would not have been possible to refilm scenes because of time and
financial constraints. Tim O’Riordan was responsible for the editing and post-production work that resulted in
the final version of the DVD used in the trial. Feedback on the DVD as used by participants was sought as part
of the research trial and is described elsewhere in this report.
Patient and public involvement (PPI) was central to this project, with two PPI representatives on the TMG
attending TMG meetings and commenting on all stages of the process, and with the patient charity Asthma
UK being a partner in the process. With the partnership of the charity and the active involvement of patients
in all stages of the trial, in particular in the development and optimisation of the DVD intervention and
booklet, we feel that there was complete PPI involvement overall. We did not experience any difficulty in
obtaining PPI or in acting on it and would recommend that further trials in this clinical area integrate PPI into
their processes as much as possible and involve patient charities if possible.
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Chapter 6 Process evaluation
In line with Medical Research Council (MRC) guidance for developing and evaluating complexinterventions38 and the MRC process evaluation framework,39 qualitative and quantitative process
evaluations were nested within the trial to allow for a more detailed exploration of aspects that may be
relevant to trial outcomes that might inform policy and practice. The qualitative process evaluation was
conducted after the BREATHE trial 3-month follow-up with a sample of participants who had taken part in
the intervention arms of the trial, to capture their perspectives on the interventions and understand what
aspects were perceived as strengths and weaknesses.
The aim of the quantitative process evaluation was to explore participants’ reported expectations of the
interventions, their experiences and their level of engagement with the interventions. Measures for the
quantitative process evaluation were taken immediately after randomisation and at each of the 3-month,
6-month and 12-month follow-up time points. Like the qualitative process evaluation, only those who had
taken part in the intervention arms of the trial were included.
The methodology and findings of the qualitative and quantitative process evaluations are each reported in
more detail in the following sections.
Qualitative process evaluation
The qualitative process evaluation aimed to explore the experiences of participants in the intervention arms
(DVD and face-to-face physiotherapy) of the BREATHE trial, to understand what patients perceive as the
strengths and weaknesses of the different modes of delivery of breathing retraining.
Methodology
Semistructured telephone interviews were used to explore participants’ experiences of breathing retraining
for asthma delivered by DVD or face-to-face physiotherapy. Participants were eligible for inclusion if they
had taken part in one of the two intervention arms of the trial. Initially, consecutive sampling of participants
in the pilot for the main trial was used. Purposive sampling was used towards the end to ensure adequate
representation of male participants. Recruitment continued until the data reached saturation (i.e. no new
themes were being raised). The final sample consisted of 11 women and five men between the ages of 23
and 70 years [mean (SD) age 55.2 (12.9) years]. There were eight participants (two men) in the DVD group
and eight participants (three men) in the face-to-face physiotherapy group.
The transcripts were analysed by EAC using inductive thematic analysis. Transcripts were read carefully
several times to ensure familiarity with the data. A coding manual was developed on the first few
transcripts to ensure transparent and systematic coding of data and this was frequently revised. Themes
were continually compared with newly coded transcripts to ensure that they applied to the data. The
coding manual was then checked with LY and a sample of texts second coded, to ensure good inter-rater
reliability. Themes were checked for differences as a function of group (intervention arm).
Results
Five main themes emerged: reasons for taking part, experience of breathing retraining, impact of breathing
retraining, benefits of breathing retraining and problems with breathing retraining. These are discussed in
the following sections.
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Reasons for taking part
Reasons for taking part included being asked to, to enhance progress in research, to feel better/reduce
symptoms and to reduce the use of medication. Some participants took part because a health-care
professional asked them to:
I had my um annual asthma check-up and they just asked me if I would do it kind of there and then
so I just said that I would.
P9, female, DVD
Some participants had always supported research and felt that it was their duty to give something back to
help enhance progress with regard to research and knowledge:
because I would support research that is going to improve things for human beings.
P16, male, face-to-face physiotherapy
Many participants felt that it would help improve their health and symptoms:
I was just hoping it would . . . help my breathing when I went up hills . . . because that’s what I was
particularly concerned with.
P2, female, DVD
Related to this, many participants wanted to reduce their use of medication. Although they took it as
required, they wanted to be less dependent on it:
I liked the idea of a natural solution to the asthma rather than having to take medication.
P4, female, face-to-face physiotherapy
Experience of breathing retraining
The participants in the face-to-face group had a positive impression of the physiotherapist, who tailored
the treatment to their needs, and found the sessions motivational.
All of the participants in the face-to-face group had a positive impression of the physiotherapist as friendly,
very helpful, supportive and patient:
the lady that did them was really, really nice. She wasn’t condescending in any way, she was really
patient, she was very quick to praise when you did it right.
P14, female, face-to-face physiotherapy
Participants mentioned that the physiotherapist tailored the treatment to their needs, rather than offering
a ‘one size fits all’ approach. When they were experiencing difficulties, she reviewed the techniques and
helped to break down goals into more manageable ones. For example, one participant described this
experience of improving nose breathing:
When I spoke to [the physiotherapist] about it um, originally because I was having problems with it,
she said just try and set myself little goals. So what I sort of do is when sort of leave the house I sort
of set myself a goal to breathe through my nose to a certain point and then I will do it again, you
know, I will get to this point and then I will try and breathe through my nose again.
P5, female, face-to-face physiotherapy
The physiotherapist also tailored support as participants needed, which facilitated mastery of the techniques:
. . . when she said, ‘Now, I need you to do these exercises at home’, she saw the look on my face and
she said, ‘Would you like me to write the instructions down?’ And I said, ‘Yes, please’. And so that,
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because I’d already done the actual training bit in my session the instructions put it back into my mind
what I had to do and I found it really, really informative.
P14, female, face-to-face physiotherapy
The face-to-face physiotherapy group also found seeing the physiotherapist motivational. Knowing that
they would attend appointments prompted them to prioritise practising breathing techniques:
I liked having the person there. It is not so much that she told me off when I hadn’t done the exercises
but it is like an extra conscience.
P5, female, face-to-face physiotherapy
The materials used by participants in the DVD group (booklet and DVD) were also considered useful.
Participants liked the booklet as it reminded them to carry out their exercises, was helpful to refer to when
practising and enabled them to log results. Participants also found that the DVD helped when practising
the exercises. However, although some preferred the DVD because it showed them how to perform the
exercises, some preferred the booklet because it could be carried anywhere:
. . . with the DVD it was actually showing you.
P11, male, DVD
I liked the booklet better . . . because I could just pick it up and, you know, look at it and um do some
of the exercises when I wanted to.
P2, female, DVD
Generally, participants felt that the booklet and the DVD complemented each other:
I found by reading the booklet and then watching the DVD the two matched and I could see what
was meant.
P13, female, DVD
Impact of breathing retraining
The three main ways that participants felt that their lives were impacted by breathing retraining were in
undergoing regular practice, having an increased awareness of breathing and developing new habits.
Many participants reported initially practising breathing techniques regularly (more than three times a day),
in line with recommendations, and felt that this had facilitated development of new habits. Also, many
mentioned increased awareness of their breathing. Talking to the physiotherapist or watching the DVD
and practising the exercises made them aware that they had been breathing incorrectly:
I’m a habitual mouth breather and to realise that I’d been breathing wrong all my life was a bit of an
eye opener.
P10, female, face-to-face physiotherapy
I do try to make myself aware of breathing through my nose all the time.
P11, male, DVD
Many participants mentioned being able to perform stomach breathing and nose breathing automatically.
They had internalised this new way of breathing so it became a habit:
I can at rest actually do the stomach breathing pretty much naturally now.
P3, female, DVD
I still try and do it [nose breathing].
P12, male, face-to-face physiotherapy
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Benefits of breathing retraining
Participants also mentioned many health benefits that they associated with breathing retraining, including
increased control over breathing, reduced need for medication, feeling more relaxed and improved health
and QoL. Almost all participants mentioned increased control over breathing. They reported being able to
use the techniques to breathe through asthma attacks:
I had two asthma attacks last year . . . and um actually being able to do this breathing helped a lot
and I didn’t have to go to hospital.
P14, female, face-to-face physiotherapy
Related to this, breathing retraining was often associated with a reduced need for medication. Many
participants were able to use breathing techniques rather than reaching for a reliever inhaler when they
felt symptoms coming on:
I don’t have to keep getting my inhaler and taking my inhaler um, I can literally just um do some of
these breathing and I feel much better.
P5, female, face-to-face physiotherapy
Participants also mentioned that the breathing techniques helped them to relax:
. . . when things have got a bit busy I have sort of been very conscious to do it and I’ve found it very
helpful and very calming.
P15, male, face-to-face physiotherapy
Other benefits attributed to breathing retraining under the umbrella of improved health and QoL included
being less wheezy, sleeping better and having more energy:
I sleep so much better.
P14, female, face-to-face physiotherapy
I also used to get very wheezy first thing in the morning and that doesn’t seem to be happening now.
P3, female, DVD
Problems with breathing retraining
Participants also mentioned problems with breathing retraining. These included difficulties finding time to
practise and difficulties mastering techniques. Many participants said that it was difficult to find time to
practise the breathing techniques before they were able to fit them fitted into their daily routine:
Initially quite hard to get started. It was finding the time I think um and putting aside a regular time so
that I didn’t skip things.
P13, female, DVD
Barriers included busy schedules and difficulties trying to fit the exercises in during the daytime while at
work, meaning that high levels of motivation were required to carry them out:
I could do as many BREATHE’s in the evening when I’m sat at home . . . but finding the time
throughout the day when I’m at work, that was a bit more challenging.
P5, female, face-to-face physiotherapy
Many participants also mentioned difficulties with mastering the techniques. Many participants found
breath holding most difficult:
. . . the most difficult I found holding my breath.
P4, female, face-to-face physiotherapy
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Ease of mastering the techniques varied. Participants usually found it easier to carry out the techniques
if they had previous experience of them. Apart from one participant in the face-to-face group who
experienced severe problems with breath holding, an inability to carry out the techniques appeared more
common in the DVD group:
I have to say um, no matter how I tried, and on the DVD it said it would come eventually, I cannot
breathe through my diaphragm.
P7, female, DVD
Some participants found it difficult to apply the techniques in particular situations:
I can’t quite master the stomach breathing when I am moving around, but no doubt that will come.
P3, female, DVD
Discussion
Reasons for taking part in the BREATHE trial included being asked to, to enhance progress in research,
to feel better/reduce symptoms and to reduce medication use. Participants in the face-to-face group had
a positive impression of the physiotherapist, liked receiving treatment tailored to their needs and found
meetings motivational. All participants liked the materials. The impact of breathing retraining included
regular practice of the exercises leading to increased awareness of breathing and the development of new
habits. The perceived benefits of breathing retraining included increased control over breathing, a reduced
need for medication, feeling more relaxed and improved health and QoL. However, problems included
difficulties in finding time to practise and with mastering techniques.
Strengths and limitations of the study
This is the first full analysis of patients’ experiences of breathing retraining for asthma self-management.
However, it has several limitations. Although participants were randomised to their treatment arm of the
trial, they self-selected into this nested qualitative process evaluation. Despite attempts to reduce socially
desirable responding, participants may have felt pressure to report positive outcomes. In addition, the
interviewer may have brought bias from being involved in creating the intervention, although participants
were unaware of this.
Interpretation of the findings in relation to previously published work
There was very little intentional non-engagement in breathing retraining. Participants wanted to improve
their asthma control and reduce their reliance on medication. Previous research has also shown that people
with asthma adopt non-pharmacological methods of management to reduce reliance on medication.37,40
Most participants reported practising intensively (more than three times a day) for the initial 3–4 weeks, as
recommended by the physiotherapist and in the booklet. Following this, participants reported increased
awareness of their breathing and that breathing techniques had become habitual, in line with research
showing that habit formation is an effective health behaviour change strategy.41
Participants in the face-to-face group were very positive about the physiotherapist. Many said that the
meetings motivated them to carry on with their exercises, with participants in the DVD group stating that
they would have preferred to see the physiotherapist. Similarly, in a trial of vestibular rehabilitation for
dizziness delivered with or without telephone support, all participants reported preferring telephone
support.42 A reported inability to master certain techniques appeared to be more common in the DVD
group. Although many face-to-face physiotherapy participants mentioned finding diaphragm breathing,
breath holding and slow breathing difficult initially, several in the DVD group reported being unable to
master diaphragm breathing. Those who saw the physiotherapist said that she had tailored the treatment to
their needs and they felt able to improve with this support and encouragement. However, the BREATHE trial
showed that face-to-face physiotherapy was only marginally more effective than the DVD. Similarly, in a trial
of vestibular rehabilitation, telephone support did not lead to greater improvements than a booklet.35
Although personal contact may enhance confidence in carrying out techniques, this does not necessarily
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lead to greater benefits. However, a minority of individuals may need face-to-face instruction to master
novel techniques. The perceived benefits of breathing retraining included better asthma control, meaning
that participants were able to breathe their way through asthma attacks and, in some cases, possibly even
avoid hospital admissions; reduced use of reliever medication, meaning that participants felt more in control
of their asthma and less worried if an inhaler was not available; feeling more relaxed; and sleeping better.
Participants also reported having more energy and feeling better. These benefits are similar to those found
in previous breathing retraining trials.3,17 Many participants reported difficulties with finding time to perform
the breathing exercises until they were able to make them part of their routine. One participant reported
dropping out of the trial because of difficulty finding time to practise. People who saw the booklet during
the development phase predicted that it would be difficult for those working full-time and/or with young
children to find time to practise the exercises.37 However, in contrast to previous findings,37 all participants
saw the relevance of breathing retraining, possibly because the trial was open only to those whose QoL was
affected by asthma.
Implications for health care and recommendations for research
Breathing retraining was well received by participants in both groups, with many reporting improved
well-being, and is likely to be acceptable and valued as an adjuvant treatment in general practice, whether
delivered face-to-face or by DVD. Given the greatly increased availability of DVD delivery, plus the limited
increased benefit provided by face-to-face physiotherapy, making the breathing training DVD (and booklet)
widely available may lead to improved asthma control in the general population. This could be tested in a
large-scale RCT. To increase the confidence of individuals carrying out breathing retraining delivered by
DVD, it might be helpful to inform them that research has demonstrated equivalent benefit of the DVD
delivery method to face-to-face physiotherapy. Also, individuals offered breathing retraining delivered by
DVD could be provided with a telephone number to contact in case they experienced difficulties in
mastering the techniques, to enhance the benefits of breathing retraining. Overall, though, breathing
training is likely to be well received as a method of asthma management.
Quantitative process evaluation
The objective of the quantitative process evaluation was to quantify patient-reported expectations of
treatment, experiences of treatment and engagement. This process evaluation included five main sets
of analyses:
1. Sensitivity analyses – of engagement with and amount of practice of the BREATHE exercises reported at
3 months’ follow-up. The rationale for these analyses was to assess treatment efficacy in participants
who met ‘threshold engagement’ levels; that is, efficacy is expected to be greater in those who have
looked at the DVD/booklet and carried out breathing retraining at least once, and to investigate
whether participants who practised the exercises more regularly derived more benefit.
2. Between-group differences – to explore whether there was a difference between the two intervention
groups on measures of expectancy, experience, treatment engagement and practical barriers.
3. Predictors of the amount of practice and continuous engagement – to assess whether expectancy,
experience and practical barriers are associated with the amount of practice (at 3 months) and
continuous engagement (at 6 and 12 months).
4. Analyses were carried out to model the theory of planned behaviour and explore whether intentions,
the amount of practice, engagement and continued engagement can be predicted by the model.
5. The factor structure of the Problematic Experiences of Therapy Scale (PETS)43 was checked using
exploratory factor analysis as it has not previously been used in an asthma population.
Methodology
Immediately after randomisation, participants in the two intervention groups (DVD or face-to-face
physiotherapy) were shown the booklet and asked to complete a questionnaire assessing expectancy
(their beliefs about asthma and their first impressions of the intervention to which they had been
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allocated). At the 3-month follow-up, participants in the two intervention groups were asked to complete
brief questionnaires relating to their experiences of treatment, engagement with treatment and perceived
barriers to carrying out the treatment. Questions to assess whether or not participants continued using the
two treatments were included at the 6- and 12-month follow-ups.
Measures
Expectancy (baseline)
Beliefs about asthma
l Perceived causes. A single item from the Brief Illness Perceptions Questionnaire (IPQ) was used.44 People
with asthma commonly attribute the cause of their asthma to external factors such as being hereditary
or being caused by a respiratory virus, pollution or allergies.44,45 According to the common sense model
of illness, such beliefs can have an impact on a variety of illness outcomes.46 Research has shown that
external causal attributions are associated with adherence to asthma medication; however, it is unclear
whether these beliefs are associated with higher or lower levels of adherence.47,48 The impact of causal
attributions on illness outcome has not yet been explored in relation to other types of asthma treatment
such as breathing retraining. The Brief IPQ item asks people to write their own top three (in rank order)
perceived causes of their illness; therefore, we did not need to use or create a list. However, as the most
common items selected by people with asthma are hereditary, a respiratory virus, pollution and allergies,
we expected these to be the main responses to this question.
l Perceived chronicity. A single item was used to measure whether or not participants believed that asthma
was a chronic condition.49 Many people with asthma perceive their illness to be an acute episodic illness
rather than a chronic one. The belief that they have asthma only if they are having symptoms (the ‘no
symptoms, no asthma’ belief) is associated with low adherence to inhaled corticosteroids and beliefs that
inhaled corticosteroids are important to use when symptomatic but not asymptomatic, and with lower
participation in self-management tasks such as peak flow monitoring or routine doctor visits.49
First impressions of the treatment
l Expectancy. Expectancy (improvements that a person believes will be personally achieved during
treatment)50 is an important non-specific factor that can impact on the adherence to and outcome
of treatment.51 As well as being an important non-specific factor, outcome expectancy (along with
self-efficacy) is also a central tenet of Bandura’s social cognitive theory.52 It was expected that the
face-to-face treatment group would reach greater levels of expectancy than the home-based treatment
group. Expectancy was measured using the three expectancy items from the Credibility/Expectancy
Questionnaire,50 which were standardised and summed for analysis.
l Self-efficacy. Self-efficacy is a well-documented predictor of treatment outcome and, together
with expectancy, has been associated with subjective recovery and adherence to physiotherapy53
and outcomes such as AQLQ score in people with asthma.54,55 The items selected were based on
Lorig’s three-item Exercise Regularly Scale,56 which was created to assess self-efficacy to perform
self-management behaviours in people with chronic disease, correctly, every day and without making
their symptoms worse. The three self-efficacy items are rated on a scale from 0 to10. Responses were
summed and averaged for analysis.
l Perceived need for support (baseline). A single-item question was included to assess how important
the participants (in both active treatment groups) felt it would be to receive physiotherapist support
(i.e. whether the physiotherapist sessions were anticipated by participants to be useful and adding
value beyond the booklet itself, regardless of whether or not they would be receiving this support).
l Theory of planned behaviour. The theory of planned behaviour model hypothesises that attitudes,
subjective norms and perceived behavioural control will predict intentions and that intentions and
perceived behavioural control will predict behaviour (engagement and amount of practice). Consistent
with guidance on constructing a theory of planned behaviour questionnaire,57 semistructured
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qualitative interviews were conducted to elicit salient beliefs to create appropriate items relating to the
components of the model.37 Items in each subscale were summed to create a composite score for
analysis. The factor structure of the constructs was checked using exploratory factor analysis, with
principal axis factoring and direct oblimin rotation, and internal reliability was checked using
Cronbach’s alpha. The structure and internal reliability of the constructs were suitable for further
analysis, with the exception of control-related beliefs, which were of borderline acceptability (α = 0.69).
Therefore, the two items in the control-related beliefs construct were used separately as single items in
further analyses. Redundancy (indicated by multicollinearity) were also noted within the attitudes,
subjective norms and intentions constructs. Although the constructs were summed for these analyses,
future work could reduce participant burden by using a single item for each of these constructs.
¢ Attitudes – three items were created to assess the belief that carrying out the intervention would
be good/bad, beneficial/harmful or useful/useless. Items were reverse coded so that higher scores
reflected a more positive attitude. The internal reliability of the construct was excellent (α = 0.94).
¢ Subjective norms – three items were created to assess the perception that important others
believed that carrying out the intervention would be good/bad, beneficial/harmful or useful/useless.
Items were reverse coded so that higher scores reflected a more positive view (α = 0.98).
¢ Perceived behavioural control – two items were created to assess the perception that it would be
possible to carry out the intervention and that participants were confident that they could carry out
the intervention (α = 0.89).
¢ Intentions – intentions were assessed by three items measuring whether participants would try to,
intended to and wanted to carry out the intervention (α = 0.96). Because of a ceiling effect
(n = 168, 44% of participants endorsing the maximum scores), the data were recoded into a binary
variable (high = 21/low < 21).
¢ Beliefs (attitude related) – four items were created to assess whether the intervention would be
relevant, reduce the use of a reliever inhaler, help the patient to feel more in control of asthma and
help the patient to feel more relaxed (α = 0.87).
¢ Beliefs (control related) – two items were created to assess whether the intervention was perceived
to be time-consuming and difficult to fit into the daily routine. These were used in the analysis as
single items.
Treatment experience (3 months’ follow-up)
l Enjoyment. Intrinsic motivation is an important factor in adherence to rehabilitation and exercise.58,59
Enjoyment is a factor that is considered to underlie intrinsic motivation.60,61 Given the different aspects
of the trial intervention, it was expected that participants would enjoy the therapist appointments,
relaxation and controlled breathing, but dislike the controlled breath holding. It was unclear whether
they would enjoy or dislike carrying out additional physical exercise/activity. The single item measuring
enjoyment used by Reeve,60 with responses measured on a scale from 0 to 10, ranging from not at all
enjoyable to extremely enjoyable, was selected for this study. To allow for the expectation that some
might find the controlled breath holding aversive (a stronger response than not enjoyable), the scale
was adapted from extremely enjoyable to not at all enjoyable to extremely enjoyable to extremely
unpleasant. This question wording presents less bias, allowing a non-judgemental basis for participants
to provide more honest answers. The question was repeated six times in relation to the different aspects
of the intervention (stomach breathing, nose breathing, slow breathing, controlled breath holding,
relaxation training and, in the physiotherapy group only, appointments with the physiotherapist).
l Perceived need for support. A single-item question was included to assess change since baseline in
how important the participants (in both the DVD group and the physiotherapy group) perceived the
physiotherapist support to be (i.e. whether the physiotherapist sessions were perceived by participants
to be useful and to add value beyond the booklet itself, regardless of whether they received this
support or not).
l Perceptions of the physiotherapist (physiotherapy group only). The Treatment Appraisal Questionnaire62
contains five single items (measured on a scale from 1 to 7) relating to ‘perceptions of the therapist’.
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The items assess the degree of trust in the therapist, confidence in the therapist’s qualifications and
competence and the extent to which participants feel comfortable talking to the therapist about their
health and believe that the therapist wants to help them. These factors may all be relevant to
participants undergoing face-to-face treatment. Because of a ceiling effect (n = 74, 77% of participants
endorsing the maximum score), the data were recoded into a binary variable (high = 35/low < 35).
l Problematic Experiences of Therapy Scale. Participants’ perceptions of any adherence problems were
measured using the PETS.43 The PETS was developed to measure patient perceptions of barriers to
adherence to home-based rehabilitation. The four validated PETS subscales were included (problems
due to symptoms – three items; problems due to uncertainty about the therapy – three items; problems
due to doubts – three items; and practical problems – five items), along with a new theoretically
derived subscale to measure problems due to lack of support (three items).
l Treatment engagement. A range of items was included to measure participants’ level of engagement
with breathing retraining in terms of how much they carried out breathing retraining and which
techniques they used. The following items were included:
¢ Carrying out the breathing retraining:
¢ Number of weeks that the breathing retraining was carried out for.
¢ Days per week on average that the breathing retraining was carried out for.
¢ Times per day on average that the breathing retraining was carried out for.
¢ Engagement – engagement is a composite binary variable in which ‘engaged’ was defined as
giving any response above ‘never started’ to any of the first three questions above (number of
weeks, days per week and times per day). Participants were defined as non-engaged if they did
not start breathing retraining at all.
¢ Reason for stopping regular breathing retraining (because they no longer have symptoms of
asthma or for other reasons).
¢ Continuation with occasional breathing retraining (despite not carrying out regular breathing
retraining) – specified in relation to as many as applied out of stomach breathing, nose
breathing, slow breathing, controlled breath holding or relaxation training.
¢ Total time spent on each type of technique:
¢ stomach breathing (number of weeks/hours per day)
¢ nose breathing (number of weeks/hours per day)
¢ slow breathing (number of weeks/minutes per day)
¢ controlled breath holding (number of weeks/minutes per day)
¢ relaxation training (number of weeks/minutes per day).
¢ Amount of practice – amount of practice is a continuous variable that was calculated by multiplying
the responses to the first three questions within the ‘Carrying out the breathing retraining’ section.
These questions related to the number of weeks, number of days per week and number of times
per day, on average, that the breathing retraining was carried out. Participants who did not engage
with the breathing retraining were excluded from the analyses.
Continued treatment engagement (6 and 12 months’ follow-up)
l Five items were included to measure whether participants had continued to carry out breathing
retraining at 6 and 12 months. The five items consisted of one question for each technique (stomach
breathing, nose breathing, slow breathing, controlled breath holding and relaxation training) to find
out how often participants had carried out the exercises [measured on a five-point scale ranging from
never to regularly (most days)].
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Results
Sensitivity analyses for engagement with and amount of practice of breathing exercises
reported at 3 months’ follow-up
These are reported with the main trial results (see Chapter 3, Patient engagement with the intervention in
the active treatment arms.)
Analyses of between-group differences to explore whether there is a difference between
the two intervention groups on measures of expectancy, experience, treatment
engagement and practical barriers
T-tests and chi-squared tests were used to explore whether there were any differences between the
treatment groups on measures of expectancy, experience, treatment engagement and practical barriers.
Content analysis was performed on the three open-ended text items that measured perceived causes. A total
of 937 responses were given, the majority of which could be grouped into eight main themes: allergies
(245 responses), health issues (142 responses, such as viral infections, radiotherapy, obesity, pregnancy/
menopause, glandular fever and childhood conditions), smoking (114 responses), pollution/environmental
causes (104 responses), hereditary causes (79 responses), stress/psychological causes (65 responses), weather
(65 responses) and exercise (59 responses). The three categories with the highest frequencies (allergy, health
issues and smoking) were binary coded into present/absent in the data and used in between-group analyses.
Participants could attribute up to three causes. Using this recoded data, a total of 192 participants (49%)
believed that their asthma was caused by allergies, 120 (31%) by health issues and 110 (28%) by smoking.
With regard to perceived chronicity, 44% of participants thought of asthma as a chronic disease, with the
remainder reporting some degree of the ‘no symptoms, no asthma’, acute episodic disease belief (16%
believed that they had asthma most of the time, 20% some of the time and 21% only when they were
having symptoms). The data were analysed in relation to each of these four categories separately.
There were no significant differences between the two treatment arms with regard to beliefs about the causes
or chronicity of asthma. However, having been given the booklet to look through and told what group they
had been allocated to, the face-to-face physiotherapy group had more positive perceptions of breathing
retraining than the DVD group. (Table 49). Being aware that they would be receiving physiotherapist support
led to significantly more positive attitudes and attitude-related beliefs, a greater sense of perceived behavioural
control and higher intentions to carry out breathing retraining in the physiotherapy group. Those anticipating
physiotherapist support were significantly less likely to believe that carrying out breathing retraining would be
too time-consuming or difficult to fit into their daily routine. Those who were aware that they had been
randomised to the physiotherapist group felt a significantly greater need for the physiotherapist support than
those who were aware that they had been randomised to the DVD group.
The majority of participants in the face-to-face physiotherapy group found the appointments with the
physiotherapist to be extremely enjoyable (93% rated the appointments as ≥ 8 out of 10) and 77% had
the best possible perceptions of their physiotherapist. Those in the face-to-face physiotherapy group
continued to perceive a significantly greater need for physiotherapist support than those in the DVD group
and they also reported a significantly more positive treatment experience in relation to enjoyment of
stomach breathing, nose breathing and relaxation training than those in the DVD group. They also
experienced significantly fewer problems as a result of symptoms, uncertainty, doubt and lack of support.
There were no differences between the face-to-face physiotherapy group and the DVD group in terms of
the level of enjoyment of controlled breath holding or practical problems (Table 50).
Overall, engagement with breathing retraining was extremely high, with 98.1% of responders reporting
that they had attempted at least one of the breathing retraining techniques (Table 51). Only five participants
(1.9%), who were all allocated to the DVD group, reported not attempting any breathing retraining at all.
Participants who had received face-to-face physiotherapy were significantly more likely than those in the
DVD group to have carried out breathing retraining more times per day, more days per week and for more
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weeks, and to have completed more practice sessions. This particularly applied to the stomach breathing
and nose breathing, but also to the slow breathing and controlled breath holds to a lesser, but still
significant, extent. Among those who stopped regular practice (n = 97), those in the face-to-face
physiotherapy group were significantly more likely to continue with occasional practice of nose breathing.
The positive effect of physiotherapist support on stomach breathing and nose breathing also had lasting
effects, with participants in the physiotherapy group continuing to carry out the stomach breathing and nose
breathing significantly more often than those in the DVD group at both 6 months’ and 12 months’ follow-up
(Table 52).
TABLE 49 Beliefs about asthma and first impressions of the treatment in the face-to-face physiotherapy and
DVD arms
Beliefs about asthma and first impressions of
treatment
Treatment arm, baseline
Group differencea p-valueDVD Physiotherapy
Beliefs about asthma, n (%)
Perceived causes
Cause 1 – allergy 125 (48) 67 (51) 0.29 0.592
Cause 2 – health issues 81 (31) 39 (30) 0.09 0.762
Cause 3 – smoking 69 (26) 41 (31) 0.93 0.335
Perceived chronicity 2.03 0.566
All the time 112 (45) 54 (42)
Most of the time 41 (16) 18 (14)
Some of the time 45 (18) 31 (24)
Only when symptoms present 52 (21) 27 (21)
First impressions of treatment, mean (SD)b
Expectancy (n= 243, n= 124) –0.11 (2.74) 0.24 (2.66) –1.20 (–0.95 to 0.23) 0.233
Self-efficacy (n= 252, n = 129)c 7.70 (1.62) 8.01 (1.48) –1.84 (–0.62 to 0.05) 0.067
Perceived need for physiotherapist support –
baseline (n= 250, n = 127)c
2.15 (1.26) 3.43 (0.87) –11.48 (–1.49 to –1.06) 0. 001
Theory of planned behaviour constructs
Attitudes (n = 239, n = 119)c 16.45 (3.75) 17.74 (2.82) –3.64 (–1.96 to –0.66) 0.001
Subjective norms (n= 235, n= 117)c 16.82 (3.89) 17.62 (3.72) –1.85 (–1.62 to –0.04) 0.059
Perceived behavioural control (n= 251,
n = 130)c
11.05 (2.64) 12.07 (2.37) –3.84 (–1.56 to –0.47) 0.001
Intentions, n (%) (n= 249, n= 129) 99 (40) 69 (54) 6.49 0.011
Beliefs (attitude related) (n = 245, n= 125)c 21.99 (4.23) 23.07 (4.37) –2.31 (–1.98 to –0.19) 0.020
Beliefs (control related)
Time-consuming (n = 252, n= 127)c 4.10 (1.80) 3.65 (1.73) –2.31 (0.03 to 0.83) 0.024
Difficult to fit into routine (n= 252,
n= 126)c
3.33 (1.74) 2.86 (1.73) –2.47 (0.08 to 0.86) 0.013
a For categorical variables [baseline scores presented as n (%)] chi-squared test statistics are presented; for continuous
variables [baseline scores presented as mean (SD)] parametric t-test statistics and 95% CIs are presented (bootstrapped
when specified).
b n values represent numbers of included participants in the DVD and physiotherapy groups respectively.
c Bootstrapped 95% CI and p-value reported.
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TABLE 50 Perceived experience of carrying out breathing retraining in the face-to-face physiotherapy and DVD arms
Treatment experiencea
Treatment arm, 3-month
follow-up
Group differenceb p-valueDVD Physiotherapy
Enjoyment of treatment, mean (SD)
Stomach breathing (n= 159, n= 104) 6.13 (1.99) 7.42 (1.67) –5.71 (–1.75 to –0.85) < 0.001
Nose breathing (n= 160, n = 104) 6.06 (2.18) 7.52 (1.78) –5.96 (–1.95 to –0.98) < 0.001
Slow breathing (n= 159, n= 103) 6.22 (2.01) 6.69 (2.12) –1.81 (–0.98 to 0.04) 0.072
Controlled breath holding (n= 158, n = 103) 5.54 (2.29) 5.43 (2.18) 0.41 (–0.44 to 0.68) 0.681
Relaxation training (n= 155, n= 102) 6.97 (1.80) 7.62 (2.38) –2.32 (–1.19 to –0.10) 0.022
Appointments with physiotherapist (physiotherapy
group only) (n = 103), median (IQR); minimum,
maximum
9 (9–10); 1, 10
Perceived need for physiotherapist support
(3 months) (n = 158, n = 101), mean (SD)
1.85 (1.38) 3.64 (0.72) –13.73 (–2.05 to –1.54) < 0.001
Perceptions of physiotherapist (physiotherapy
group only) (n = 96), n (%)
74 (77)
PETS, n (%)
Problems due to symptoms (n = 155, n= 103) 49 (31.6) 21 (20.4) 3.94 0.047
Problems due to uncertainty (n= 156,
n = 101)
75 (48.1) 14 (13.9) 31.71 < 0.001
Problems due to doubts (n= 166, n= 105) 90 (54.2) 24 (22.9) 25.95 < 0.001
Practical problems (n= 166, n = 105) 141 (84.9) 84 (80.0) 1.11 0.291
Problems due to lack of support (n= 166,
n = 105)
74 (44.6) 17 (16.2) 23.24 < 0.001
a n values represent numbers of included participants in the DVD and physiotherapy groups respectively.
b Unless specified otherwise, for categorical variables [baseline scores presented as n (%)] chi-squared test statistics are
presented; for continuous variables [baseline scores presented as mean (SD)] parametric t-test statistics and 95% CIs
are presented.
TABLE 51 Engagement and number of practice sessions completed in the face-to-face physiotherapy and DVD arms
Engagement and number of practice
sessionsa
Treatment arm, 3-month
follow-up
Group differenceb p-valueDVD Physiotherapy
Carrying out the breathing retraining
Engagement with breathing retraining (overall)
(n = 261, n= 132), n (%)
256 (98.1) 132 (100) 2.56 0.110
Number of weeksc,d (n = 165, n = 103), mean (SD) 3.68 (1.38) 4.32 (0.87) –4.67 (–0.92 to –0.38) 0.001
Days per weekc,e (n= 165, n= 103), mean (SD) 2.52 (1.20) 3.08 (1.02) 4.07 (–0.83 to –0.28) 0.001
At least twice per day (n = 164, n= 105), n (%) 46 (28.0) 58 (55.2) 19.96 < 0.001
Amount of practice sessions completed (overall)c
(n = 164, n= 102), mean (SD)
48.56 (44.71) 75.01 (46.38) –26.45 (–37.68 to –14.97) 0.001
Stopped regular practice as no asthma symptoms
(n = 162, n= 105), n (%)
14 (8.6) 5 (4.8) 1.45 0.228
Stopped regular practice for other reasons
(n = 160, n= 101), n (%)
61 (38.1) 27 (26.7) 3.60 0.058
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Correlates and predictors of the amount of practice and continued engagement
Analyses were carried out to assess whether expectancy, experience and practical barriers were associated
with amount of practice (at 3 months) and continued engagement (at 6 months and 12 months). As
engagement was 98% in the DVD group and 100% in the face-to-face physiotherapy group, there was
no variation in the data to be able to carry out the planned analyses in relation to non-engagement.
TABLE 51 Engagement and number of practice sessions completed in the face-to-face physiotherapy and DVD
arms (continued )
Engagement and number of practice
sessionsa
Treatment arm, 3-month
follow-up
Group differenceb p-valueDVD Physiotherapy
Stopped regular practice but continued with occasional practice, n (%)
Overall (n = 66, n= 31) 61 (92.4) 30 (96.8) 0.69 0.407
Stomach breathing (n = 61, n= 30) 44 (72.1) 26 (86.7) 2.39 0.122
Nose breathing (n= 61, n = 30) 38 (62.3) 26 (86.7) 5.72 0.017
Slow breathing (n= 61, n= 30) 42 (68.9) 19 (63.3) 0.28 0.599
Controlled breath holding (n= 61, n= 30) 13 (21.3) 6 (20.0) 0.02 0.885
Relaxation training (n = 61, n= 30) 27 (44.3) 10 (33.3) 1.00 0.318
Total time spent on each breathing technique, mean (SD)
Stomach breathing
Number of weeksd (n= 159, n= 100) 3.53 (1.56) 4.35 (1.05) –5.03 (–1.16 to –0.49) 0.001
Hours per dayf (n = 157, n= 99) 1.39 (0.99) 2.11 (1.20) –5.00 (–1.01 to –0.42) 0.001
Nose breathing
Number of weeksd (n= 159, n= 101) 3.52 (1.66) 4.33 (1.03) –4.81 (–1.14 to –0.47) 0.001
Hours per dayf (n = 157, n= 101) 1.81 (1.27) 2.45 (1.34) –3.81 (–0.97 to –0.34) 0.001
Slow breathing
Number of weeksd (n= 160, n= 101) 3.44 (1.53) 3.89 (1.27) –2.55 (–0.80 to –0.11) 0.012
Minutes per day
g
(n= 159, n= 101) 2.10 (1.35) 2.45 (1.28) –2.05 (–0.68 to –0.02) 0.039
Controlled breath holding
Number of weeksd (n= 160, n= 101) 2.88 (1.76) 3.32 (1.57) –2.08 (–0.79 to –0.07) 0.020
Minutes per dayh (n= 159, n= 101) 1.74 (1.09) 1.83 (1.11) –0.69 (–0.37 to 0.19) 0.497
Relaxation training
Number of weeksd (n= 160, n= 101) 3.01 (1.86) 3.29 (1.66) –1.27 (–0.70 to 0.16) 0.217
Minutes per dayi (n= 160, n= 101) 1.86 (1.24) 1.64 (1.20) 1.41 (–0.10 to 0.50) 0.159
a n values represent numbers of included participants in the DVD and physiotherapy groups respectively.
b For categorical variables [baseline scores presented as n (%)] chi-squared test statistics are presented; for continuous
variables [baseline scores presented as mean (SD)] parametric t-test statistics and 95% CIs are presented (bootstrapped
when specified).
c Bootstrapped 95% CIs and p-values reported.
d Coding: 0= did not use, 1= 1 week, 2= 1–2 weeks, 3 = 3–5 weeks, 4= 6–8 weeks, 5=≥ 9 weeks.
e Coding: 0= did not use, 1= 1–2 days, 2= 3–4 days, 3= 5–6 days, 4=most days.
f Coding: 0= did not use, 1=≤ 1 hour, 2=≤ half a day, 3= > half a day, 4=most of the day.
g Coding: 0= did not use, 1= up to 5 minutes, 2= 6–10 minutes, 3= 11–20 minutes, 4= 21–30 minutes,
5=≥ 30 minutes.
h Coding: 0= did not use, 1= up to 2 minutes, 2= 3–5 minutes, 3= 6–8 minutes, 4 =≥ 8 minutes.
i Coding: 0= did not use, 1= up to 5 minutes, 2= 6–10 minutes, 3= 11–15 minutes, 4=≥ 15 minutes.
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For the continuous outcomes (amount of practice at 3 months and continued engagement at 6 months
and 12 months), point-biserial (for binary expectancy variables) and bivariate (for continuous expectancy
variables, treatment experience and practical barriers) correlations were used to identify significant variables
to be entered into multiple linear regressions for each outcome. All of the correlations are presented in
Appendix 13 and significant correlations are presented in Table 53.
Among the correlations, a moderate-sized effect size was found for the relationship between self-efficacy
and amount of practice at 3 months and continued engagement at both 6 and 12 months, but only in the
DVD group. Believing that asthma was caused by allergy was associated with more practice at 3 months in
the face-to-face physiotherapy group. Believing that asthma was caused by health issues was associated
with less continued engagement at 12 months in the DVD group. Believing that asthma was caused by
smoking was associated with both more practice at 3 months in the DVD group and greater continued
engagement at 12 months in the face-to-face physiotherapy group.
In the DVD group, higher expectancy (agreeing strongly that asthma symptoms will be improved by breathing
retraining), greater self-efficacy for breathing retraining and greater perceived behavioural control regarding
breathing retraining were associated with more practice at 3 months and greater continued engagement at
6 months. However, the only one of these factors that predicted greater continued engagement at 12 months
was self-efficacy for breathing retraining. In addition, stronger intentions to carry out breathing retraining were
associated with greater continued engagement at 6 and 12 months in the DVD group. Although the perceived
need for support was high in the face-to-face physiotherapy group at baseline, it did not relate to the amount
of practice or continued engagement.
In the DVD group, greater enjoyment of treatment was associated with more practice at 3 months and
greater continued engagement at 6 and 12 months for all aspects of breathing retraining (stomach breathing,
nose breathing, slow breathing, controlled breath holds and relaxation). However, the findings were less
TABLE 52 Continued engagement at 6 and 12 months in the face-to-face physiotherapy and DVD arms
Exercisea
Treatment arm, mean (SD)
Group differenceb p-valueDVD Physiotherapy
6-month follow-up
Number included 156 96
Stomach breathing 2.18 (1.24) 2.94 (1.02) –5.04 (–1.05 to –0.46) < 0.001
Nose breathing 2.43 (1.31) 2.83 (1.19) –2.46 (–0.73 to –0.08) 0.014
Slow breathing 2.22 (1.20) 2.48 (1.11) –1.73 (–0.56 to 0.36) 0.085
Controlled breath holding 1.92 (1.26) 1.81 (1.16) 0.70 (–0.20 to 0.42) 0.512
Relaxation training 1.83 (1.24) 2.01 (1.30) –1.12 (–0.51 to 0.14) 0.264
12-month follow-up
Number included 153 96
Stomach breathing 2.18 (1.18) 2.72 (1.12) –3.59 (–0.84 to –0.25) < 0.001
Nose breathing 2.31 (1.25) 2.66 (1.26) –2.09 (–0.67 to –0.02) 0.037
Slow breathing 2.20 (1.17) 2.38 (1.07) –1.21 (–0.47 to 0.11) 0.226
Controlled breath holding 1.84 (1.20) 1.66 (1.03) 1.22 (–0.11 to 0.47) 0.225
Relaxation training 1.75 (1.22) 1.93 (1.19) –1.16 (–0.49 to 0.13) 0.249
a Coding: 0= never, 1= once or twice, 2= sometimes, 3= often, 4= regularly (most days).
b Parametric t-test statistics and 95% CIs are presented (bootstrapped when specified).
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TABLE 53 Expectancy, experience and practical barriers variables that were significantly correlated with amount of practice (at 3 months) and continued engagement
(at 6 and 12 months)
Amount of practice at 3 months
Continued engagement at
6 months 12 months
DVD Physiotherapy DVD Physiotherapy DVD Physiotherapy
l Cause: smoking
l Asthma present ‘most of
the time’
l Expectancy
l Self-efficacy
l Perceived behavioural
control
l Stomach breathing
l Nose breathing
l Slow breathing
l Controlled breath holding
l Relaxation training
l Perceived need for support
(3 months)
l Problems due to uncertainty
l Problems due to doubts
l Practical problems
l Problems due to lack
of support
l Cause: allergy
l Stomach breathing
l Nose breathing
l Perceived need for
support (3 months)
l Perceptions of
physiotherapist
l Problems due
to doubts
l Practical problems
l Problems due to
lack of support
l Expectancy
l Self-efficacy
l Perceived behavioural control
l Intentions
l Stomach breathing
l Nose breathing
l Slow breathing
l Controlled breath holding
l Relaxation training
l Problems due to symptoms
l Problems due to uncertainty
l Problems due to doubts
l Practical problems
l Problems due to lack
of support
l Stomach breathing
l Nose breathing
l Controlled breath
holding
l Relaxation training
l Cause: health issues
l Self-efficacy
l Intentions
l Stomach breathing
l Nose breathing
l Slow breathing
l Controlled breath holding
l Relaxation training
l Problems due to doubts
l Practical problems
l Problems due to lack
of support
l Cause: smoking
l Stomach breathing
l Slow breathing
l Controlled breath holding
l Relaxation training
l Perceived need for
support (3 months)
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consistent for the face-to-face physiotherapy group. Greater enjoyment of treatment was associated with
more practice at 3 months for stomach and nose breathing, greater continued engagement at 6 months
for stomach breathing, nose breathing, controlled breath holding and relaxation and greater continued
engagement at 12 months for stomach breathing, slow breathing, controlled breath holding and relaxation.
Experience of appointments with the physiotherapist was not related to practice or continued engagement.
With regard to practical barriers, in the DVD group problems due to uncertainty were associated with less
practice at 3 months and less continued engagement at 6 months. Problems due to doubts, practical
problems and lack of support were associated with less practice at 3 months in both the DVD group and
the face-to-face physiotherapy group. Problems due to doubts and practical problems were associated with
less continued engagement at 6 and 12 months in the DVD group only. Problems due to lack of support
were associated with less continued engagement at 6 months in the DVD group only. Problems due to
symptoms were associated with less continued engagement at 6 months in the DVD group only.
The significant correlates shown in Table 53 were input into the multiple regression detailed in Appendix 14
to predict the amount of practice at 3 months. More practice at 3 months was predicted by fewer practical
problems and fewer problems due to lack of support (R2 = 0.33, (F17,66 = 1.92; p < 0.05). This model
explained 33% of the variance in practice at 3 months. This means that individuals who experienced fewer
practical problems in carrying out breathing retraining and fewer problems due to lack of support
practised more.
The significant correlates shown in Table 53 were input into the multiple regression detailed in Appendix 15
to predict continued engagement at 6 months. More engagement at 6 months was predicted by fewer
problems due to symptoms, fewer problems due to doubts and finding relaxation training enjoyable. This
model explained 24% of the variance in continued engagement at 6 months (F14,174 = 3.97; p < 0.001).
According to this model, individuals who experienced fewer problems due to symptoms and doubts and
who found relaxation training more enjoyable were more likely to continue to engage with breathing
training at 6 months.
The significant correlates shown in Table 53 were input into the multiple regression in Appendix 16 to
predict variables associated with continued engagement at 12 months. The overall model was significant,
explaining 17% of the variance in continued engagement at 12 months (F12,173 = 3.05; p < 0.001).
However, no individual predictors of continued engagement at 12 months were identified.
Analyses to model the theory of planned behaviour and explore whether intentions,
amount of practice, engagement and continued engagement can be predicted by
the model
The theory of planned behaviour hypothesises that attitudes, subjective norms and perceived behavioural
control will predict intentions and that intentions and perceived behavioural control will predict behaviour
(amount of practice and continued engagement at 6 months and 12 months). Correlational analyses
indicated that there is a strong relationship among most of the variables (see Appendix 17).
A logistic regression was carried out to assess the role of attitudes, subjective norms and perceived
behavioural control in the prediction of intentions (see Appendix 18). Overall, the model was a good fit to
the data (χ2 (6) = 154.23; p < 0.001). Perceived behavioural control was found to be a significant predictor
of intentions (odds ratio 2.21, 95% CI 1.79 to 2.72), but attitudes and subjective norms were not.
A hierarchical linear regression assessed the role of intentions and perceived behavioural control in
predicting continued engagement at 6 months (see Appendix 19). The final model, in which perceived
behavioural control was the only significant predictor of continued engagement, explained 3% of the
variance in continued engagement at 6 months: (F2,242 = 7.31; p < 0.001).
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A multiple regression was carried out to assess the role of intentions and perceived behavioural control in
predicting continued engagement at 12 months (see Appendix 20). Intention was entered in the first step
and was a significant predictor (95% CI 0.40 to 2.71). Although neither factor was significant at the
second step, the model was a significant predictor, explaining 3% of the variance (F2,238 = 3.87; p < 0.05).
Finally, a multiple regression was carried out to assess the role of intentions and perceived behavioural
control in predicting the amount of practice at 3 months (see Appendix 21). No significant predictors
were identified. The model explained 1% of the variance in the amount of practice at 3 months
(F2,257 = 2.99; p = 0.05).
Checking the factor structure of the Problematic Experiences of Therapy Scale
The factor structure of the PETS was checked using exploratory factor analysis [principal axis factoring, with
oblique (direct oblimin) rotation to allow for correlations between factors] as (1) it has not previously been
used in an asthma population and (2) the ‘problems due to lack of support’ subscale questions were new
and had not previously been validated. The model was forced into the hypothesised five-factor solution and
items 3 and 5 were excluded from the analysis because of multicollinearity. The fit of the final model was
good. The determinant (0.00002) indicated no further multicollinearity and the Kaiser–Meyer–Olkin (KMO)
measure of sampling adequacy indicated that the data were suitable for factor analysis (KMO = 0.86).
Bartlett’s test of sphericity was significant (χ2 (105) = 2283.81; p < 0.001), indicating that there was a
sufficient relationship between the variables. Communalities were all > 0.5, indicating sufficient common
variance between the variables. The pattern matrix (see Appendix 22) showed that all items loaded clearly
onto their intended factors (all loadings were > 0.63, with no cross-loading). The biggest amount of
variance in the data set was explained by the new ‘problems due to lack of support’ subscale, which
accounted for 44.49% of the total variance, substantially more than any of the other subscales (which
ranged between 6.64% and 15.25%).
All subscales showed good internal consistency. The inter-item correlation matrices were all > 0.3 and the
corrected item–total correlations were also well above 0.3. The overall Cronbach’s alpha values were all
good and ranged from 0.76 to 0.90 (see Appendix 22). A higher Cronbach’s alpha value (increasing
from 0.85 to 0.90) could have been achieved if item 15 were deleted from the ‘problems due to lack of
support’ subscale. However, it was decided to retain the item as it had a good theoretical fit and seemed
suitable according to all other aspects of the exploratory factor and Cronbach’s alpha analyses. Appendix 23
shows the component correlation matrix between the five factors. It is interesting to note that there are both
positive and negative relationships between the factors.
Discussion
After being informed of group allocation, the face-to-face physiotherapy group had more positive
perceptions of breathing retraining than the DVD group, including greater intentions to carry out the
exercises and being less likely to believe that carrying out breathing retraining would be too time-consuming
or difficult to fit into their daily routine. This suggests that physiotherapy delivered by a physiotherapist may
be more positively received than a DVD, and health-care professionals need to think of ways to enhance the
appeal of breathing retraining delivered by DVD in practice. Those who were aware that they had been
randomised to the physiotherapist group also felt a significantly greater need for physiotherapist support than
those who were aware that they had been randomised to the DVD group. This suggests that the anticipation
of support can raise expectations about how much that support is needed. This should be taken into account
when considering patient expectation management in clinical practice. This is particularly important as the
face-to-face physiotherapy group continued to perceive a need for physiotherapist support.
The face-to-face physiotherapy group found the appointments with the physiotherapist to be extremely
enjoyable and reported greater enjoyment of the stomach breathing, nose breathing and relaxation
exercises than those in the DVD group. They also experienced significantly fewer problems due to
symptoms, uncertainty, doubt and lack of support. This shows that the participants in the face-to-face
physiotherapy group felt supported by the physiotherapist and suggests that seeing a physiotherapist is the
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ideal treatment for maximising enjoyment of breathing retraining. However, as the trial was carried out by
a single physiotherapist, it is not clear whether these findings were the result of individual factors related
to the physiotherapist or simply the act of seeing a physiotherapist. Further research is needed to explore
experiences of breathing retraining carried out by more than one physiotherapist. Overall, levels of
engagement with breathing retraining were extremely high, suggesting that access to a DVD plus the
Breathing Freely booklet is sufficient for enabling engagement.
Those in the face-to-face physiotherapy group also spent significantly more time practising breathing
retraining and were more likely to continue to carry out the stomach breathing and nose breathing
exercises at 6 and 12 months than those in the DVD group. This may be because their initial greater levels
of practice led to stomach and nose breathing becoming new habits, in line with research that habit
formation is an effective behaviour change strategy.41
A moderate effect size was found for the relationship between self-efficacy and amount of practice at
3 months and continued engagement at both 6 and 12 months, but only in the DVD group. This suggests
that if people with asthma are being expected to undertake breathing retraining with just the support of a
DVD, it is important that they are confident that they can carry out breathing retraining correctly every
day and without making their symptoms worse. However, although the perceived need for support was
high in the face-to-face physiotherapy group at baseline, it did not relate to the amount of practice or
continued engagement.
Believing asthma to be caused by health issues was associated with less continued engagement at
12 months in the DVD group. This is in line with the medical model: if people believe that asthma is not
under their control, they may be less likely to engage with interventions to reduce symptoms.
In the DVD group, greater enjoyment of treatment was associated with more practice at 3 months and
greater continued engagement at 6 and 12 months, for all aspects of breathing retraining. This suggests
that if people with asthma are being expected to undertake breathing retraining delivered by DVD, it may
be helpful to maximise enjoyment by presenting it in an attractive way. However, these findings were less
consistent for those in the face-to-face physiotherapy group, maybe because seeing the physiotherapist
provided them with greater extrinsic motivation to practise initially.
In the DVD group, more problems due to uncertainty, doubts, practical problems and lack of support were
associated with less practice at 3 months and less continued engagement. This suggests that, if people
with asthma are not confident about breathing retraining and do not feel supported in carrying it out, they
may experience problems in engaging with it. Future research could examine whether or not this issue
might be addressed by providing some (e.g. telephone or online) access to physiotherapist support.
Conclusions
Implications for health care and recommendations for research
Almost all participants engaged with breathing retraining, suggesting that it is likely to be valued as a method
of asthma management. Participants in the face-to-face physiotherapy group enjoyed the techniques more,
reported practising more at 3 months and demonstrated greater continued engagement at 6 and 12 months,
but this was not associated with better outcomes. In the DVD group, those who enjoyed the techniques more
and reported greater confidence in their ability to carry them out also practised more at 3 months and
demonstrated greater continued engagement with the techniques at 6 and 12 months.
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Chapter 7 Discussion
Study findings
Overview
We report the results of a pragmatic, three-arm, parallel-group RCT comparing the effectiveness of a
breathing retraining programme for people with suboptimal asthma control delivered by a self-guided
programme (as a DVD with a supporting booklet, both developed for the study) with the effectiveness of a
three-session face-to-face breathing retraining programme delivered by a respiratory physiotherapist and a
control consisting of usual care. To our knowledge this is by far the largest and most rigorous study on
breathing retraining exercise to be reported in the world literature. This was designed as a ‘pragmatic’
study, that is, one that had broad entry criteria to allow the participation of most people with asthma in the
community and that included study measurements and procedures that interfered as little as possible with
usual clinical care. Only two study-related visits were made (at baseline and 12 months), with two further
postal questionnaires at 3 and 6 months, and normal care was allowed to proceed over the 12 months of
the study. We supplemented visit measurements and questionnaire data with routinely collected clinical
data from the GP medical record. Our primary outcome was asthma-related QoL, with measurement of a
range of other patient-reported outcomes, objective physiological outcomes and health resource use
outcomes. A formal health economic evaluation was built into the programme and both qualitative and
quantitative process evaluations were carried out. The study was set in primary care, recruiting from
research general practices in Wessex through the CRN, and we successfully achieved recruitment targets,
with a high level of retention in the study. We received good feedback from the practices hosting the study,
from patients and from staff; it was an enjoyable and happy study to be involved in for all concerned.
Key outcomes
The study was powered to show the superiority of both active arms over usual care in terms of
asthma-related QoL and to show equivalence between the active arms, with equivalence margins being those
used in a previous HTA asthma study, which resulted in a New England Journal of Medicine publication.63
Health-related QoL is the outcome measure that best captures the overall effect of asthma on a patient and
we used a very well-validated and widely used instrument to measure this key patient-centred factor in our
study as the primary outcome. We were indeed able to show superiority of both active treatment arms over
usual care and to show equivalence between the two active treatment arms. The improvements in AQLQ
scores were observed by the first (3-month) post-intervention assessment and were maintained or increased
over the course of the study. We were also able to show lower asthma-related health-care costs in both active
treatment arms than in the usual-care arm, which represents a ‘dominant’ health economic assessment, that
is, better outcomes were achieved for lower costs to the NHS. The costs were lowest in the DVD arm, with an
82% chance that usual care was dominated by the provision of the DVD programme.
There was no significant observed change in lung function or in airway inflammation either within or
between randomisation treatment arms over the 12 months of the study. There were consistent trends
towards modest improvements in asthma symptom scores and other patient-reported outcome measures,
asthma attacks, respiratory-related GP consultations and rescue bronchodilator use in the breathing retraining
arms compared with the usual-care arm, but none of these reached statistical significance thresholds, other
than a low-magnitude improvement in the (already low) depression scores in the DVD treatment arm
compared with the usual-care arm. The consistent trends towards improvement with breathing retraining but
lack of statistical significance observed for most patient-reported and health resource use measures may
indicate that these are chance findings or, more likely, a lack of power of the study to show differences
between groups for these outcomes. The reduction in number of asthma attacks is particularly interesting
and has not previously been reported in association with breathing retraining, but this study is much larger
than previous studies that have been carried out and so is better able to detect a signal. Asthma attacks are
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relatively uncommon in patients with mild-to-moderate asthma and so a larger study would be needed to
provide a large enough sample to determine whether breathing exercises can indeed reduce asthma
exacerbations. However, asthma attacks (as defined by the prescribing of oral corticosteroids for worsening
asthma, as recommended by the ERS/ATS Task Force on asthma outcomes)33 were numerically reduced in this
study by approximately one-third in those undergoing breathing retraining. As there was no significant effect
on lung function or airway inflammation, it seems that, if a reduction in exacerbations is confirmed in further
studies, the mechanism is likely to reflect consulting behaviour and tolerance of symptoms, rather than
pathophysiological changes in objective asthma severity. Presented with a patient with asthma attending for
worsening asthma symptoms, GPs have limited therapeutic options, and prescription of a course of oral
steroids is the most likely action. Some of these episodes may spontaneously resolve without steroids and it is
plausible that breathing exercises allowed better symptom control or tolerance on the part of the patient, and
so they deferred presentation to a GP, which could have resulted in the prescription of oral steroids. Adverse
events were rare, were similar between treatment arms and were of the order of magnitude expected in a
12-month study of this size. There was no suggestion that breathing retraining delivered by either modality
caused problems for patients or had any associated adverse events.
The process evaluations confirmed that breathing retraining was acceptable to participants in the study,
most of whom felt it to be relevant and useful. Some of the participants in the DVD arm felt that they
would liked to have had access to a professional to clarify certain things and to help them through the
programme, although the equivalence in outcomes indicates that this was not something that was needed
for the breathing retraining to have an effect in this group of patients. We found a NNT of 40 for one
patient to benefit from face-to-face physiotherapy compared with the self-guided programme, indicating
that for the great majority the self-guided intervention can provide effective breathing retraining. It
remains possible that different groups, for example those with more severe asthma or those with more
severely impaired QoL, may benefit more from seeing a physiotherapist. Future studies are needed to
identify the minority who would benefit from seeing a professional rather than undertaking a self-guided
programme.
Clinical relevance and magnitude of effect
We achieved a statistically significant improvement in both active arms compared with usual care, but,
as this was a large study, it is important to consider the clinical relevance of the improvements that we
observed as well as the statistical significance. The MCID for a patient to notice a difference in QoL is 0.5
for the AQLQ instrument,24 with a change of 1.0 equating to a large improvement. In both the DVD arm
and the physiotherapy arm we observed a mean improvement of 1.1 from baseline, so on average patients
felt considerably better with regard to how their asthma was affecting their life. Approximately two-thirds
of all patients in both breathing retraining arms achieved the MCID of 0.5 over the study period, with
three-quarters reaching the MCID for improvement in the PP population, which may better reflect those
who actually received the breathing retraining. In terms of how large or small these improvements are in
relation to improvements seen with pharmacological interventions commonly used as add-on treatments to
inhaled corticosteroids for people with asthma, we may compare them with those seen in another HTA
programme-funded UK primary care pragmatic asthma study reported by Price et al.63 in the New England
Journal of Medicine, which compared the effectiveness of add-on long-acting beta-agonists (LABAs) with
the effectiveness of leukotriene receptor antagonists (LTRAs) in a directly comparable population to that
in our study, UK primary care-treated adult asthma patients found by screening to have suboptimally
controlled asthma. This study lacked a control arm but, compared with baseline values, the mean
improvements in AQLQ score in the ITT population were 1.0 in the LABA group and 0.8 in the LTRA
group, so slightly lower than those that we observed with breathing retraining.
In our study, we did observe an improvement in AQLQ score in the usual-care arm of a lesser but large
magnitude, with a mean improvement of 0.8 in the ITT population at 12 months and with 56% reaching
the MCID threshold. Improvements in QoL are generally seen in the control and placebo arms in asthma
RCTs. This improvement is likely to relate partly to the well-described beneficial effects of trial involvement
and partly to a ‘regression to the mean’ effect consequent to our recruitment criterion of impaired QoL.
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However, we did find significant improvements over the usual-care arm in both active intervention arms,
with the mean improvements over usual care being 0.28 (95% CI 0.11 to 0.44) in the DVD arm and
0.24 (95% CI 0.04 to 0.44) in the physiotherapy arms. Although these levels are below the 0.5 threshold
for the MCID, it should be noted that 0.5 relates to the MCID for the individual patient and not for the
mean between-group differences. Indeed, it has recently been reported by Bateman et al.64 in a networked
meta-analysis of the magnitude of AQLQ changes associated with pharmacological interventions in asthma
that this threshold is never reached in RCTs. This study reports the mean improvement in AQLQ score over
the control for patients not fully controlled with inhaled corticosteroids as 0.35 (95% CI 0.27 to 0.43) for
the addition of a LABA, 0.20 (95% CI 0.13 to 0.27) for the addition of a LTRA, 0.01 (95% CI –0.20 to
0.22) for the addition of theophylline, 0.30 (95% CI 0,20 to 0.40) for the addition of omalizumab and
0.06 (95% CI –0.18 to 0.30) for the addition of a short-acting beta-2 agonist. The improvements over the
control that we observed for breathing retraining are therefore of comparable magnitude to those seen
with commonly used pharmacological strategies in RCTs, slightly less than those associated with LABAs
and slightly greater than those associated with LTRAs.
As recommended by Guyatt et al.32 in the interpretation of AQLQ data in clinical trials, and using the
formula that they recommend, we included a NNT for one patient to benefit above usual-care analysis.
This provided NNTs of eight for the DVD group and seven for the physiotherapy group, which we could
consider low compared with many commonly used interventions in clinical practice.
These findings suggest that breathing retraining has an important and clinically relevant role for patients who
are uncontrolled on standard asthma therapy and may be considered as well as, or instead of, an increase
in medication. Further studies incorporating ‘responder analyses’ are needed to clarify whether there are
specific characteristics of individual patients to indicate whether a pharmacological or a non-pharmacological
adjuvant treatment (or both) will be most effective. The heterogeneity of asthma is increasingly recognised6
and the concepts of stratified and ‘personalised, precision’ medicine are increasingly being applied. With
the demonstration in our study of the effectiveness of breathing retraining delivered through a simple and
cost-effective self-guided intervention, we feel that this could now become a standard treatment option for
people with asthma and that breathing dysfunction could be viewed as a ‘treatable trait’ when personalising
treatment for individual patients.65
Mechanism of effect
The mechanism of effect of breathing retraining on improving QoL in this study cannot be definitively
ascertained, but it does not appear to reflect changes in the pathophysiology of the condition, as reflected by
lung function or airway inflammation. Likewise, improvements in anxiety or depression between treatment
arms were either not significant or of low magnitude and so cannot fully explain the patient-experienced
benefits. It is interesting that asthma symptom scores showed only a trend towards a modest improvement
over the study period in those undergoing breathing retraining, which was of lower magnitude (in terms of
the MCID) than the change in QoL. This implies that reduced symptoms did not fully explain why patients felt
so much better and unaffected by their asthma and may indicate a greater tolerance, understanding and
acceptance of the symptoms; these were still present but were less distressing and were accepted and coped
with better. It is plausible that the possession of a simple non-pharmacological strategy for dealing with
symptoms when they occur provided patients with more confidence and improved self-management skills.
Indeed, the qualitative interviews carried out as part of the process evaluation would tend to support
this hypothesis.
The AQLQ instrument has four subdomains that can be analysed separately: symptoms, activity, environment
and emotions. Other than the activity and environment subdomains in the physiotherapy arm, all of these
domains showed statistically significant improvements in both breathing retraining arms compared with the
control arm, with the largest magnitude improvements being in the emotions domain. This implies that
breathing retraining has a wide-ranging impact on the way that asthma affects a patient, which includes less
impact of symptoms and environmental triggers, the ability to undertake higher levels of activity and, in
particular, less emotional impact. The mechanism of effect is therefore likely to be complex and multifaceted,
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with effects on the perception of symptoms, behaviours and emotions but not on the underlying
pathophysiology of the illness.
Patient perspectives and process evaluation
The process evaluation, with both quantitative (questionnaire-based) and qualitative components, showed
that patients engaged well with both of the breathing retraining programmes and felt that both the DVD
and the booklet were useful. Some participants in the DVD arm felt that they would have liked to see a
health professional as part of the retraining process, although the lack of difference in outcomes between
the active treatment arms indicates that this was probably not necessary for the majority of patients. As we
recruited patients with milder disease from the broad asthma population, who had not actually presented
with problems and asked for professional help, it is possible that there remains a subgroup with more
severe problems who would gain greater benefits from seeing a physiotherapist in person. However, in the
broad asthma population, a simple self-guided programme (a DVD with our theory-based behaviour change
booklet) would seem to be capable of providing an inexpensive and convenient intervention for many
people with asthma that does not necessitate a commitment of resources to allow far greater access to
respiratory physiotherapists in the community.
Adverse events
There have been no suggestions of treatment-related adverse effects from breathing retraining exercises in
the literature to date, but in this large study we carried out a careful analysis of any potential downsides
for patients undergoing breathing retraining programmes. We collected information on all respiratory
adverse events and adverse events that could plausibly be related to the breathing programmes, including
musculoskeletal and psychological/psychiatric adverse events, and on all significant adverse events. Overall,
the adverse event profile was as expected in the recruited population and adverse events were not felt by
the PIs to be study related, with fewer adverse events in the active arms than in the control arm and DVD
and physiotherapy programmes appearing to be well tolerated.
Health resource use and asthma-related costs
The asthma-related costs in the study were lower in the active arms than in the usual-care arm, implying
that the interventions have the potential to both improve outcomes and reduce costs, with lowest costs in
the DVD arm. The main cost items for each group were asthma-related medications and GP consultations.
There was no single factor driving the lower costs in the active arms, but we saw trends towards lower GP
consultation rates, lower rescue bronchodilator use and lower exacerbation risk. None of these reductions
was individually statistically significant when comparing the active arms with the control arm, although
the sample size was inadequate to provide sufficient statistical power to test these outcomes. The mean
number of respiratory-related GP consultations was 1.8 in the control arm compared with 1.5 in both
the physiotherapy arm and the DVD arm and the percentage of participants having one or more asthma
attacks requiring oral steroids was 15% in the control arm, 11% in the physiotherapy arm and 9% in
the DVD arm. There was an 82% probability of usual care being dominated by the breathing retraining
programme delivered by a DVD (lower costs and better outcomes) and the economic evaluation concluded
that in this patient sample the self-guided programme was more cost-effective than the provision of
face-to-face physiotherapy, by having outcomes within the equivalence margin and costing less.
Strengths and weaknesses of the study
This study has many strengths and a few weaknesses. This is by far the largest study of breathing
retraining in asthma to have been reported and we know of no other studies of comparable size currently
under way or planned. To our knowledge, this is the first study of breathing retraining in asthma that has
compared a face-to-face programme with a self-guided programme and the first to have a rigorous,
prospective health economic evaluation and process evaluations embedded within it.
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In terms of study design, this study followed two previous smaller studies from the study team17,19 that
together represent an evaluation strategy in keeping with the recommendations of the MRC framework
for the evaluation of complex interventions,38 with this project being a Phase IV study. The study design
was a ‘pragmatic’ RCT, with a focus on confirming the clinical effectiveness and cost-effectiveness of
breathing retraining in a broad and representative primary care population. We therefore had wide entry
criteria and study procedures that were designed to be as easy to comply with as possible and to interfere
with normal care (other than the provision of the interventions) as little as possible. This allowed primary
care sites to host the study without too much disruption to usual care and, we believe, encouraged patient
participation. We were able to recruit and retain 655 primary care patients into a 12-month study that
required informed consent, study visits and questionnaire completion. The study was designed and
supervised by a multidisciplinary team, with strong PPI input at all stages provided by our very active PPI
representatives and by the patient charity Asthma UK, which was a full partner in the project from its
inception. The multidisciplinary team included physiotherapists, primary and secondary care clinicians,
scientists, primary and secondary care respiratory nurses, health psychologists, behaviour change experts
specialising in developing and evaluating self-guided behaviour change interventions, statisticians and
health economists. The involvement of researchers with a general practice background facilitated a study
design that was feasible and acceptable in a busy ‘routine care’ setting and acceptable to patients with
mild-to-moderate asthma. The use of an internal pilot allowed hindrances to recruitment and study
procedures to be identified and corrected early in the study, with subsequent smooth running of the main
trial. Regular steering group meetings were well attended and active, and the team was fortunate to have
the support of very interested and active TSC and DMEC members. There was a regular exchange of
information with the funder, the National Institute for Health Research (NIHR) HTA programme, as well as
the provision of support. Other NIHR structures also provided excellent support to the study. The SCTU
undertook trial management most effectively, with several changes in key personnel not impairing the
continuity and effectiveness of the team. The friendly, accessible and proactive involvement of the SCTU
team was a key strength in delivering a successful study. Invaluable support was provided by the NIHR
CRN team involved in the study, with strong support from the research nurse team with regard to the
recruitment of practices and patients. There was good partnership with the NHS organisations (clinical
commissioning groups and trusts) involved in the study, who also provided support. The general practices
hosting the study were invariably supportive and appreciated the pragmatic design of the study and the
involvement of practice asthma nurses in the study. Very good feedback was received from the recruiting
sites and the GPs, practice nurses and practice managers involved, who were positive about the study and
enjoyed their involvement in it. A key strength underlying these effective partnerships was good and open
communication throughout the study, allowing ‘buy-in’ and effective team working. As a result of these
good relationships, coupled with a sound study design, we were able to recruit beyond the original
recruitment targets and to achieve high retention rates.
Another strength of the study is that we used a variety of clinically relevant outcome measures, including a
panel of validated patient-reported outcome measures in questionnaire format, physiological lung function
measures (that included quality-assured spirometry measured by trained and accredited respiratory nurses)
and airway inflammation measures. In addition, patients provided consent to access their routine primary
care medical records, which allowed us to collect consultation, prescribing and other health resource use
data. This combination of outcome measures allowed us to assess the effects of the intervention on QoL,
the key patient-focused outcome measure that reflects patients’ experience of their disease and the
amount of disturbance that it causes in their lives, and relate this to other physiological and psychological
measures. This multidimensional assessment allows some insight into the mechanisms of effect of this
complex intervention and further helps to dispel the myths propagated by some proponents of breathing
retraining (such as some of those advocating the Butekyo method) that breathing exercises can ‘cure’
asthma and replace the need for anti-inflammatory and bronchodilator medication.66–68 In keeping with
our previous studies, we found no significant effect of the interventions on parameters measuring the
pathophysiology of asthma, such as lung function and airway inflammation, despite a significant lessening
of the impact of asthma on people’s lives.
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A key strength of the study was the rigorous development process used for transferring the physiotherapy-
based programme to a self-guided intervention, with printed support material. The development process
that we have described is based on a well-established methodology using an iterative process and extensive
and effective patient input. Members of the intervention development team were very experienced, having
previously developed a number of effective self-guided interventions in other clinical areas, and applied a
tried and tested procedure to develop and refine the materials. The involvement of experienced qualitative
researchers allowed patient perspectives to be efficiently and accurately gathered and assessed and to be
effectively incorporated into the intervention. A professional media production firm was used to produce
the high-quality and patient-friendly self-guided intervention. The self-guided intervention proved to be
accessible and well received by patients of all educational levels. The same team designed and performed
the process evaluation (including both the qualitative evaluation and the quantitative evaluation), which has
contributed to the assessment of the intervention and will inform subsequent implementation work. We
were also fortunate to identify experienced local physiotherapists with expertise in breathing retraining who
were able to assist with the DVD development and provide the face-to-face physiotherapy intervention.
Similarly, a strength of the study was the involvement of health economists at all stages, from protocol
design to writing of the report. The health economic evaluation was seamlessly integrated into the study
design and execution. High-quality health economic information is imperative in the current medicopolitical
environment if a new intervention is going to be accepted and utilised in clinical care and promoted by
commissioners. We believe that the powerful and persuasive health economic arguments, combined
with the simplicity and ease of provision of the self-guided intervention, will allow rapid uptake and
implementation throughout the NHS, to the benefit of patients.
A further strength of the study was the full involvement of the statistical team at all stages of the project,
with input from statisticians on the TSC and the DMEC throughout the study. The choice of primary
outcome, primary and secondary statistical analyses and regression models was made with the help of
consensus processes after long and constructive debate. The use of the full ITT population in the primary
effectiveness analysis, with a number of prespecified sensitivity analyses on the PP population, using
different ways of handling missing data and using different regression models, allows confidence to be had
in the key messages of the study. The statistically significant superiority of usual care and the equivalence
of the self-guided and physiotherapy-based programmes (using prespecified equivalence margins) were
maintained in all sensitivity analyses, adding to the confidence that this was a correct finding.
In terms of the limitations of the study, the CONSORT diagram shows that only 10% of the total primary
care asthma population invited by post to participate in the study responded to the invitation. It is possible
that these respondents represent an atypical sample of patients and that the response to the intervention
could be different in the total population. The demographic and asthma severity profile of respondents
were, however, typical of those of UK asthma populations. We also feel that our recruitment rate was much
higher than that achieved by most asthma studies and it is well documented that the evidence base for
asthma guidelines comes from studies with tight inclusion and exclusion criteria that result in < 2% of all
community-treated patients being eligible.69 One cannot force patients to enter trials and we feel that
changes in the design of the study and the processes used would not improve on the recruitment rate that
we achieved. However, there is now the need for evaluated implementation studies to confirm that the
benefits seen in our ‘real-world’ but trial-consenting population can be translated to the wider adult asthma
population, as the intervention is made available. Such assessments will need to use routinely collected data
or minimally intrusive outcome measures if they are to capture outcomes in the wider population.
Approximately 40% of our responders had unimpaired asthma-related QoL and so were ineligible for the
study. This is in keeping with previous population-based studies on QoL in asthma, with the majority being
found to have impaired health. We feel that those with unimpaired QoL are probably already coping well
with their illness and so are not in need of further help from an intervention such as breathing retraining;
however, this applies only to a minority of adult asthma sufferers in the UK and so there is potentially a
wide use for this intervention in routine practice.
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Our study sample size was powered on the primary outcome measure, the AQLQ. For a number of the
secondary outcome measures, including asthma attacks, GP consultations and rescue medication prescriptions,
we observed numerical, but non-significant or marginally significant, improvements in outcome in the
breathing retraining arms compared with the usual-care arm. We cannot say whether these improvements
were chance findings or whether lack of statistical power prevented a significant result being seen. This is
particularly true of asthma attacks as these occur only in about 1 in 10 patients with mild-to-moderate asthma
treated in the community over a single year. Larger studies would be needed to investigate this fully. As all of
these factors (consultations, asthma attacks and rescue medication prescriptions) can be assessed through the
analysis of routinely collected data, this could be investigated in implementation studies using analysis of
anonymised routine data.
Participants in our study were aware of which study arm they had been allocated to. Although this is a
limitation, it is clearly not possible to ‘blind’ a participant in such a study to group allocation. The study
was, however, ‘observer blinded’, with the research nurses collecting data and the statistical team blinded
as to study arm allocation until the statistical report was finalised. The control arm in this study consisted
of usual care and so those in the active arms had a greater provision of care. Although it is possible
that participants randomised to the usual-care arm were disappointed not to be receiving an active
intervention, they were assured that at the completion of the study they would be offered the intervention
if it was found to be effective. It is noteworthy that there was a large improvement in QoL in the control
arm during the study, probably reflecting the beneficial effects of trial involvement and a ‘regression to the
mean’ effect. Those in the DVD arm received audio-visual and printed support materials but there was no
provision of additional care, whereas those in the physiotherapy arm underwent three face-to-face visits
with a respiratory physiotherapist and also received the printed support materials. Additional professional
care can improve health outcomes in a non-specific placebo-like way. In previous studies earlier in the
MRC complex intervention framework process, we included additional professional contact in the control
arm17,19 and observed similar improvements in the breathing retraining arm compared with the control
arm. As this was a Phase IV pragmatic study, we felt that usual care was the appropriate comparator as it
provided a better estimate for the health economic evaluation and provides better information for pragmatic
implementation. In this situation the new intervention is provided in addition to current usual care. In our
study we did see large improvements in the usual-care arm, although less than in the active arms, reflecting
the well-described phenomenon whereby patients benefit simply from taking part in research trials.
Our study included only adults. The intervention materials were designed for adults and would not be
transferable to younger age groups without modification. There is anecdotal and very limited study
evidence that breathing retraining is feasible and effective in adolescents and in younger children.70
Asthma has a high prevalence in younger people and there is considerable public and parental interest in
non-drug interventions for asthma in children. There is therefore still a need for studies to clarify the
clinical effectiveness and cost-effectiveness of breathing retraining interventions in younger people. As we
excluded children and adolescents, the groups in whom asthma is most prevalent, the average age of our
trial population was higher than that in population-based asthma demographic data. It is possible that there
was some under-representation of younger adults, who are generally harder to recruit to time-consuming
clinical trials, but the demography in our trial was similar to that in other pragmatic community-based adult
asthma clinical trials. For example, in the study by Price et al.,63 the mean age of subjects was 46 years, 56%
were aged ≥ 46 years and the overall demographic profile was similar to ours.
We were able to provide the intervention only to English-language speakers in this study. There is therefore
a need to transfer the intervention into other languages and to frame it in culturally appropriate forms for
ethnic minorities. Consideration of adaptations for people with limited literacy skills or learning disabilities is
also needed.
Our study provided part of the self-guided intervention in the form of a DVD, although potentially this could
be provided in other formats, including for the internet and smartphone-based platforms. The DVD format
was chosen, first, to control access to the programme in the trial and, second, as this format was very
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commonly used at the time of the study. We had the ability to provide inexpensive DVD players to anyone
randomised to this arm of the study who did not already have access to a DVD player, but no one needed
this. However, with advances in digital technology and the widespread use of streaming and downloads
over the internet, and the wide ownership and use of smartphones, DVDs are now used less frequently. We
cannot guarantee that the intervention would provide identical outcomes if provided as an internet-based
platform and so this needs to be investigated in further studies. We are currently transferring the content of
the DVD to an internet-streamed breathing retraining programme and piloting its use.
Comparison with the results of other studies
The literature on breathing retraining for asthma provided through health professional-delivered
face-to-face programmes is reasonably extensive and convincing, such that the UK BTS/SIGN asthma
guideline71 and the WHO GINA guideline72 both recommend breathing retraining as an option for patients
uncontrolled on standard therapy, on the basis of a meta-analysis of the improvement in asthma in RCTs.
Our finding that physiotherapy was superior to usual care was therefore in keeping with this evidence base.
Our study extends this evidence as the pragmatic design allows greater external validity and confidence in
generalising the findings than those of previous studies, which have often used selected populations and
atypical clinical settings as opposed to UK general practice. The lack of improvement in lung function and
airway inflammation is in accordance with the majority of the current literature, although there are some
small studies (some with methodical problems) that have reported improvements in pathophysiological
parameters.
Very few previous studies have investigated audio-visual programmes for breathing retraining that do
not involve contact with a health professional and none have compared face-to-face breathing retraining
with such programmes. The equivalence that we have demonstrated between face-to-face physiotherapy
and the DVD programme is therefore a novel finding and of considerable significance in terms of
implementing the intervention. Despite the evidence of effectiveness for breathing retraining and the
guideline recommendations, the vast majority of patients who could benefit do not currently have access
to such training and many who do have to pay a private practitioner (often unregulated) for it.
Other novel aspects of our study include its size, duration and range of outcome measures and the rigorous
health economic evaluation and process evaluations. These evaluations suggest that the widespread
provision of the self-guided breathing retraining programme is likely to be well accepted and to reduce NHS
costs for asthma patients.
Implications for services and future research
We report a Phase IV study of breathing retraining for adults with asthma who are uncontrolled on their
current treatment, which has shown improved outcomes and reduced costs of a breathing retraining
programme delivered by DVD. On the basis of this evidence, we feel that this intervention is potentially of
benefit to the majority of adults with asthma in the community and can be delivered to them as a low-cost,
and logistically viable, self-guided programme that has the potential to reduce NHS costs as well as benefit
patients. We therefore feel that implementation studies are now needed, to optimise delivery and to assess
the effects of providing the intervention in a wide and community-based programme. This has implications
for service delivery.
Specific research issues that should be addressed include assessing the effectiveness of the programme
delivered though internet-based and smartphone-based platforms. We are currently in the process of
carrying out the technical work necessary for this. Comparisons of the acceptability and effectiveness of
different delivery methods are needed. We would hope to make these comparisons and are in discussion
with our charity partner, Asthma UK, on how to structure and deliver the intervention most effectively.
DISCUSSION
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Given the effectiveness of the intervention in an adult population, we feel that there is a need for research
to be carried out in a paediatric population, among whom there is great interest in such interventions.
It is not justifiable to automatically extrapolate the results of asthma trials in older age groups to children,
although this has frequently been carried out, often inappropriately. In addition, the framing of the
intervention and the language and directions provided will need to be adapted for younger people.
As mentioned earlier, there is also a need to frame and translate the intervention for specific groups,
such as ethnic minorities, those with health literacy problems and those with learning disabilities.
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Chapter 8 Conclusions
The majority of adults with asthma have impaired QoL, despite the wide availability of effectivepharmacotherapy. Breathing retraining exercises have a good evidence base as adjuvant treatment
to improve QoL for people with asthma when taught by a physiotherapist in a face-to-face programme.
However, although recommended in national and international guidelines, such programmes are
under-used because suitably trained specialist therapists are not available to most people who could
benefit. We created a self-guided intervention (DVD plus supporting booklet), involving a multidisciplinary
professional team, with extensive patient input, and using a qualitative, iterative methodology. Our aim
was to transfer the content of a physiotherapy breathing retraining programme to an attractive and
accessible format suitable for patients to use at home, at a time convenient to them. We performed a
12-month, three-armed, parallel-group, observer-blinded RCT involving consenting adults with asthma
treated in the community in a primary care setting to compare the effects of the new self-guided
intervention with the effects of a three-session face-to-face physiotherapy breathing retraining programme
plus the booklet and usual care. Asthma-related QoL was the primary outcome. The study was powered to
show the superiority of both breathing retraining programmes over usual care and the equivalence of the
self-guided and face-to-face physiotherapy programmes and succeeded in doing so. The improvement in
QoL was similar to that reported in a meta-analysis of the effects on QoL of add-on pharmacological
interventions for uncontrolled patients. There was no significant change in lung function or airway
inflammation associated with breathing retraining by either route, implying that the interventions did not
alter the underlying biological pathophysiology of asthma. Consistent (but statistically non-significant)
trends in improvement in other patient-reported outcome measures (including symptom scores and anxiety
and depression scores) and in asthma attacks, GP consultations and rescue medication use were observed
with the active interventions compared with usual care. Both active programmes were well received, acted
on and accepted by patients and there was no evidence of adverse effects. Asthma-related health-care
costs were lower in both of the active arms than in the usual-care arm, with the self-guided intervention
having the lowest costs and a > 80% probability of being the ‘dominant’ health economic strategy, that is,
the strategy with better outcomes at lower costs.
Physiotherapy breathing retraining exercises are therefore acceptable, clinically effective and cost-effective
for adults with asthma and may be delivered by a simple self-guided intervention (our DVD plus our
theory-based behaviour change booklet). There is now a need for research on effectively implementing this
intervention within usual care and to investigate the effects of similar interventions adapted for other
patient groups not studied during this project.
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Appendix 1 Numbers of patients randomised by
study practice and treatment arm
TABLE 54 Numbers of patients randomised by study practice and treatment arm
Practice
Treatment arm, n
Overall, nDVD Physiotherapy Usual care
Adelaide Surgery 1 1 1 3
Alma Medical Practice 3 2 4 9
Barton-on-Sea Surgery 19 9 19 47
Bosmere Medical Practice 14 7 15 36
Brook Lane Surgery 7 4 7 18
Clanfield Surgery 4 2 4 10
Cowplain Family Practice 5 3 5 13
Derby Road Surgery 6 2 5 13
Forest End Surgery 6 3 6 15
Forton Medical Centre 12 6 13 31
Friarsgate Surgery 18 9 19 46
Gosport Medical Centre 8 4 8 20
Heyward Road Surgery 2 1 3 6
Highcliffe Medical Centre 6 3 5 14
Highlands Practice 8 4 7 19
Homewell Practice 13 7 14 34
Kirklands Surgery 7 4 7 18
Lordshill Health Centre 8 4 6 18
New Forest Medical Centre 4 3 4 11
Nightingale Surgery 9 5 9 23
North Baddesley Surgery 4 1 3 8
Old Fire Station Surgery 5 3 6 14
Osborne Practice 9 4 8 21
Park and St Francis Surgery 11 5 10 26
Portsdown Group Practice 18 9 19 46
Ramillies Surgery 4 2 5 11
Regents Park Surgery 3 1 2 6
Ringwood Medical Centre 10 6 10 26
Stoke Road Medical Centre 5 3 6 14
Sunnyside Medical Centre 4 1 4 9
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TABLE 54 Numbers of patients randomised by study practice and treatment arm (continued )
Practice
Treatment arm, n
Overall, nDVD Physiotherapy Usual care
Three Swans Surgery 7 3 6 16
Waterbrook Medical Practice 9 4 8 21
Waterside Medical Practice 10 6 11 27
Woolston Lodge Surgery 2 1 3 6
Total 261 132 262 655
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Appendix 2 Missing baseline primary and
secondary outcomes by treatment arm
TABLE 55 Missing baseline primary and secondary outcomes by treatment arm
Outcome
Treatment arm, n (%)
Overall (N= 655),
n (%)DVD (N= 261) Physiotherapy (N= 132) Usual care (N= 262)
AQLQ 17 (6.5) 12 (9.1) 16 (6.1) 45 (6.9)
Nijmegen questionnaire 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.3)
HADS 4 (1.5) 1 (0.8) 1 (0.4) 6 (0.9)
EQ-5D
Mobility 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.3)
Self-care 3 (1.1) 1 (0.8) 0 (0.0) 4 (0.6)
Usual activities 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.3)
Pain/discomfort 2 (0.8) 1 (0.8) 1 (0.4) 4 (0.6)
Anxiety/depression 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.3)
EQ-5D VAS 5 (1.9) 1 (0.8) 4 (1.5) 10 (1.5)
ACQ 3 (1.1) 0 (0.0) 0 (0.0) 3 (0.5)
FEV1 15 (5.7) 2 (1.5) 9 (3.4) 26 (4.0)
FeNO 23 (8.8) 6 (4.5) 20 (7.6) 49 (7.5)
FVC 15 (5.7) 2 (1.5) 9 (3.4) 26 (4.0)
FEV1-to-FVC ratio 15 (5.7) 2 (1.5) 9 (3.4) 26 (4.0)
FEV1% predicted 15 (5.7) 2 (1.5) 9 (3.4) 26 (4.0)
PEFR 17 (6.5) 3 (2.3) 13 (5.0) 33 (5.0)
Smoking status 2 (0.8) 0 (0.0) 0 (0.0) 2 (0.3)
Weight 3 (1.1) 0 (0.0) 1 (0.4) 4 (0.6)
Height 2 (0.8) 0 (0.0) 1 (0.4) 3 (0.5)
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Appendix 3 Patient withdrawals by
treatment arm
TABLE 56 Patient withdrawals by treatment arm
Reason for withdrawal
Treatment arm, n (%)
Total (N= 655)
n (%)
DVD
(N= 261)
Physiotherapy
(N= 132)
Usual care
(N= 262)
Withdrew from the study 13 (5.0) 3 (2.3) 5 (1.9) 21 (3.2)
Primary reason for withdrawal
Away for several months 0 (0.0) 1 (33.3) 0 (0.0) 1 (4.8)
No longer wants to take part 1 (7.7) 0 (0.0) 2 (40.0) 3 (14.3)
Did not attend 12-month follow-up 1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
Family reasons 1 (7.7) 1 (33.3) 1 (20.0) 3 (14.3)
Husband unwell/family illness 2 (15.4) 0 (0.0) 0 (0.0) 2 (9.5)
Left practice 2 (15.4) 0 (0.0) 0 (0.0) 2 (9.5)
Did not receive DVD 1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
Requested to be deleted 1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
Notified nurse that since starting the trial
asthma worsened
1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
Study has not helped asthma 0 (0.0) 1 (33.3) 0 (0.0) 1 (4.8)
Too busy – life commitments 1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
Death 1 (7.7) 0 (0.0) 2 (40.0) 3 (14.3)
No reason given 1 (7.7) 0 (0.0) 0 (0.0) 1 (4.8)
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Appendix 4 Baseline characteristics of the patient
withdrawals and non-withdrawals
TABLE 57 Baseline characteristics of the withdrawals and the non-withdrawals
Characteristic Withdrawals (N= 21) Non-withdrawals (N= 634)
Sex, n (%)
Male 5 (23.8) 231 (36.4)
Female 16 (76.2) 403 (63.6)
Age (years)
Number included 21 634
Median (IQR) 59 (51.5–64.5) 56 (46–64)
Minimum, maximum 23, 70 16, 70
Weight (kg)
Number included 21 630
Median (IQR) 77 (68–90) 81.42 (18–46)
Minimum, maximum 54, 118
Height (cm)
Number included 21 630
Median (IQR) 161.5 (157–170) 166.56 (9.06a)
Minimum, maximum 152, 175
Smoking status, n (%)
Current smoker 0 (0.0) 50 (7.9)
Previous smoker 6 (28.6) 212 (33.4)
Never smoker 15 (71.4) 370 (58.4)
What they currently smoke, n (%)
Cigarettes 0 (0.0) 33 (5.2)
Tobacco 0 (0.0) 18 (2.8)
Cigars 0 (0.0) 1 (0.2)
What they used to smoke, n (%)
Cigarettes 5 (23.8) 191 (30.1)
Tobacco 0 (0.0) 10 (1.6)
Cigars 1 (4.8) 1 (0.2)
Cigarettes/tobacco 0 (0.0) 4 (0.6)
Cigarettes/cigars 0 (0.0) 4 (0.6)
Tobacco/cigars 0 (0.0) 1 (0.2)
Cigarettes/tobacco/cigars 0 (0.0) 1 (0.2)
continued
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TABLE 57 Baseline characteristics of the withdrawals and the non-withdrawals (continued )
Characteristic Withdrawals (N= 21) Non-withdrawals (N= 634)
Average cigarettes/day for ever smokers, n
Median (IQR) 10 (6.5–20) 15 (8–20)
Minimum, maximum 5, 20 1, 100
Pack-years of smoking
Number included 6 238
Median (IQR) 23.25 (6.5–57.25) 11.85 (3–25)
Minimum, maximum 2, 100 0.05, 300
Age diagnosed with asthma (years)
Number included 21 629
Median (IQR) 37 (14–52) 28 (11–45)
Minimum, maximum 3, 60 1, 68
Family history of asthma, n (%)
Mother
Yes 3 (14.3) 103 (16.2)
No 18 (85.7) 513 (80.9)
Unknown 0 (0.0) 13 (2.1)
Father
Yes 2 (9.5) 72 (11.4)
No 17 (81.0) 528 (83.3)
Unknown 2 (9.5) 29 (4.6)
Siblings
Yes 6 (28.6) 157 (24.8)
No 14 (66.7) 426 (67.2)
n/a 0 (0.0) 43 (6.8)
Children
Yes 4 (19.0) 202 (31.9)
No 15 (71.4) 305 (48.1)
n/a 2 (9.5) 123 (19.4)
Other family members
Yes 5 (23.8) 226 (35.6)
No 15 (71.4) 379 (59.8)
Unknown 1 (4.8) 11 (1.7)
Asthma triggers, n (%)
Cats 13 (61.9) 275 (43.4)
Dogs 8 (38.1) 170 (26.8)
Dust 16 (76.2) 521 (82.2)
Exercise 14 (66.7) 462 (72.9)
Pollen 13 (61.9) 417 (65.8)
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TABLE 57 Baseline characteristics of the withdrawals and the non-withdrawals (continued )
Characteristic Withdrawals (N= 21) Non-withdrawals (N= 634)
Smoke 13 (61.9) 444 (70.0)
Stress 10 (47.6) 323 (50.9)
Food 5 (23.8) 128 (20.2)
Others 17 (81.0) 484 (76.3)
FeNO (p.p.b.)
Number included 18 588
Median (IQR) 21.5 (15.75–32.75) 22 (14–34)
Minimum, maximum 5, 202 0, 159
FEV1 (l)
Number included 20 609
Median (IQR) 2.3 (1.9–2.9) 2.6 (0.8a)
Minimum, maximum 1.5, 4.1
FVC (l)
Number included 20 609
Median (IQR) 3.0 (2.3–3.5) 3.4 (0.9a)
Minimum, maximum 2.1, 5.0
FEV1-to-FVC ratio
Number included 20 609
Median (IQR) 0.8 (0.8–0.9) 0.8 (0.1a)
Minimum, maximum 0.6, 0.9
FEV1% predicted
Number included 20 609
Median (IQR) 90.5 (77.8–103.8) 90.7 (20.0a)
Minimum, maximum 69, 112
PEFR
Number included 20 602
Median (IQR) 406.0 (355–529) 422.2 (117.1a)
Minimum, maximum 292, 623
n/a, not applicable; p.p.b., parts per billion.
a SD.
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Appendix 5 Supplementary information and
sensitivity analyses on rescue inhaler use
TABLE 58 Distribution of rescue inhaler use by treatment arm in the 12 months post randomisation in the
PP population
Number of rescue inhalers
Treatment arm, n
Total, nDVD Physiotherapy Usual care
0 63 22 44 129
1 30 22 57 109
2 31 13 28 72
3 18 16 23 57
4 21 12 23 56
5 16 3 10 29
6 10 6 9 25
7 5 2 5 12
8 6 3 11 20
9 4 2 3 9
10 5 1 5 11
11 1 0 1 2
12 1 3 5 9
13 1 2 0 3
14 1 2 0 3
16 1 0 1 2
17 0 0 1 1
18 0 0 2 2
22 0 0 2 2
26 0 0 1 1
28 1 0 0 1
40 0 1 0 1
Total 215 110 231 556
TABLE 59 Unadjusted analysis of the negative binomial regression for rescue inhaler use in the 12 months post
randomisation in the PP population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 1.04 0.80 to 1.35 0.76
DVD vs. usual care 0.86 0.69 to 1.07 0.18
DVD vs. physiotherapy 0.83 0.63 to 1.08 0.17
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TABLE 60 Adjusted analysis of the negative binomial regression for rescue inhaler use in the 12 months post
randomisation in the PP population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 1.04 0.78 to 1.40 0.94
DVD vs. usual care 0.93 0.73 to 1.19 0.78
DVD vs. physiotherapy 0.89 0.66 to 1.21 0.66
a Adjusted for age, sex, BTS treatment step, baseline smoking status, baseline HADS scores and baseline Nijmegen score.
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Appendix 6 Supplementary information and
sensitivity analyses on asthma exacerbation frequency
TABLE 61 Group differences in asthma exacerbations in the 12 months post randomisation in the PP populationa
Oral corticosteroid courses
Treatment arm, n
Total, nDVD Physiotherapy Usual care
0 193 97 195 485
1 16 9 26 51
2 2 3 8 13
3 2 0 1 3
4 2 1 0 3
10 0 0 1 1
Total 215 110 231 556
a Adjusted for exacerbations in the previous 12 months, age, sex, BTS treatment step and smoking status.
TABLE 62 Unadjusted analysis of the negative binomial regression for asthma exacerbations in the 12 months post
randomisation in the PP population
Comparison Unadjusted IRR 95% CI p-value
Physiotherapy vs. usual care 0.73 0.35 to 1.50 0.38
DVD vs. usual care 0.66 0.37 to 1.20 0.18
DVD vs. physiotherapy 0.92 0.43 to 1.95 0.82
TABLE 63 Adjusted analysis of the negative binomial regression for asthma exacerbations in the 12 months post
randomisation in the PP population
Comparison Adjusted IRRa 95% CI p-value
Physiotherapy vs. usual care 0.79 0.33 to 1.90 0.81
DVD vs. usual care 0.69 0.33 to 1.42 0.45
DVD vs. physiotherapy 0.87 0.34 to 2.19 0.93
a Adjusted for age, sex, BTS treatment step and smoking status.
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Appendix 7 Numbers of participants in the
per-protocol population having none or one or more
respiratory-related general practitioner consultations
in the 12 months post randomisation
TABLE 64 Numbers of participants in the PP population having none or one or more respiratory-related GP
consultations in the 12 months post randomisation by treatment group
Number of GP consultations
Treatment arm, n
Total, nDVD Physiotherapy Usual care
None 52 25 45 122
≥ 1 163 85 186 434
Total 215 110 231 556
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Appendix 8 Supplementary information and
sensitivity analyses on the primary outcome (Asthma
Quality of Life Questionnaire)
TABLE 66 3-month adjusted change in AQLQ score in the DVD, physiotherapy and usual-care treatment arms on
the ITT population
AQLQ subdomain
Treatment arm, adjusted mean differencea (95% CI)
Adjusted mean
differenceb (95% CI)
Physiotherapyc vs.
usual care DVD vs. usual care
DVD vs.
physiotherapyc
DVD vs.
physiotherapyc
Total 0.41 (0.20 to 0.63)** 0.29 (0.11 to 0.47)** –0.12 (–0.35 to 0.10) –0.10 (–0.34 to 0.13)
Symptoms 0.51 (0.26 to 0.76)** 0.38 (0.18 to 0.59)** –0.13 (–0.38 to 0.13) –0.09 (–0.36 to 0.17)
Activities 0.24 (–0.001 to 0.48)* 0.29 (0.09 to 0.48)* 0.05 (–0.20 to 0.30) 0.03 (–0.22 to 0.29)
Emotion 0.42 (0.13 to 0.71)* 0.23 (–0.01 to 0.47) –0.19 (–0.49 to 0.11) –0.13 (–0.44 to 0.18)
Environment 0.42 (0.15 to 0.70)** 0.26 (0.03 to 0.49)* –0.17 (–0.45 to 0.12) –0.16 (–0.46 to 0.13)
*p ≤ 0.05, **p< 0.001.
a Adjusted for prespecified list of covariates.
b Adjusted for prespecified list of covariates along with a new covariate – amount of practice.
c Excluding participants who did not engage with the breathing retraining at 3 months.
TABLE 65 12-month adjusted change in AQLQ score in the DVD, physiotherapy and usual-care treatment arms in
the ITT population
AQLQ subdomain
Treatment arm, adjusted mean differencea (95% CI)
Adjusted mean
differenceb (95% CI)
Physiotherapyc vs.
usual care DVD vs. usual care
DVD vs.
physiotherapyc
DVD vs.
physiotherapyc
Total 0.22 (0.003 to 0.43)* 0.28 (0.12 to 0.45)* 0.07 (–0.15 to 0.28) 0.03 (–0.20 to 0.27)
Symptoms 0.25 (0.01 to 0.49)* 0.24 (0.05 to 0.43)* –0.01 (–0.25 to 0.24) –0.01 (–0.28 to 0.25)
Activities 0.07 (–0.17 to 0.30) 0.23 (0.05 to 0.41)* 0.16 (–0.07 to 0.40) 0.13 (–0.13 to 0.38)
Emotion 0.37 (0.08 to 0.65)* 0.38 (0.16 to 0.60)** 0.01 (–0.28 to 0.30) 0.02 (–0.29 to 0.33)
Environment 0.21 (–0.06 to 0.48) 0.33 (0.11 to 0.54)* 0.12 (–0.16 to 0.39) 0.09 (–0.20 to 0.39)
*p ≤ 0.05, **p< 0.001.
a Adjusted for prespecified list of covariates.
b Adjusted for prespecified list of covariates along with a new covariate – amount of practice.
c Excluding participants who did not engage with the breathing retraining at 3 months.
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Appendix 9 Adverse event categories
l Abdominal/gastrointestinal: vaginal discharge, testicular pain, rectal bleeding, abdominal pain –
complains of adhesions, altered bowel habit – complains of adhesions, diarrhoea, menorrhagia, bacterial
vaginosis, amenorrhoea, gastric band erosion, laparoscopic vaginal hysterectomy, gastritis, vaginal
discharge, oral thrush, haemorrhoids, vaginal thrush, suspected urinary tract infection, vulvovaginal
candidiasis, epigastric pain plus dysfunctional breathing, pain from pre-existing umbilical hernia, caecal
volvulus, small bowel obstruction, colitis, vomiting, vomiting (flu), non-specific abdominal pain, gastric
bypass surgery, irritable bowel syndrome, abdominal cramps and diarrhoea, epigastric pain episode
linked to ongoing acid reflux, abdominal cramps – gastroenteritis, lower abdominal pain, abdominal
pain, breathlessness related to abdominal pain, increased nausea, abdominal pain (right iliac fossa),
lower abdominal pain with loose stools, per vaginal bleed post large loop excision of the transformation
zone of the cervix, small bowel obstruction, ileus, umbilical hernia repair.
l Acute exacerbation of asthma: acute asthma exacerbation, asthma exacerbation, exacerbation of
asthma/COPD, asthma flair, green sputum worsening (acute exacerbation of asthma), productive cough
worsening (acute exacerbation of asthma), mild exacerbation of asthma, chesty cough (acute asthma
exacerbation), cough/wheeze (infected exacerbation of asthma), asthma attack, chest infection/asthma
exacerbation, infective exacerbation of asthma.
l Chest pain and cardiovascular: chest pain, chest pains, chest pains with palpitations, chest wall pain,
costochondritis, chest pain? – hiatus hernia, rib pain, chest pain – acute coronary syndrome, myocardial
infarction, chest pain secondary to indigestion, exertional chest pain (while hovering), chest pain
(musculoskeletal), dull pain around right lateral chest wall, pleuritic left-sided chest pain.
l Increased asthma symptoms: cough, wheeze tachycardia, worsening of asthma, wheeze, chest
tightness, wheeze plus shortness of breath, shortness of breath, mild wheeze, shortness of breath on
exertion, cough, dyspnoea, asthma triggered by pollen, ongoing asthma symptoms, wheezy cough,
acute wheezy bronchitis, respiratory symptoms limiting exercise activities, poor asthma control, nocturnal
cough/wheeze, feels unable to fully inhale.
l Malignancy: malignant lymphoma, malignant neoplasm breast – review, prostate cancer, follicular
papillary carcinoma.
l Musculoskeletal: Baker’s cyst, cervicalgia, golfer’s elbow, degenerative change in lumbosacral region,
left leg pain, lacerated left middle finger, back pain, aching muscles, shoulder pain, left arm pain, leg
cramps, back pain following fall, arthralgia of hands/shoulders, knee pain, shoulder pain, tennis elbow,
lateral epicondylitis, ankle pain, ankle and hip pain, sprain (left) lateral collateral knee ligament, hip
pain, acute lumbar back pain, sprain (left) lateral collateral ligament, neck pain, joint aches (virus), joint
ache, right knee replacement surgery, left-sided jaw pain, neck pain, lower back pain, fracture of lower
vertebra, right shoulder rotator cuff tear, gout, fractured right rib, prolapsed intervertebral lumbar disc
(worsening of), right shoulder rotator cuff sprain, right bicep tendon rupture, frozen shoulder (right),
worsening of frozen shoulder (right), rotator cuff syndrome, left-sided muscle tightness in neck,
septic arthritis.
l Neurological: tremor, right-hand numbness, headache – different from migraine, neuralgic pain,
neuropathic pain, headache, right-sided body numbness, transient ischaemic attack, chronic inflammatory
demyelinating polyneuropathy, fatigue, dizziness, double vision, nausea, cerebral venous thrombosis,
left-sided numbness, tinnitus, giant cell arteritis, post-FeNO test breathlessness, light-headedness and
clammy, migraine.
l Psychological/psychiatric: shortness of breath (panic attack), anxiety, depression, insomnia, low mood,
panic attacks, recurrence of depressive episode, low mood, overbreathing, stress.
l Respiratory tract infection/cough: acute laryngitis, bibasilar collapse, bronchitis, chest infection, chest
infection/shortness of breath on exertion, chest rattle, chesty cough, cold, cold virus – hoarseness and
cough, cold virus – sore throat and cough, congestion with cold, cough and shortness of breath,
coryzal, cough (flu), cough (post viral), cough (upper respiratory tract infection), cough? – viral
laryngitis, cough with green phlegm, wheeze, shortness of breath, crackles and phlegm, cough/cold,
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dry cough, ear infection, fever (flu), flu-like virus, green sputum, green sputum (upper respiratory tract
infection), haemoptysis, influenza A, laryngitis, lower respiratory tract infection, mild cough, night
cough, pharyngitis, pleural effusion, pneumonia, post viral cough and wheeze, productive cough,
productive cough (lower respiratory tract infection), Pseudomonas – chest infection, Pseudomonas
aeruginosa infection, respiratory heart infection, respiratory tract infection, shortness of breath
(pneumonia), sore throat (virus), stridor, upper respiratory chest infection, viral cold and cough, viral
illness causing wheeze, fever, chest tightness, viral infection, viral upper respiratory tract infection,
worsening cough with wheeze and shortness of breath.
l Rhinitis/rhinosinusitis: (sinusitis) blocked nose, (sinusitis) earache, (sinusitis) sore eyes, acute sinusitis,
allergic rhinitis, blocked ear – left sided, catarrh, chronic rhinitis, congestion, earache/congested sinuses,
Eustachian tube dysfunction, inflamed left ear canal, nasal congestion, otitis media, post-nasal drip,
runny nose, sinusitis, worsening hay fever, worsening of otitis externa.
l Miscellaneous: acute tonsillitis, anaemia, balanitis, benign paroxysmal positional vertigo, blepharitis,
calf pain, chalazion (eyelid cyst), conjunctivitis, contact dermatitis, contraception, cough? gastric reflux?
post-nasal drip, dysfunctional breathing, Eustachian tube dysfunction (bilateral), excision of thyroglossal
cyst, eye symptoms, facial pain, fever, flu symptoms, heterozygous factor V Leiden mutation,
hoarseness, itch, left otalgia, neck swelling, occasional feeling below sternum of ‘racing’ – fluttering,
feels winded, open wound on scalp, oral thrush, otitis externa, pleural effusion, post-spirometry chest
discomfort, problems with crumbling teeth, pyrexia (virus), scolding injury, seborrheic dermatitis,
sensation of mucus in throat, snoring symptoms, swollen tongue, tight/sore throat, tonsillitis, urinary
tract infection, urticarial rash, virus affecting ears, throat and stomach, watery eyes.
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Appendix 10 List of all serious adverse
events reported
TABLE 67 List of all serious adverse events (SAEs) reported
Arm Patient ID
Date of onset of
SAE Main symptom Seriousa Causalityb
DVD 11011 14 January 2013 Gastric band erosion 3 5
11023 30 December 2012 Chest pain 3 5
12114 03 April 2014 Acute exacerbation of asthma 3 3
15207 26 November 2013 Chest pain (musculoskeletal) 3 5
17121 08 August 2013 Non-specific abdominal pain 3 5
20244 07 February 2014 Asthma exacerbation 3 3
21269 09 March 2014 Transient ischaemic attack 3 3
31447 03 March 2015 Abdominal pain 3 5
32446 05 June 2015 Chest infection/coronary artery disease 3 3
39613 20 July 2015 Acute exacerbation of asthma 3 3
40596 05 June 2015 Death – cardiac arrest 1 5
Physiotherapy 10014 17 April 2013 Malignant lymphoma 2 5
12067 28 October 2013 Chest pain with palpitations 3 5
38576 17 November 2014 Septic arthritis 3 5
38582 16 March 2015 Asthma exacerbation 3 3
Usual care 12057 24 May 2014 Hospitalised – chest infection 3 3
12091 28 December 2013 Chest pain 3 5
12127 31 October 2013 Gastritis 3 5
12195 26 May 2014 Chest pain secondary to hiatus hernia 3 5
01 September 2014 Abdominal pain
14095 26 April 2014 Death – pulmonary oedema 1 5
15203 16 June 2014 Caecal volvolus 3 5
31 July 2014 Colitis
17173 23 July 2014 Pneumonia 3 3
18184 02 March 2014 Stridor 3 5
20238 11 April 2014 Death – pleural effusion 1 5
25294 27 July 2014 Urinary tract infection 3 3
30395 26 December 2014 Influenza A 3 5
31434 24 March 2015 Pneumonia 3 4
31501 04 July 2014 Cerebral venous thrombosis 3 3
continued
DOI: 10.3310/hta21530 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 53
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
119
TABLE 67 List of all serious adverse events (SAEs) reported (continued )
Arm Patient ID
Date of onset of
SAE Main symptom Seriousa Causalityb
32449 10 September 2014 Acute coronary syndrome 3 5
34477 24 December 2014 Chest pain – non cardiac 3 5
27 June 2014
22 June 2014
37547 15 July 2015 Per vaginal bleed post large loop excision
of the transformation zone of the cervix
3 5
38570 22 November 2014 Pulmonary embolism 2 5
02 December 2014 Lower respiratory tract infection
38572 14 February 2015 Small bowel obstruction 3 5
38587 10 September 2015 Tonsillitis 3 5
39575 09 January 2015 Infective exacerbated asthma 3 3
a Why was the event serious?: 1 = resulted in death, 2= life-threatening, 3= required hospitalisation or prolongation of
existing hospitalisation, 4 = resulted in persistent or significant disability/incapacity, 5= congenital anomaly/birth defect.
b Investigator’s opinion – causal relationship to SAE: 1 = definitely, 2 = probably, 3 = possibly, 4= unlikely, 5= not related.
APPENDIX 10
NIHR Journals Library www.journalslibrary.nihr.ac.uk
120
Appendix 11 List of all adverse events (maximum
grade) reported by treatment arm
TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Abdominal/
gastrointestinal
Testicular pain 10004 11 October 2013 2 5
Gastric band erosion 11011 14 January 2013 3 3 5
Haemorrhoids 13051 06 May 2014 3 5
Suspected urinary tract
infection
13053 11 June 2014 2 5
Pain from pre-existing
umbilical hernia
15201 UNK May 2013 2 5
Non-specific abdominal
pain
17121 08 August 2013 2 3 5
Irritable bowel syndrome 24307 15 October 2014 1 5
Abdominal cramps and
diarrhoea
25303 18 December 2014 1 4
Abdominal cramps –
gastroenteritis
27466 30 May 2015 2 5
Abdominal pain 31447 23 March 2015 3 3 5
Breathlessness related to
abdominal pain
32409 17 April 2015 2 5
Acute exacerbation of
asthma
Acute exacerbation of
asthma
10003 11 February 2013 2 3
Asthma exacerbation 10031 11 July 2013 2 3
Exacerbation of COPD 12064 03 March 2014 2 3
Acute asthma exacerbation 12114 03 April 2014 3 3
Asthma flair 15157 29 August 2014 1 3
Asthma exacerbation 19221 UNK February 2014 1 3
Asthma exacerbation 20244 07 February 2014 2 3 3
Exacerbation of asthma 31433 09 January 2015 1 3
Acute exacerbation of
asthma
31453 21 April 2015 2 3
Acute respiratory distress
syndrome
32446 05 June 2015 3 3 3
Cough/wheeze (infected
exacerbation of asthma)
33511 15 December 2014 2 3
Acute exacerbation of
asthma
33521 27 December 2014 1 3
Acute exacerbation of
asthma
33522 UNK February 2015 2 3
Asthma exacerbation 34476 15 May 2015 3
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TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Acute exacerbation of
asthma
34516 22 June 2015 2 3
Asthma attack 35545 15 August 2015 2 3
COPD exacerbation 36529 22 March 2015 3 3
Exacerbation of asthma 37538 15 December 2014 2 3
Asthma exacerbation 38562 17 March 2015 2 3
Asthma exacerbation 39613 20 July 2015 3 3 3
Chest pain and
cardiovascular
Atrial fibrillation 10020 23 March 2013 2 5
Chest pain 11023 30 December 2012 2 3 5
Hypertension 13053 30 October 2013 3 5
Chest pain
(musculoskeletal)
15207 26 November 2013 2 3 5
Chest pain 17108 25 January 2014 2 4
chest pain 24307 26 May 2014 2 4
Palpitations 31481 17 March 2015 1 4
Chest pain related to
abdominal pain
32409 17 April 2015 2 5
Cardiac disorder 32446 26 May 2015 4 3 5
Chest soreness 39613 01 November 2015 1 3 3
Cardiac arrest 40596 05 June 2015 5 5
Palpitations 40609 26 February 2015 1 5
Left lateral chest wall pain 40614 02 December 2015 1 5
Increased asthma
symptoms
Worsening of asthma 12114 24 February 2014 1 3
Worsening of asthma 13053 06 August 2013 2 3
Cough 15157 09 June 2014 1 3
Wheeze 16136 UNK April 2014 1 3
Cough 16160 31 March 2014 1 3
Shortness of breath 18172 18 October 2013 1 3
Cough 18172 28 May 2014 1 3
Cough 19221 UNK February 2014 1 3
Cough 21269 06 March 2014 1 3
Cough 23300 27 December 2014 1 3
Cough 25298 01 November 2014 1 3
Shortness of breath from
hay fever
25308 09 June 2014 1 3
Wheezy cough 25332 01 April 2014 1 3
Cough 26336 24 June 2014 1 3
Tight chest 30391 13 October 2014 1 3
Increasing shortness of
breath
31401 15 May 2014 2 3
Poor asthma control 31455 UNK November 2014 1 3
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TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Worsening of asthma 32451 UNK February 2015 2 3
Shortness of breath 34438 15 September 2014 1 3
Cough 34476 24 December 2014 1 3
Cough/wheeze 34516 15 May 2015 1 3
Worsening of asthma
(cough and wheeze)
37539 05 December 2014 3 3
Chest tightness 37549 20 February 2015 2 3
Feels unable to fully inhale 38562 11 October 2015 2 3
Malignancy Malignant neoplasm breast
– review
13051 01 April 2014 3 5
Prostate cancer 24289 05 January 2015 3 5
Follicular papillary
carcinoma
30426 21 May 2014 4 3 5
Musculoskeletal Baker’s cyst 10003 30 September 2013 1 5
Golfer’s elbow 10004 11 February 2013 2 4
Lacerated left middle finger 10020 23 September 2013 1 5
Aching muscles 10033 06 August 2013 1 5
Left arm pain 12064 17 September 2013 2 4
Leg cramps 12085 06 May 2014 1 5
Back pain following fall 12089 20 June 2014 2 5
Lateral epicondylitis 13051 06 May 2014 3 5
Right shoulder rotator cuff
strain
31433 14 October 2014 2 5
Neck pain 33522 UNK November 2014 2 4
Spinal stenosis 40596 13 March 2015 2 5
Right frozen shoulder 40598 01 May 2015 1 5
Back pain 42618 28 October 2015 2 5
Lower back pain 42629 19 August 2015 1 5
Hip pain 43651 02 July 2015 1 5
Neurological Right-hand numbness 12049 31 October 2013 1 4
Headache – different from
migraine
12089 07 November 2013 2 4
Right-sided body numbness 21269 09 March 2014 4 4
Transient ischaemic attack 21269 09 March 2014 3 3 5
Fatigue 31420 27 November 2014 1 4
Dizziness 33495 22 September 2014 2 4
Tinnitus 36535 UNK April 2015 2 5
continued
DOI: 10.3310/hta21530 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 53
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
123
TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Psychological/
psychiatric
Anxiety with depression 13045 30 December 2013 2 3
Insomnia 13051 04 October 2013 3 3
Depression 16136 UNK September 2013 2 3
Depression 20248 01 September 2014 1 3
Depression 22275 UNK January 2014 1 3
Anxiety 32404 UNK March 2015 1 3
Anxiety 35540 28 December 2014 1 3
Depression 35545 UNK May 2015 2 3
Low mood 38580 UNK January 2015 1 3
Memory loss 40596 22 December 2014 2 3
Anxiety attack 43637 21 October 2015 1 3
Respiratory tract
infection/cough
Chest infection 12064 21 May 2014 2 5
Chesty cough 12114 11 October 2013 2 5
Upper respiratory tract
infection
13061 26 September 2013 1 4
Chest infection 15155 31 December 2013 1 4
Chest infection 15157 07 May 2014 1 5
Productive cough 16136 UNK April 2014 1 5
Green sputum 16160 03 April 2014 1 5
Chesty cough 17108 08 April 2014 2 4
Laryngitis 17144 16 December 2013 1 5
Worsening of cough 18172 13 June 2014 1 5
Bronchitis 19221 UNK November 2013 1 5
Chest infection 20249 12 April 2014 1 5
Cold 21269 04 November 2014 1 5
Cold 23315 01 January 2015 1 5
Upper respiratory tract
infection
23316 13 March 2014 1 5
Chest infection 23359 23 January 2015 1 5
Chest infection 24289 15 July 2014 1 5
Viral cough 25332 14 December 2014 1 5
Lower respiratory tract
infection
25376 25 December 2014 1 5
Viral infection 26323 18 January 2015 1 5
Chest infection 26374 02 December 2014 1 5
Upper respiratory tract
infection
27337 05 July 2014 1 5
Cold 27367 05 October 2014 1 5
Upper respiratory tract
infection
27466 05 January 2015 2 5
Sore throat 29463 08 December 2014 1 5
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TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Chesty cough 30391 24 March 2015 1 5
Productive cough 31401 07 November 2014 2 4
Upper respiratory tract
infection
31420 29 December 2014 2 4
Chest infection 31447 09 June 2015 2 4
Upper respiratory tract
infection
31481 01 February 2015 1 4
Chest infection 32407 UNK December 2014 2 5
Chest infection 32446 05 June 2015 3 3 5
Lower respiratory tract
infection
32451 11 March 2015 2 5
Chesty cough 33511 26 January 2015 2 4
Productive cough (lower
respiratory tract infection)
33520 10 December 2014 1 4
Chest infection 33521 12 December 2014 1 4
Cold 33522 UNK February 2015 1 4
Upper respiratory tract
infection
34456 22 May 2015 2 5
Cough and hoarse voice 34476 16 January 2015 2 5
Worsening cough with
wheeze and shortness of
breath
34516 02 October 2014 2 4
Cold 35531 01 December 2014 1 5
Upper respiratory tract
infection
35540 01 January 2015 2 4
Sore throat 36554 30 July 2015 1 5
Post viral cough and
wheeze
37549 06 January 2015 2 5
Viral cold and cough 38560 28 December 2014 1 5
Chest infection/shortness
of breath on exertion
38561 02 January 2015 2 4
Chest infection 38579 09 April 2015 2 5
Cold virus – hoarseness
and cough
38580 08 October 2015 1 5
Chest infection 38592 19 May 2015 2 4
Cough 38602 11 December 2014 2 5
Cough and brown phlegm 39613 08 December 2014 2 5
Upper respiratory tract
infection
41648 20 December 2015 1 5
Lower respiratory tract
infection
42618 20 April 2015 1 5
Acute bronchitis 43638 18 November 2015 1 5
Cough 43646 23 March 2015 1 5
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TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Chest infection 43651 03 January 2016 1 5
Cough 43652 05 January 2016 2 5
Rhinitis/rhinosinusitis Chronic rhinitis 10031 07 August 2013 2 5
Worsening hay fever 12114 23 May 2014 1 5
Otitis media 13051 17 January 2014 3 5
Nasal congestion 15155 17 August 2013 1 4
(Sinusitis) sore eyes 16196 26 December 2013 1 5
Inflamed left ear canal 23316 18 February 2014 1 5
Sinusitis 25308 25 January 2015 1 5
Congestion 29463 08 December 2014 1 5
Worsening of otitis externa 31401 15 May 2014 2 5
Eustachian tube
dysfunction
31447 10 December 2014 1 4
Earache 34476 26 March 2015 1 5
Acute sinusitis 35531 01 December 2014 2 4
Blocked ear 36535 UNK April 2015 2 5
Post-nasal drip 38568 08 May 2015 2 4
Eustachian tube
dysfunction
43638 08 October 2015 1 5
Miscellaneous Watery eyes 10004 08 April 2013 2 5
Scolding injury 10020 02 October 2013 1 5
Eye symptoms 10033 31 October 2013 1 5
Occasional feeling below
sternum of ‘racing’ –
fluttering, feels winded
12085 06 May 2014 1 5
Urticarial rash 13045 13 January 2014 2 5
Urinary tract infection 13051 30 May 2014 2 5
Snoring symptoms 13052 02 January 2014 2 5
Facial pain 20244 07 March 2014 1 4
Benign paroxysmal
positional vertigo
29463 25 June 2014 1 4
Sensation of mucus in
throat
31435 UNK September 2014 2 4
Facial pain 34476 26 March 2015 1 5
Post-spirometry chest
discomfort
37549 02 September 2014 1 5
Temporomandibular joint
disorder
38597 UNK February 2015 3 5
Blocked ear right 38603 UNK April 2015 1 5
Lower back pain
(secondary to car accident
in 2006)
38622 10 July 2015 1 5
Claudication left calf 40596 26 January 2015 1 5
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TABLE 68 List of all adverse events (maximum grade) reported (as categorised by PIs) in the DVD arm (continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Fever 42629 30 August 2015 1 5
Vertigo 43631 21 June 2015 1 5
UNK, unknown.
a Grade: 1=mild, 2=moderate, 3= severe, 4= life-threatening, 5= death related to adverse event.
b Why was the event serious?: 1 = resulted in death, 2= life-threatening, 3= required hospitalisation or prolongation of
existing hospitalisation, 4 = resulted in persistent or significant disability/incapacity, 5= congenital anomaly/birth defect.
c Investigator’s opinion – causal relationship to adverse event: 1 = definitely, 2= probably, 3 = possibly, 4 = unlikely,
5= not related.
TABLE 69 List of all adverse events (maximum grade) reported (as categorised by PIs) in the physiotherapy arm
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Abdominal/
gastrointestinal
Vaginal discharge 10001 22 January 2013 1 5
Abdominal pain 10032 08 March 2013 2 5
Haemorrhoids 13060 22 January 2014 2 5
Gastric bypass surgery 20267 29 March 2014 2 3 5
Increased nausea 33507 UNK October 2014 2 4
Acute exacerbation of
asthma
Asthma exacerbation 10001 24 September 2013 2 3
Productive cough
worsening (acute
exacerbation of asthma)
18183 05 February 2014 1 3
Acute exacerbation of
asthma
25379 22 November 2014 2 3
Exacerbation of asthma 25379 13 February 2015 2 3
Exacerbation of asthma 31417 15 July 2014 2 3
Asthma exacerbation 31432 12 October 2014 2 3
COPD exacerbation 37537 03 August 2015 3 3
Chest infection/asthma
exacerbation
38576 28 September 2015 3 3
Asthma exacerbation 38582 16 March 2015 3 3 3
Asthma exacerbation 40600 24 March 2015 1 3
Chest pain and
cardiovascular
Deep-vein thrombosis 10014 18 September 2013 3 5
Chest pains with
palpitations
12067 28 October 2013 2 3 5
Pleuritic left-sided chest
pain
19220 04 July 2014 1 4
Chest pain 33507 20 October 2014 2 4
Costochondritis 34460 15 July 2014 2 5
Costal margin chest pain 43650 15 June 2015 1 5
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TABLE 69 List of all adverse events (maximum grade) reported (as categorised by PIs) in the physiotherapy arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Increased asthma
symptoms
Cough 10032 21 November 2013 1 3
Wheeze plus shortness of
breath
17110 15 March 2014 3 3
Worsening of asthma 17123 11 December 2013 2 3
Cough 17128 10 August 2014 1 3
Wheeze 18175 17 September 2013 1 3
One wheeze 18183 05 February 2014 1 3
Wheeze 19220 06 January 2014 1 3
Cough, dyspnoea and
wheeze
23360 18 June 2014 1 3
Cough 23362 27 October 2015 1 3
Cough 24311 26 October 2014 1 3
Worsening of asthma 25291 13 April 2014 1 3
Increase in asthma
symptoms
25305 01 October 2014 1 3
Cough and wheeze 25379 13 March 2015 2 3
Cough 26341 04 May 2014 1 3
Cough 27338 23 February 2015 1 3
Respiratory symptoms
limiting exercise activities
31424 16 May 2015 1 3
Cough 31486 03 September 2014 2 3
Cough 32492 13 January 2015 2 3
Increased cough, wheeze
and shortness of breath
37550 13 April 2015 2 3
Cough 38564 05 September 2015 1 3
Malignancy Malignant lymphoma 10014 17 April 2013 3 5
Musculoskeletal Shoulder pain 12040 01 July 2013 2 5
Ankle and hip pain 13060 09 September 2013 3 4
Back pain 13060 03 February 2014 3 5
Joint aches (virus) 18183 12 September 2014 1 5
Left-sided jaw pain 25325 12 September 2014 1 5
Fractured right rib 31424 UNK January 2015 2 5
Septic arthritis 38576 18 November 2014 3 3 5
Sciatica 43635 19 March 2015 1 5
Knee pain 43639 01 July 2015 1 5
Shoulder pain 43643 28 July 2015 1 5
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TABLE 69 List of all adverse events (maximum grade) reported (as categorised by PIs) in the physiotherapy arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Neurological Neuropathic pain 13060 27 June 2013 2 5
Chronic inflammatory
demyelinating
polyneuropathy
21346 19 November 2014 2 5
Tinnitus 36543 UNK November 2014 1 5
Psychological/
psychiatric
Anxiety 26321 UNK May 2014 1 3
Stress 33519 UNK October 2014 2 4
Respiratory tract
infection/cough
Sore throat 10032 01 September 2013 1 5
Congestion with cold,
cough and shortness of
breath
17110 10 February 2014 2 5
Sore throat (virus) 18183 12 September 2014 1 5
Bronchitis 18219 UNK January 2014 1 5
Green sputum 19220 06 January 2014 1 5
Cough/cold 20250 24 December 2013 1 5
Chest infection 21268 22 March 2014 1 4
Viral cough 23284 29 December 2014 1 5
Chest infection 23312 24 November 2014 1 5
Viral illness causing
wheeze, cough, fever and
chest tightness
23343 28 December 2014 1 5
Upper respiratory chest
infection
23360 09 December 2014 1 5
Cold 23362 26 January 2015 1 5
Viral illness 25291 15 December 2014 1 5
Cough and cold 25325 09 September 2014 1 5
Chest infection 25330 17 July 2014 1 5
Chest infection 25379 24 February 2015 2 5
Cold 26321 28 January 2015 1 5
Cold 26381 20 January 2015 1 5
Chest infection 27338 11 December 2014 1 5
Upper respiratory tract
infection
28383 20 February 2015 1 5
Upper respiratory tract
infection
30399 27 December 2014 1 5
Lower respiratory tract
infection
31432 12 October 2014 2 4
Cold virus (sore throat and
cough)
37537 24 July 2015 2 5
Sore throat 37550 13 April 2015 1 5
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TABLE 69 List of all adverse events (maximum grade) reported (as categorised by PIs) in the physiotherapy arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Chest infection 38593 25 September 2015 2 4
Cough 39574 15 December 2014 2 5
Rhinitis/rhinosinusitis Chronic rhinitis 18183 12 September 2014 1 5
Earache/congested sinuses 25325 20 October 2014 1 5
Nasal congestion 28383 2 5
Left ear infection 31419 UNK June 2014 2 4
Runny nose 32492 13 January 2015 2 5
Miscellaneous Urinary tract infection 10014 29 May 2013 2 5
Itch 12040 19 February 2014 1 4
Otitis externa 13047 21 October 2013 1 5
Calf pain 13060 18 July 2013 3 5
Blepharitis 13072 13 March 2014 1 5
Pyrexia (virus) 18183 12 September 2014 1 5
Virus affecting ears, throat
and stomach
28387 13 March 2015 1 5
Oral thrush 31474 03 February 2015 1 5
Acute tonsillitis 34514 20 June 2015 2 5
Hoarseness 38564 14 November 2014 1 5
UNK, unknown.
a Grade: 1=mild, 2=moderate, 3 = severe, 4= life-threatening, 5= death related to adverse event.
b Why was the event serious?: 1 = resulted in death, 2= life-threatening, 3= required hospitalisation or prolongation of
existing hospitalisation, 4 = resulted in persistent or significant disability/incapacity, 5= congenital anomaly/birth defect.
c Investigator’s opinion – causal relationship to adverse event: 1= definitely, 2= probably, 3= possibly, 4 = unlikely,
5= not related.
TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Abdominal/
gastrointestinal
Rectal bleeding 10005 01 July 2013 2 5
Altered bowel habit –
complains of adhesions
10013 14 December 2013 2 5
Bacterial vaginosis 10021 19 June 2013 2 5
Laparoscopic vaginal
hysterectomy
12068 17 March 2014 3 3 5
Gastritis 12127 31 October 2013 2 3 5
Abdominal pain 12195 01 September 2014 3 3 5
Epigastric pain plus
dysfunctional breathing
13073 23 September 2013 2 5
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Colitis 15203 31 July 2014 3 3 5
Vomiting (flu) 16187 UNK December 2013 1 5
Epigastric pain episode
linked to ongoing acid
reflux
27349 07 October 2014 1 5
Lower abdominal pain 31434 13 June 2014 2 4
Gastritis 32416 UNK September 2014 2 5
Abdominal pain 34459 12 May 2015 1 5
Lower abdominal pain with
loose stools
34500 01 December 2014 2 4
Per vaginal bleed post large
loop excision of the
transformation zone of the
cervix
37547 15 July 2015 2 3 5
Umbilical hernia repair 38572 17 February 2015 3 3 5
Acute exacerbation of
asthma
Asthma exacerbation 10030 03 January 2014 3 3
Exacerbation of asthma/
COPD
12057 08 January 2014 2 3
Asthma exacerbation 12068 25 August 2013 2 3
Exacerbation of asthma 12137 20 March 2014 2 3
Asthma exacerbation 17125 20 January 2014 2 3
COPD 17173 10 September 2013 2 3
Asthma exacerbation 18182 UNK May 2014 2 3
Exacerbation of asthma 23283 17 March 2014 1 3
Asthma exacerbation 23342 01 August 2014 1 3
One exacerbation of
asthma
26350 08 April 2014 1 3
Exacerbation of asthma 31425 UNK November 2014 1 3
One exacerbation of
asthma
31429 12 February 2015 1 3
Acute exacerbation of
asthma
31434 13 November 2014 2 3
Asthma exacerbation 31436 24 May 2014 1 3
Asthma exacerbation 31503 30 October 2014 2 3
Acute exacerbation of
asthma
34499 23 February 2015 2 3
Acute exacerbation of
asthma
34500 21 January 2015 2 3
Asthma exacerbation 34515 06 May 2015 2 3
Asthma exacerbation 36555 09 February 2015 3 3
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Exacerbation of asthma 38572 19 October 2014 3 3
Infective exacerbation of
asthma
39575 09 January 2015 3 3 3
Exacerbation of asthma 42616 13 July 2015 1 3
Exacerbation of asthma 43641 11 September 2015 1 3
Chest pain and
cardiovascular
Palpitations 12043 15 August 2013 2 3
Chest pain 12091 28 December 2013 2 3 5
Chest pain? – hiatus hernia 12195 26 May 2014 2 3 5
High blood pressure 13066 30 May 2014 3 4
Chest pain 13073 04 October 2013 3 5
Collapsed and died – post
mortem report found
pulmonary oedema with a
background of dilated
cardiomyopathy and
thyroid disease
14095 26 April 2014 1 3 5
Chest pain 18184 16 October 2013 1 5
Rib pain 20260 24 February 2014 1 5
Chest pain 28390 UNK November 2014 2 5
Palpitations 31434 24 March 2015 3 3 4
Chest pain – acute
coronary syndrome
32449 10 September 2014 3 3 5
Exertional chest pain (while
hovering)
33510 02 September 2014 2 4
Chest pain 34477 24 December 2014 2 3 5
Pulmonary embolism 38570 22 November 2014 3 3 5
Atrial fibrillation 38572 02 August 2015 3 5
Palpitations 40608 09 November 2015 1 5
Increased asthma
symptoms
Wheeze tachycardia 11017 02 May 2013 3 3 3
Worsening of asthma 12137 17 January 2014 2 3
Wheeze 16147 UNK December 2013 2 3
Cough 17125 01 December 2013 2 3
Cough 17173 04 April 2014 1 3
Cough 18170 05 May 2014 1 3
Shortness of breath 18184 28 February 2014 2 3
Cough 18211 02 December 2013 1 3
Wheeze 19228 06 October 2014 1 3
Cough 21282 21 December 2014 1 3
Cough 23342 25 April 2014 1 3
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Cough and wheeze 24357 16 March 2015 1 3
Shortness of breath 25293 02 June 2014 1 3
Ongoing asthma symptoms 25294 14 April 2014 1 3
Slight breathlessness 25324 17 September 2014 1 3
Cough 25412 31 August 2014 1 3
Cough and wheeze 27333 24 September 2014 1 3
Asthma symptoms 30398 UNK September 2014 1 3
Tight chest 31422 16 May 2014 2 3
Shortness of breath 31470 26 April 2015 2 3
Poor asthma control 31503 18 February 2015 2 3
Slight wheeze 32400 08 January 2015 2 3
Cough 32403 UNK November 2014 2 3
Increasing shortness of
breath
33504 12 July 2014 2 3
Cough 34440 11 November 2014 1 3
Breathlessness 34459 UNK December 2014 2 3
Cough and wheeze 34515 29 June 2015 2 3
Asthma worsening 37527 UNK January 2015 1 3
Cough and wheeze 37547 18 May 2015 2 3
Wheeze and shortness of
breath
38567 14 December 2014 2 3
Shortness of breath on
exertion
38604 28 February 2015 2 3
Cough 42615 29 December 2014 1 5
Musculoskeletal Degenerative change in
lumbosacral region
10005 21 May 2013 2 5
Back pain 10024 30 September 2013 2 5
Arthralgia of hands/
shoulders
12100 24 March 2014 2 5
Shoulder pain 13046 18 March 2014 3 5
Cervicalgia 17099 09 June 2014 2 5
Neck pain 17173 20 May 2014 1 5
Joint ache 19228 06 October 2014 1 5
Right knee replacement
surgery
23280 01 December 2014 2 3 5
Neck pain 26317 13 July 2014 1 5
Low back pain 31406 UNK July 2014 2 4
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Right shoulder rotator cuff
tear
31421 16 November 2014 3 5
Gout 31422 27 March 2015 2 4
Prolapsed intervertebral
lumbar disc (worsening of)
31425 31 October 2014 2 4
Right shoulder rotator cuff
sprain
31429 02 September 2014 2 4
Worsening of frozen
shoulder (right)
31437 UNK April 2015 2 4
Rotator cuff syndrome 31445 UNK January 2014 1 4
Back pain 33513 23 February 2015 1 4
Cervicalgia 34500 13 May 2015 2 4
Left-sided muscle tightness
in neck
35541 17 May 2015 1 4
Cervicalgia 35544 UNK January 2015 3 5
Tennis elbow 43630 17 November 2015 1 5
Rotator cuff syndrome 43641 06 May 2015 2 5
Neurological Tremor 10021 12 November 2013 1 5
Neuralgic pain 13046 15 November 2013 2 5
Headache 19228 06 October 2014 1 5
Dizziness 31425 UNK July 2014 2 4
Nausea 31434 24 March 2015 2 3 4
Cerebral venous
thrombosis
31501 04 July 2014 3 3 5
Headache 33504 12 July 2014 2 4
Light-headed symptoms 33513 03 June 2015 1 4
Giant cell arteritis 38570 24 October 2014 3 3 5
Post FeNO test
breathlessness, light-
headedness and clammy
38572 30 September 2015 2 5
Migraine 43649 05 March 2015 1 5
Psychological/
psychiatric
Mood swings 10021 08 May 2013 2 3
Anxiety (worsening) 12043 24 September 2013 3 3
Lethargy 13046 08 October 2013 2 5
Anxiety with depression 13073 13 June 2014 3 3
Shortness of breath (panic
attack)
16151 15 April 2014 1 3
Anxiety 17099 06 August 2013 2 3
Anxiety 17125 27 June 2014 2 3
Depression 21282 UNK November 2014 1 3
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Depression 23344 UNK October 2014 1 3
Depression 25378 15 October 2014 1 3
Low mood 31406 UNK December 2014 2 3
Depression 31429 02 April 2015 2 3
Recurrence of depressive
episode
31437 UNK October 2014 2 3
Low mood 31484 28 January 2015 2 3
Anxiety 32416 UNK September 2014 2 3
Anxiety attack 33504 30 March 2015 2 3 3
Respiratory tract
infection/cough
Acute lower respiratory
tract infection
12057 24 May 2014 2 3 4
Lower respiratory tract
infection
12062 11 February 2014 2 5
Chest infection 12068 26 March 2014 2 5
Upper respiratory tract
infection
12075 24 December 2013 2 5
Chesty cough 12082 10 January 2014 1 5
Cough ongoing 12137 31 March 2014 2 5
Sore throat 16139 16 August 2014 1 5
Productive cough 16147 UNK December 2013 2 5
Shortness of breath (flu) 16187 UNK December 2013 1 5
Pneumonia 17173 23 July 2014 3 3 5
Cough (post viral) 18182 UNK March 2014 1 5
Stridor 18184 02 March 2014 2 3 5
Dry cough 18209 15 August 2014 1 5
Productive cough 18216 19 March 2014 1 5
Cough with green phlegm 19240 UNK December 2013 1 5
Chest infection 20246 11 November 2013 1 5
Chest infection 20260 10 November 2013 1 5
Chesty cough 20265 22 August 2014 1 5
Chest infection 20277 UNK May 2014 1 5
Cold 21270 24 November 2014 1 5
Lower respiratory tract
infection
21282 04 October 2014 1 5
Bronchitis 22276 UNK December 2013 1 4
One episode of coughing 23280 15 October 2014 1 5
Viral infection (green
sputum, cough)
23283 08 December 2014 1 5
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Chest infection 23287 01 December 2014 1 5
Flu-like virus 23288 31 December 2014 1 5
Chest infection 23342 04 April 2014 1 5
Chest infection 24309 18 December 2014 1 5
Chest infection 24357 24 January 2015 1 5
Respiratory heart infection 25294 01 April 2014 1 5
Sore throat 25324 29 December 2014 1 5
Pharyngitis 25329 01 May 2014 1 5
Cold 25331 15 December 2014 1 5
Cold 25412 11 April 2015 1 5
Cough? viral laryngitis 26317 18 August 2014 1 5
Cough with green sputum 26335 25 November 2014 1 5
Upper respiratory tract
infection
26339 18 October 2014 1 5
Upper respiratory tract
infection
26350 30 January 2015 1 5
Cough and cold 26371 17 February 2015 1 5
Chesty cough 27349 28 May 2014 1 5
Upper respiratory tract
infection
28388 26 February 2015 1 5
Chest infection 29413 01 April 2015 1 5
Chest infection 29462 15 April 2015 1 5
Influenza A 30395 26 December 2014 3 3 5
Lower respiratory tract
infection
30398 20 December 2014 1 5
Sore throat 31422 02 March 2015 1 4
Haemoptysis 31434 24 March 2015 2 3 4
Productive cough 31436 24 May 2014 2 4
Chest infection 31482 30 December 2014 2 4
Chesty cough 31503 03 February 2015 2 4
Sore throat 32400 08 January 2015 2 5
Night cough 32488 01 March 2015 2 4
Chesty cough 33504 UNK November 2014 1 4
Cold virus 34439 15 October 2014 1 5
Chest infection 34458 UNK April 2015 1 5
Chest infection 34496 25 February 2015 2 4
Chest infection 34499 23 November 2014 2 4
Coryzal 35544 25 June 2015 3 5
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Pharyngitis 36533 25 March 2015 1 5
Chest rattle 36552 10 August 2015 1 4
Cough, wheeze, shortness
of breath, crackles and
phlegm
36555 27 October 2014 3 4
Upper respiratory tract
infection
37547 25 February 2015 2 5
Pseudomonas aeruginosa
infection
38563 17 May 2015 3 4
Acute laryngitis 38567 22 June 2015 2 5
Lower respiratory tract
infection
38570 02 December 2014 3 3 5
Sore throat – fungal mouth
infection
38581 27 January 2015 2 5
Cold virus 38583 11 October 2015 1 5
Chest infection 38590 24 January 2015 1 5
Bronchiectasis – infective
exacerbation
38591 07 September 2015 1 5
Cold virus 38636 28 November 2015 1 5
Cough 39611 18 April 2015 1 5
Cough 42620 29 April 2015 1 5
Rhinitis/rhinosinusitis Acute sinusitis 10036 30 January 2014 2 5
Acute sinusitis 12137 27 May 2014 1 5
Congestion 18209 15 August 2014 1 5
Nasal congestion 19228 06 October 2014 1 5
Acute sinusitis 20260 15 September 2014 1 5
Allergic rhinitis 20265 05 May 2014 1 5
Sinusitis 23342 16 January 2015 1 5
Sinusitis 25293 06 August 2014 1 5
Allergic rhinitis 27349 12 June 2014 1 5
Eustachian tube
dysfunction
31429 11 March 2015 1 4
Acute sinusitis 33510 UNK December 2014 2 4
Sinus pain 34440 UNK March 2015 1 5
Sinusitis 37547 01 March 2015 2 5
Sinusitis 38563 17 August 15 2 4
Rhinitis 38606 05 July 2015 2 5
Acute sinusitis 43641 09 December 2015 1 5
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TABLE 70 List of all adverse events (maximum grade) reported (as categorised by PIs) in the usual-care arm
(continued )
Category of main
symptom Nature of adverse event
Patient
ID Date of onset
Severity
of adverse
eventa Seriousb Causalityc
Miscellaneous Anaemia 10021 18 February 2013 2 5
Open wound on scalp 10030 28 June 2013 1 5
Problems with crumbling
teeth
12042 21 August 2013 2 3 5
Balanitis 12043 21 March 2014 1 5
Contact dermatitis 12068 12 November 2013 1 5
Excision of thyroglossal cyst 13046 01 October 2013 2 5
Dysfunctional breathing 13073 03 September 2013 2 5
Pyrexia 18184 28 February 2014 2 5
Pleural effusion 20238 11 April 2014 1 3 5
Flu symptoms 23319 UNK February 2014 1 5
Urinary tract infection 25294 27 July 2014 2 3 5
Cough? gastric reflux?
post-nasal drip
25375 UNK August 2014 1 5
Neck swelling 26350 06 January 2015 1 5
Oral thrush 29462 24 September 2014 1 5
Fever 31434 24 March 2015 2 3 4
Seborrheic dermatitis 31437 UNK October 2014 2 5
Oral thrush 31450 18 December 2014 1 4
Oral thrush 31503 11 March 2015 2 4
Tonsillitis 38587 10 September 2015 3 3 5
UNK, unknown.
a Grade: 1=mild, 2=moderate, 3 = severe, 4= life-threatening, 5= death related to adverse event.
b Why was the event serious?: 1 = resulted in death, 2= life-threatening, 3= required hospitalisation or prolongation of
existing hospitalisation, 4 = resulted in persistent or significant disability/incapacity, 5= congenital anomaly/birth defect.
c Investigator’s opinion – causal relationship to adverse event: 1= definitely, 2= probably, 3= possibly, 4 = unlikely,
5= not related.
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Appendix 12 Unit costs of the interventions and
primary care and other service use
TABLE 71 Unit costs of the interventions and primary care and other service use (2014/15 prices)
Service Unit cost (£) Source
GP consultation 45.00 PSSRU73
Out-of-hours clinic 135.00 PSSRU73
Walk-in clinic 135.00 PSSRU73
Outpatient 135.00 PSSRU73
A&E visit 177.00 PSSRU73
Inpatient admission 2581.00 NHS Reference Costs
2014 to 201574
Intervention: face-to-face physiotherapy 83.45 Trial estimate
Intervention: DVD 2.85 Trial estimate
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Appendix 13 Correlation coefficients (Pearson’s r)
between expectancy, experience and practical barriers
associated with amount of practice (at 3 months)
and continued engagement (at 6 and 12 months)
TABLE 72 Correlation coefficients (Pearson’s r) between expectancy, experience and practical barriers associated
with amount of practice (at 3 months) and continued engagement (at 6 and 12 months)
Expectancy, experience
and practical barriers
Amount of practice at
3 months
Continued engagement at
6 months 12 months
DVD Physiotherapy DVD Physiotherapy DVD Physiotherapy
Expectancy
Beliefs about asthma
Perceived causes
Cause 1 – allergy 0.14 0.20* –0.00 –0.02 0.03 0.01
Cause 2 – health
issues
–0.07 –0.05 –0.09 –0.03 –0.21** 0.08
Cause 3 – smoking 0.20* 0.05 0.05 0.17 0.10 0.27**
Perceived chronicity
All the time 0.06 0.11 0.11 0.01 0.03 0.04
Most of the time –0.25** –0.02 –0.11 0.06 –0.11 0.01
Some of the time 0.12 –0.07 0.00 –0.06 0.07 –0.13
Only when
symptoms are
present
0.02 –0.05 –0.02 –0.00 –0.00 0.09
First impressions of treatment
Expectancy 0.21** 0.02 0.23** 0.14 0.16 –0.05
Self-efficacy 0.33*** –0.04 0.38*** 0.20 0.35*** –0.05
Perceived need for support
(baseline)
–0.01 –0.03 –0.03 0.06 –0.10 –0.06
TPB: perceived behavioural
control
0.16* –0.07 0.27*** 0.06 0.15 0.03
TPB: intentions 0.14 –0.01 0.17* 0.13 0.19* 0.09
Treatment experience
Enjoyment of treatment
Stomach breathing 0.39*** 0.30** 0.37*** 0.29** 0.34*** 0.24*
Nose breathing 0.39*** 0.30** 0.36*** 0.23* 0.39*** 0.19
Slow breathing 0.36*** 0.11 0.32*** 0.18 0.32*** 0.24*
Controlled breath
holding
0.26*** 0.05 0.24** 0.25* 0.24** 0.27*
Relaxation training 0.39*** 0.10 0.32*** 0.35*** 0.25** 0.36***
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TABLE 72 Correlation coefficients (Pearson’s r) between expectancy, experience and practical barriers associated
with amount of practice (at 3 months) and continued engagement (at 6 and 12 months) (continued )
Expectancy, experience
and practical barriers
Amount of practice at
3 months
Continued engagement at
6 months 12 months
DVD Physiotherapy DVD Physiotherapy DVD Physiotherapy
Appointments with
physiotherapist
(physiotherapy group only)
0.19 0.01 0.04
Perceived need for support
(3 months)
–0.16* 0.26* –0.11 0.10 –0.14 0.32**
Perceptions of
physiotherapist
(physiotherapy group only)
0.21* 0.09 0.09
Practical barriers
PETS
Problems due to
symptoms
–0.10 –0.09 –0.18* 0.15 –0.03 0.07
Problems due to
uncertainty
–0.32*** –0.15 –0.29*** 0.10 –0.07 0.07
Problems due to doubts –0.46*** –0.20* –0.45*** –0.15 –0.30*** –0.05
Practical problems –0.38*** –0.30** –0.33*** –0.15 –0.32*** –0.12
Problems due to lack of
support
–0.25*** –0.25** –0.24** –0.16 –0.18 –0.01
*p≤ 0.05, **p< 0.01, ***p< 0.001.
TPB, theory of planned behaviour.
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Appendix 14 Multiple regression results for
expectancy, experience and practical barrier variables
associated with amount of practice (at 3 months)
TABLE 73 Multiple regression results for expectancy, experience and practical barrier variables associated with
amount of practice (at 3 months)
B SE (B) β 95% CI
Perceived causes
Cause 1 – allergy 20.15 10.65 0.22 –1.11 to 41.41
Cause 3 – smoking 8.11 11.08 0.08 –14.01 to 30.24
Perceived chronicity
Most of the time 6.52 13.57 0.05 –20.57 to 33.61
First impressions of treatment
Expectancy –1.60 2.11 –0.09 –5.80 to 2.61
Self-efficacy 0.13 4.54 0.00 –8.94 to 9.21
TPB: perceived behavioural control –2.32 2.29 –0.11 –6.89 to 2.24
Enjoyment of treatment
Stomach breathing 1.91 4.91 0.07 –7.89 to 11.71
Nose breathing 6.63 3.95 0.25 –1.25 to 14.51
Slow breathing 1.61 3.68 0.07 –5.74 to 8.96
Controlled breath holding –3.82 3.58 –0.16 –10.97 to 3.33
Relaxation training –2.25 2.46 –0.12 –7.15 to 2.65
Perceived need for support (3 months) 5.29 9.10 0.07 –12.89 to 23.46
Perceptions of physiotherapist (physiotherapy group only) 9.02 14.52 0.08 –19.97 to 38.00
PETS
Problems due to uncertainty –11.37 15.69 –0.08 –42.69 to 19.96
Problems due to doubts –2.52 14.40 –0.02 –31.27 to 26.23
Practical problems –28.44 14.05 –0.24* –56.49 to –0.39
Problems due to lack of support –29.86 14.95 –0.23* –59.72 to –0.00
*p ≤ 0.05.
SE, standard error; TPB, theory of planned behaviour.
R2 = 0.33, F17,66 = 1.92* (n= 84).
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Appendix 15 Multiple regression results for
expectancy, experience and practical barrier variables
associated with continued engagement (at 6 months)
TABLE 74 Multiple regression results for expectancy, experience and practical barrier variables associated with
continued engagement (at 6months)
B SE (B) β 95% CI
First impressions of treatment
Expectancy 0.10 0.13 0.06 –0.15 to 0.35
Self-efficacy 0.17 0.30 0.05 –0.43 to 0.76
TPB: perceived behavioural control –0.11 0.17 –0.06 –0.45 to 0.23
TPB: intentions 0.73 0.78 0.08 –0.81 to 2.28
Enjoyment of treatment
Stomach breathing 0.32 0.24 0.13 –0.16 to 0.79
Nose breathing 0.31 0.23 0.13 –0.15 to 0.76
Slow breathing –0.19 0.28 –0.08 –0.73 to 0.36
Controlled breath holding –0.00 0.22 –0.00 –0.44 to 0.43
Relaxation training 0.41 0.19 0.18* 0.04 to 0.79
PETS
Problems due to symptoms 1.75 0.88 0.16* 0.00 to 3.49
Problems due to uncertainty 0.34 0.90 0.03 –1.43 to 2.12
Problems due to doubts –2.20 0.86 –0.22** –3.89 to –0.50
Practical problems –1.28 0.93 –0.10 –3.11 to 0.54
Problems due to lack of support –0.88 0.82 –0.08 –2.51 to 0.74
*p ≤ 0.05, **p< 0.01, ***p< 0.001.
SE, standard error; TPB, theory of planned behaviour.
R2 = 0.24, F14,174 = 3.97*** (n= 189).
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Appendix 16 Multiple regression results for
expectancy, experience and practical barrier variables
associated with continued engagement (at 12 months)
TABLE 75 Multiple regression results for expectancy, experience and practical barrier variables associated with
continued engagement (at 12 months)
B SE (B) β 95% CI
Perceived causes
Cause 2 – health issues –0.65 0.66 –0.07 –1.95 to 0.65
Cause 3 – smoking 1.19 0.70 0.12 –0.19 to 2.57
First impressions of treatment
Self-efficacy 0.17 0.27 0.05 –0.36 to 0.70
TPB: intentions –0.09 0.68 –0.01 –1.44 to 1.26
Enjoyment of treatment
Stomach breathing 0.16 0.26 0.07 –0.35 to 0.67
Nose breathing 0.36 0.22 0.17 –0.08 to 0.80
Slow breathing –0.02 0.27 –0.01 –0.55 to 0.51
Controlled breath holding 0.01 0.21 0.01 –0.40 to 0.42
Relaxation training 0.29 0.19 0.14 –0.08 to 0.67
Perceived need for support (3 months) –0.17 0.23 –0.06 –0.62 to 0.28
PETS
Problems due to doubts –0.28 0.74 –0.03 –1.74 to 1.19
Practical problems –1.27 0.87 –0.11 –2.99 to 0.45
***p< 0.001.
SE, standard error; TPB, theory of planned behaviour.
R= 0.17, F12,173 = 3.05*** (n = 186).
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Appendix 17 Correlation coefficients (Pearson’s r)
between the components of the theory of planned
behaviour
TABLE 76 Correlation coefficients (Pearson’s r) between the components of the theory of planned behaviour
1 2 3 4 5 6 7 8 9
1. Attitude
(α = 94)
2. Subjective
norms (α = 0.98)
0.71***
3. Perceived
behavioural
control (α = 0.89)
0.26*** 0.20***
4. Intentions
(α = 0.96)
0.24*** 0.25*** 0.58***
5. Beliefs (attitude
related) (α = 0.87)
0.44*** 0.29*** 0.55*** 0.36***
6. Beliefs (control
related –1) –
time-consuming
0.21*** 0.17*** 0.23*** 0.16** 0.05
7. Beliefs (control
related –2) – fit
daily routine
0.26*** 0.25*** 0.35*** 0.27*** 0.15** 0.53***
8. Amount of
practice
0.13* 0.12 0.14* 0.12 0.15** 0.27*** 0.21***
9. Continued
engagement
(6 months)
0.13* 0.05 0.24*** 0.17** 0.24*** 0.32*** 0.32*** 0.51***
10. Continued
engagement
(12 months)
0.05 0.03 0.15* 0.17** 0.18** 0.22*** 0.19** 0.55*** 0.76***
*p ≤ 0.05, **p< 0.01, ***p< 0.001.
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Appendix 18 Hierarchical logistic regression
results for the role of attitude, subjective norms and
perceived behavioural control in the prediction
of intentions
TABLE 77 Hierarchical logistic regression results for the role of attitude, subjective norms and perceived
behavioural control in the prediction of intentions
B SE (B) Wald Odds ratio [exp(B)] 95% CI
Attitude –0.03 0.06 0.26 0.97 0.86 to 1.10
Subjective norms 0.09 0.05 3.20 1.10 0.99 to 1.22
Perceived behavioural control 0.79 0.11 54.95*** 2.21 1.79 to 2.72
Beliefs (attitude related) 0.04 0.05 0.93 1.04 0.96 to 1.14
Beliefs (control related –1) – time-consuming –0.05 0.09 0.30 0.95 0.79 to 1.14
Beliefs (control related –2) – fit daily routine 0.01 0.10 0.01 1.01 0.83 to 1.23
***p< 0.001.
SE, standard error.
Model χ2 [degrees of freedom (df) = 6, n = 336]= 154.23, p< 0.001; Nagelkerke R2 = 0.49; Hosmer–Lemeshow χ2
(df= 8) = 49.92, p< 0.001).
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Appendix 19 Hierarchical linear regression results
for the role of intention and perceived behavioural
control in the prediction of continued engagement
(at 6 months)
TABLE 78 Hierarchical linear regression results for the role of intention and perceived behavioural control in the
prediction of continued engagement (at 6 months)
B SE (B) β 95% CI
Step 1
Intention 1.72 0.63 0.17** 0.48 to 2.95
Step 2
Intention 0.53 0.77 0.05 –0.99 to 2.04
Perceived behavioural control 0.40 0.15 0.20** 0.10 to 0.70
**p < 0.01, ***p < 0.001.
SE, standard error.
R2 = 0.03, F2,242 = 7.31*** (n = 245).
DOI: 10.3310/hta21530 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 53
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thomas et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
153

Appendix 20 Hierarchical multiple regression
results for the role of intention and perceived
behavioural control in the prediction of continued
engagement (at 12 months)
TABLE 79 Hierarchical multiple regression results for the role of intention and perceived behavioural control in the
prediction of continued engagement (at 12 months)
B SE (B) β 95% CI
Step 1
Intention 1.55 0.59 0.17** 0.40 to 2.71
Step 2
Intention 1.20 0.72 0.13 –0.22 to 2.61
Perceived behavioural control 0.12 0.14 0.07 –0.16 to 0.40
*p ≤ 0.05, **p< 0.01.
SE, standard error.
R2 = 0.03, F2,238 = 3.87* (n= 241).
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Appendix 21 Hierarchical multiple regression
results for the role of intention and perceived
behavioural control in the prediction of amount of
practice (at 3 months)
TABLE 80 Hierarchical multiple regression results for the role of intention and perceived behavioural control in the
prediction of amount of practice (at 3 months)
B SE (B) β 95% CI
Step 1
Intention 10.71 5.80 0.11 –0.72 to 22.14
Step 2
Intention 4.78 6.87 0.05 –8.75 to 18.32
Perceived behavioural control 2.18 1.36 0.12 –0.50 to 4.86
*p ≤ 0.05.
SE, standard error.
R2 = 0.01, F2,257 = 2.99* (n= 260).
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Appendix 22 Principal axis factoring (pattern
matrix) and internal consistency of the Problematic
Experiences of Therapy Scale items
TABLE 81 Principal axis factoring (pattern matrix) and internal consistency of the PETS items
Items I II III IV V
I. Problems due to symptoms (α = 0.76)
1. I had to skip the breathing retraining because it made my symptoms worse 0.827
2. I was prevented from carrying out the breathing retraining by severe
symptoms
0.919
3. I could not carry out the breathing retraining because it caused more
symptoms
II. Problems due to uncertainty (α = 0.89)
4. I could not carry out the breathing retraining because I was unsure how to
do it properly
–0.880
5. I was unable to carry out the breathing retraining because it was difficult
to know what to do
6. I did not carry out the breathing retraining because I was worried that I
was doing it wrong
–0.755
III. Problems due to doubts (α = 0.90)
7. I skipped the breathing retraining because I was not sure if it was helping –0.881
8. I skipped the breathing retraining because it did not seem relevant to my
symptoms and problems
–0.880
9. I did not carry out the breathing retraining because I was not convinced it
was right for me
–0.915
IV. Practical problems (α = 0.89)
10. Lack of time prevented me from carrying out the breathing retraining 0.944
11. It was not possible to find suitable opportunities to carry out the
breathing retraining
0.891
12. I was too busy to carry out the breathing retraining 0.910
13. I was too tired to carry out the breathing retraining 0.631
14. I found it difficult to remember to carry out the breathing retraining 0.646
V. Problems due to lack of support (α = 0.85)
15. I did not carry out the breathing retraining because I did not receive
enough support from my family and friends
0.792
16. Lack of support from a health professional prevented me from carrying
out the breathing retraining
0.822
17. I did not carry out the breathing retraining because I did not have anyone
to support me
0.931
Item variance accounted for by factor (%) 6.64 4.77 15.25 15.25 44.49
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Appendix 23 Component Pearson’s correlation
matrices of the Problematic Experiences of Therapy
Scale subscales
TABLE 82 Component Pearson’s correlation matrices of the PETS subscales
Subscale I II III IV V
I. Problems due to symptoms
II. Problems due to uncertainty –0.337
III. Problems due to doubts –0.326 0.489
IV. Practical problems 0.166 –0.299 –0.292
V. Problems due to lack of support 0.371 –0.501 –0.448 0.491
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